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ESTRUCTURA DE LA TESIS 
Esta Tesis Doctoral se presenta en formato publicaciones donde todos los capítulos de la 
Tesis Doctoral, que se enumeran a continuación, han sido enviados a revistas indexadas en el 
Journal Citation Reports (JCR). La Tesis Doctoral comienza con un resumen que incluye una 
breve introducción a la misma junto con los objetivos, a continuación se describen los 
materiales y métodos de forma abreviada, seguida por una sección de resultados y por una 
discusión final con las conclusiones. 
CAPÍTULO I – H2AX como nuevo criterio de valoración para detectar daños en 
el ADN: aplicaciones para la evaluación de la genotoxicidad in vitro del humo de los 
cigarrillos. Este capítulo introductorio contiene una revisión detallada de la bibliografía 
especializada relativa al uso de la H2AX como biomarcador de las roturas de la doble 
cadena de ADN, además de incluir una descripción general de los criterios actuales de 
valoración que se emplean en la evaluación in vitro de la toxicología genética. 
CAPÍTULO II – Caracterización metabólica de los sistemas celulares empleados en 
los experimentos toxicológicos in vitro: línea celular pulmonar BEAS-2B como ejemplo. 
Este capítulo está centrado en comprender la competencia metabólica del sistema celular 
BEAS-2B empleado durante esta Tesis Doctoral. También subraya la importancia de la 
actividad metabólica en los sistemas in vitro en el contexto de la bioactivación de tóxicos. 
CAPÍTULO III – Evaluación del ensayo in vitro H2AX mediante “High Content 
Screening” (HCS) como nuevo test de genotoxicidad. Este capítulo describe el desarrollo 
del ensayo in vitro de la H2AX mediante HCS en células BEAS-2B. El sistema de análisis 
automatizado contribuye al alto rendimiento del ensayo y elimina la subjetividad del análisis 
manual. En este capítulo se describe una evaluación preliminar para calcular la sensibilidad y 
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la especificidad del ensayo analizando la respuesta de un grupo de controles positivos y 
negativos.  
CAPÍTULO IV – Evaluación de la genotoxicidad de tóxicos específicos del humo de 
los cigarrillos empleando el ensayo in vitro de la H2AX mediante “High Content 
Screening” (HCS). Este capítulo se centra en la aplicación del nuevo ensayo in vitro sobre la 
H2AX mediante HCS en la evaluación de las sustancias tóxicas del humo de los cigarrillos 
de la fase de partículas, tanto a nivel individual como en mezcla binaria. 
CAPÍTULO V – Caracterización de un sistema de exposición a aerosoles para la 
evaluación de la genotoxicidad del humo de los cigarrillos usando el ensayo in vitro de la 
H2AX mediante “High Content Screening” (HCS). Este capítulo describe la optimización 
del nuevo ensayo para evaluar aerosoles, seguida de la aplicación del ensayo in vitro 
optimizado de la H2AX mediante HCS en la evaluación íntegra del humo de los cigarrillos. 
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1.- RESUMEN DE LA TESIS DOCTORAL 
Hay multitud de formas en las que el ADN puede sufrir daños; una de las lesiones más graves 
son las roturas de la doble cadena, puesto que no hay ninguna cadena complementaria que 
quede intacta para actuar como plantilla durante la reparación del ADN. Esta lesión puede 
desembocar en la muerte celular si falla mecanismo de reparación; ahora bien, si se repara de 
forma incorrecta, la información del ADN puede quedar comprometida, lo que puede 
producir una mutación y, potencialmente, la conservación de la información de ADN que 
puede ser incorrecta (Jeggo y Lobrich 2007). 
La fosforilación de la histona 2AX denominada γH2AX se produce como respuesta temprana 
a las roturas de la doble cadena de ADN, y fue descrita por primera vez en 1998 (Rogakou et 
al., 1998). La fosforilación de la H2AX es un biomarcador de daño en el ADN conservado en 
las células eucariotas y, por tanto, está presente en células humanas, así como en animales y 
plantas (Redon et al., 2011). Desde su descubrimiento, este biomarcador de daño en el ADN 
ha sido empleado en diferentes ámbitos científicos, como estudios clínicos, investigación 
sobre la integridad del genoma y desarrollo de medicamentos. En el siglo XXI, el campo 
preclínico de la toxicología genética está experimentando una revolución, en la que se están 
utilizando tecnologías nuevas y emergentes para desarrollar y mejorar los métodos de análisis 
tanto como para los nuevos como para los ya existentes dentro de la toxicología genética 
(Lynch et al., 2011). En esta Tesis Doctoral, la H2AX ha sido estudiada como un nuevo 
criterio de evaluación del daño sobre el ADN, en particular de las posibles aplicaciones en la 
disciplina de la toxicología genética in vitro. Se ha sugerido que la medición de la H2AX se 
utilice como una herramienta complementaria a la batería de ensayos toxicológicos existente, 
y de forma más específica como ensayo de pre-evaluación basado en el alto rendimiento 
generado por sistemas de análisis como son: la citometría de flujo, la 
 
 
4 
 
inmunoelectrotransferencia In Cell Western y el HCS (Smart et al., 2011; Audebert et al., 
2010; Garcia-Canton et al., 2012). El capítulo I de esta Tesis Doctoral revisa los mecanismos 
de fosforilación de la H2AX y su relevancia como nuevo ensayo in vitro de genotoxicidad en 
el contexto de las pruebas in vitro de genotoxicidad actuales, tanto reguladas como no 
reguladas. 
El diseño experimental para medir la H2AX in vitro requiere la selección de un sistema 
celular, teniendo en cuenta la ruta de exposición y los requisitos metabólicos del compuesto a 
analizar. En esta Tesis Doctoral se ha previsto que el ensayo in vitro de la H2AX mediante 
HCS sea aplicado a la evaluación del humo de los cigarrillos, que constituye de forma 
irrefutable una de las principales causas del cáncer de pulmón y contribuye a otras 
enfermedades, entre las que se incluyen trastornos cardiovasculares y respiratorios. Algunos 
componentes del humo de los cigarrillos, como el benzo[a]pireno (B[a]P), no son 
genotóxicos per se, pero pueden ser metabolizados por enzimas específicas de un tejido, 
como los citocromos P450 (CYP), y transformarse en especies reactivas. Estos compuestos 
reciben el nombre de protóxicos. Por este motivo, la capacidad metabólica del sistema celular 
seleccionado tiene que caracterizarse para garantizar que los compuestos protóxicos sean 
correctamente evaluados.  
Se seleccionó como sistema celular la línea celular humana BEAS-2B derivada del pulmón. 
Esta línea celular fue establecida por Reddel y colaboradores a partir de células epiteliales 
bronquiales con fenotipo normal, inmortalizadas por el adenovirus 12-SV40/híbrido sin 
capacidad de replicación (Reddel et al., 1988). Cuando se mide la H2AX, las líneas 
celulares derivadas de los tejidos normales, como las células BEAS-2B, se consideran más 
fiables que aquellas procedentes de tejidos premalignos o tumorales. Por ejemplo, se ha 
observado que algunas líneas celulares tumorigénicas pueden ser defectuosas en algunas 
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funciones fundamentales, como mecanismos de reparación de daño en el ADN o que no 
tienen una regulación normal del ciclo celular (Hanahan y Weinberg, 2000).  
La transformación maligna celular podría afectar a la respuesta de la H2AX; por ejemplo, 
existen trabajos que demuestran una importante cantidad de H2AX en ausencia de roturas de 
la doble cadena de ADN, posiblemente como respuesta al “estres oncogénico” (Svetlova et 
al., 2010). Además, el órgano de origen de esta línea celular es de especial interés en la 
evaluación de compuestos, puesto que el objetivo principal es el pulmón. Este es el caso del 
humo de los cigarrillos, los contaminantes y los nanomateriales, entre otros (Ansteinsson et 
al., 2011; Veljkovic et al., 2011). No obstante, era necesario caracterizar de manera adicional 
las capacidades metabólicas de la línea celular BEAS-2B para respaldar un diseño 
experimental sólido de cara a la bioactivación de protóxicos. En el capítulo II de esta tesis se 
detalla la caracterización metabólica de la línea celular BEAS-2B.  
Tras nuestra evaluación usando células BEAS-2B, se puede llegar a la conclusión de que en 
estas células se detectaba una actividad limitada de las enzimas del citocromo P450 en 
comparación con las células del tejido pulmonar normal. Para evitar una evaluación 
incorrecta de los compuestos protóxicos, se incluyó en diseño experimental durante el 
desarrollo del ensayo in vitro de la H2AX una fuente externa de activación metabólica, tal y 
como se recomienda en las guías destinadas al asesoramiento de ensayos de genotoxicidad de 
medicamentos de uso humano (ICH, 2011). El desarrollo del ensayo incluyo un sistema de 
análisis automatizado basado en microscopía denominado HCS (Bickle, 2010). Existen otros 
sistemas automatizados alternativos empleados en otros estudios para medir la H2AX, como 
la citometría de flujo (Smart et al., 2011) y el sistema In Cell Western, método de inmuno-
electrotransferencia en el que se emplea una placa con múltiples pocillos (Audebert et al., 
2010). En esta Tesis Doctoral se seleccionó un panel de 22 compuestos positivos y negativos 
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empleados en evaluaciones anteriores de ensayos de genotoxicidad (Hastwell et al., 2006) y 
recomendados por el Centro Europeo para la Validación de Métodos Alternativos. Se 
calcularon la sensibilidad, especificidad y precisión del ensayo mediante HCS siguiendo las 
recomendaciones publicadas por un grupo de expertos (Kirkland et al., 2008). El panel de 
compuestos seleccionado incluía compuestos con diferentes mecanismos de acción conocidos, 
como protóxicos, agentes aneugénicos y compuestos no genotóxicos. En el capítulo III de 
esta tesis se presenta el desarrollo del ensayo in vitro de la H2AX mediante HCS y la 
evaluación preliminar de su precisión. 
Tras finalizar la evaluación del rendimiento del ensayo H2AX con sustancias tóxicas de 
referencia, aplicamos el ensayo H2AX a las sustancias tóxicas del humo de los cigarrillos y a 
la exposición al humo. El humo de los cigarrillos es una mezcla compleja, que consta de más 
de 5600 compuestos identificados (Perfetti y Rodgman, 2011). Los cálculos sugieren que la 
mezcla íntegra contiene más de 150 sustancias tóxicas conocidas (Cunningham et al., 2011), 
incluyendo compuestos clasificados por la IARC como “carcinógenos para los humanos” 
(grupo 1), por ejemplo B[a]P o 4-(metilnitrosamino)-1-(3-piridil)-1-butanona (NNK) (IARC, 
2012a; AIRC, 2012b). Los resultados experimentales obtenidos de una mezcla compleja 
podrían ser complicados de interpretar, puesto que las interacciones entre los componentes 
separados podrían influir sobre el resultado final. El fraccionamiento de la mezcla compleja 
en componentes individuales y mezclas sencillas podría ayudar a determinar los elementos 
tóxicos fundamentales presentes en el humo de los cigarrillos. La regulación de los productos 
derivados del tabaco por parte de diferentes organizaciones, como el Centro de Productos de 
Tabaco de la Administración de Alimentos y Medicamentos o el Convenio Marco de la 
Organización Mundial de la Salud para el Control del Tabaco, requiere herramientas de 
evaluación de riesgos sensibles y rápidas, que sirvan para complementar el conocimiento ya 
existente basado principalmente en datos in vivo (WHO 2008; FDA, 2012). La tarea más 
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exigente del análisis previo del potencial de genotoxicidad in vitro de un gran número de 
compuestos tanto por separado como en mezcla simple requiere un ensayo de alto 
rendimiento con un diseño experimental simplificado. Este enfoque también sirve para 
respaldar la reducción en el uso de modelos animales, tal y como recomienda el enfoque de 
las 3R (Schechtman, 2002). En esta tesis, el nuevo desarrollo del ensayo in vitro de la H2AX 
mediante HCS se aplicó a la evaluación del potencial genotóxico de algunos elementos 
tóxicos del humo de los cigarrillos (que se describen en el capítulo IV) y al humo de los 
cigarrillos (descrito en el capítulo V). 
En el capítulo IV de esta Tesis Doctoral procedimos a seleccionar una serie de sustancias 
tóxicas del humo de los cigarrillos de la fase de partículas para ser evaluadas en el nuevo 
ensayo in vitro de la H2AX mediante HCS. El hidrocarburo aromático policíclico B[a]P, las 
nitrosaminas específicas del tabaco 4-(metilnitrosamino)-1-(3-piridil)-1-butanona (NNK) y 
N-nitrosonornicotina (NNN) y el cadmio (metal pesado) fueron evaluados individualmente, 
mientras que las nitrosaminas especifícas del tabaco, NNN y NNK, también fueron evaluados 
en mezcla binaria. Las tres primeras sustancias han sido recomendadas para una reducción 
obligatoria de su nivel en los productos derivados del tabaco, mientras que para el cadmio se 
recomienda su monitorización por parte de la Organización Mundial de la Salud para el 
Control del Tabaco (WHO, 2008). 
El ensayo in vitro de la H2AX mediante HCS también se optimizó en el capítulo V para la 
evaluación de aerosoles en la fase aire-líquido. Esta metodología se considera 
fisiológicamente más relevante para la evaluación íntegra del humo directo de los cigarrillos, 
puesto que las células están expuestas directamente a la mezcla compleja de la combustión de 
productos derivados del tabaco (Phillips et al., 2005).  
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En resumen, esta Tesis Doctoral describe el desarrollo, la evaluación preliminar y la 
aplicación de un nuevo ensayo para la detección de daño en el ADN mediante el uso de 
nuevas tecnologías para automatizar la medida de la respuesta. Además, el nuevo ensayo ha 
demostrado su potencial para optimizarse y aplicarse en el campo reglamentario del tabaco 
como herramienta para efectuar un análisis inicial de un gran número de compuestos y 
mezclas, incluyendo aerosoles.  
SUMMARY 
There are multiple forms of DNA damage, one of the most deleterious lesions are double-
strand breaks (DSBs) since no complementary strand is left intact to act as a template during 
DNA repair. This lesion can lead to cell death if the repair mechanism fails, however, if 
repaired incorrectly, the DNA information can be compromised leading to mutation and 
potentially the perpetuating incorrect DNA information (Jeggo and Lobrich 2007). 
Phosphorylation of the histone 2AX resulting in γH2AX occurs as an early response to DNA 
DSBs and was first described in 1998 (Rogakou et al., 1998). The phosphorylation of H2AX 
is a conserved biomarker of DNA damage across eukaryotes and is therefore present in 
humans as well as animals and plants cells (Redon et al., 2011). Since its discovery, this 
biomarker of DNA damage has been used in different disciplines of scientific research such 
as clinical studies, genome integrity research and drug development. The field of pre-clinical 
genetic toxicology testing in the 21st century is experiencing a revolution where new and 
emerging technologies are being used to develop and improve new and existing testing 
methods in genetic toxicology (Lynch et al., 2011).  In this PhD dissertation, H2AX has 
been studied as a novel endpoint of DNA damage focusing on the potential applications in 
the discipline of in vitro genetic toxicology. The measurement of H2AX has been suggested 
as a complementary tool to the existing battery of genetic toxicology tests, more specifically 
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as a pre-screening assay based on the high throughput given by scoring systems such as flow 
cytometry, in cell western immunoblotting and High Content Screening (HCS) (Smart et al., 
2011; Audebert et al., 2010; Garcia-Canton et al., 2012). Chapter I of this PhD dissertation 
reviews the mechanisms of H2AX phosphorylation and the relevance of H2AX as a novel in 
vitro genotoxicity assay in the context of current in vitro genotoxicity tests both regulatory 
and non-regulatory. 
The experimental design for measuring H2AX in vitro requires the selection of a cell system 
taking into consideration route of exposure and metabolic requirements. In this PhD 
dissertation, the in vitro H2AX assay by HCS is planned to be applied to the evaluation of 
cigarette smoke which is known to be a major cause of lung cancer and contributes to other 
diseases including cardiovascular and respiratory related diseases. Some cigarette smoke 
constituents such as Benzo[a]pyrene (B[a]P) are not genotoxic per se, but can be metabolized 
by tissue specific enzymes such as cytochromes P450 (CYPs) into reactive species. These 
compounds are known as pro-toxicants. Therefore, the metabolic capability of the selected 
cell system needs to be characterised to ensure that pro-toxicant compounds are correctly 
evaluated.  
Here, the human lung-derived BEAS-2B cell line was selected as the cell system. This cell 
line was established by Reddel and colleagues from normal bronchial epithelial cells that 
were immortalised by a replication-defective 12-SV40/adenovirus hybrid (Reddel et al., 
1988). When measuring H2AX, cell lines derived from normal tissues, such as BEAS-2B 
cells, are considered to be more reliable than those from pre-malignant and cancer tissues. 
For instance, it has been reported that some tumorigenic cell lines can be defective in key 
functions including DNA damage repair mechanisms and lack normal cell cycle regulation 
(Hanahan and Weinberg 2000). Malignant cell transformation could affect the H2AX 
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response, for instance, there have been reports showing significant amount of H2AX in the 
absence of DNA DSBs, possibly as a response to “oncogenic stress” (Svetlova et al., 2010). 
Moreover, the organ of origin of this cell line is of special interest in the evaluation of 
compounds since the primary target is the lung. This is the case of cigarette smoke, pollutants 
and nanomaterials among others (Ansteinsson et al., 2011; Veljkovic et al., 2011). However, 
the metabolic capabilities of the BEAS-2B cell line needed to be further characterised to 
support robust experimental design for pro-toxicant bioactivation. The metabolic 
characterisation of the BEAS-2B cell line is detailed in Chapter II of this PhD dissertation.  
Following our assessment of the BEAS-2B cells, we concluded that limited cytochrome P450 
enzyme activity could be detected in BEAS-2B cells compared to normal lung-tissue. To 
avoid an incorrect evaluation of pro-toxicants, a standardised external source of metabolic 
activation was incorporated in the experimental design of the in vitro H2AX assay 
development as recommended in testing guidelines (ICH, 2011). The assay development 
included an automated microscopy-based scoring system referred to as High Content 
Screening (Bickle 2010). Other alternative automated screening systems previously used to 
measure H2AX include flow cytometry (Smart et al., 2011) and In Cell Western a multi-
well plate based immunoblotting (Audebert et al., 2010). A panel of 22 positive and negative 
compounds used in previous genotoxicity assay assessments (Hastwell et al., 2006) and 
recommended by the European Centre for the Validation of Alternative Methods (ECVAM) 
were selected. The sensitivity, specificity and accuracy of the assay by HCS were calculated 
following recommendations published by an expert group (Kirkland et al., 2008). The 
selected panel included compounds with different known mechanisms of action, such as pro-
toxicants, aneugens and non-genotoxic compounds. The in vitro H2AX assay by HCS 
development and preliminary assessment is presented in Chapter III of this PhD dissertation. 
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Following the completion of the H2AX assay performance evaluation with reference 
toxicants, we applied the H2AX assay to cigarette smoke toxicants and whole smoke 
exposure. Cigarette smoke is a complex mixture consisting of more than 5,600 identified 
compounds (Perfetti and Rodgman 2011). Estimations suggest that the whole mixture 
contains over 150 known toxicants (Cunningham et al., 2011), including compounds 
classified by IARC as “carcinogenic to humans” (Group 1) such as B[a]P and NNK (IARC, 
2012a; IARC, 2012b). Experimental results obtained from complex mixture testing could be 
difficult to interpret as interactions between single components could affect the final outcome. 
Fractionation of the complex mixture into single components and simple mixtures could 
assist with the determination of key toxic drivers present in the cigarette smoke. The 
regulation of tobacco products from different organisations such as the Food and Drug 
Administration Center for Tobacco Products (FDA CTP) and the World Health Organisation 
Framework Convention on Tobacco Control (WHO FCTC) require sensitive and fast risk 
assessment tools that complement existing knowledge based mainly on in vivo data (WHO 
2008; FDA, 2012). The challenging task of pre-screening the in vitro genotoxicity potential 
of a large number of compounds individually and in simple mixture requires a high 
throughput assay with a simplified experimental design. This approach also supports the 
reduction in the use of animal models as recommended by the 3Rs approach (Schechtman 
2002). In this PhD dissertation, the newly developed in vitro H2AX assay by HCS was 
applied to the evaluation of the genotoxic potential of cigarette smoke toxicants (described in 
Chapter IV) and whole mainstream cigarette smoke (WMCS) (described in Chapter V). 
In Chapter IV of this PhD dissertation, we selected a number of cigarette smoke toxicants 
from the particulate phase to be tested in the novel in vitro H2AX assay by HCS. The 
polycyclic aromatic hydrocarbon B[a]P, the tobacco-specific nitrosamines (TSNAs) 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and  N-nitrosonornicotine (NNN) and 
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the heavy metal cadmium were all tested individually whereas the TSNAs were also tested in 
binary mixture. The first three toxicants are recommended for mandated lowering while the 
last one is recommended for monitoring by the WHO FCTC (WHO 2008).     
The in vitro H2AX assay by HCS was also optimised in Chapter V for the evaluation of 
aerosols at the air-liquid interface. This methodology is considered more physiologically 
relevant for the evaluation of WMCS as cells are directly exposed to the complex mixture of 
combusted tobacco (Phillips et al., 2005).  
In summary, this PhD dissertation describes the development, preliminary assessment and 
application of a novel assay for the detection of DNA damage using new technologies to 
automate the measurement of the response. Furthermore, the novel assay has demonstrated 
the potential to be further optimised and applied in the area of tobacco regulation as a tool to 
pre-screen large numbers of compounds and mixtures including aerosols.  
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2.- OBJETIVOS 
 Caracterizar las capacidades metabólicas de la línea celular BEAS-2B procedente del 
pulmón para su uso in vitro en experimentos toxicológicos. 
 Determinar si la respuesta de la H2AX puede medirse en las células BEAS-2B 
mediante un sistema automatizado basado en microscopía y que es conocido como 
HCS. 
 Evaluar la sensibilidad, la especificidad y la precisión del ensayo in vitro de la 
H2AX mediante HCS con un conjunto preliminar de compuestos de referencia. 
 Determinar si el ensayo in vitro de la H2AX mediante HCS puede aplicarse a la 
evaluación de sustancias tóxicas procedentes del humo de los cigarrillos, tanto de 
forma separada como en mezcla binaria. 
 Investigar si el ensayo in vitro de la H2AX mediante HCS puede desarrollarse y 
adaptarse a la exposición de aerosoles. 
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3.- MATERIALES Y MÉTODOS 
3.1.- Líneas celulares 
La línea celular epitelial bronquial humana (BEAS-2B) fue adquirida a ATCC (Estados 
Unidos). Las células fueron conservadas en un medio de crecimiento epitelial bronquial 
(Bronchial Epithelial Growth Medium, BEGM®) a 37°C y con CO2 al 5% en un incubador 
humidificado (Lonza Group Ltd., Bélgica).  
El tipo II alveolar humano procedente de un adenocarcinoma (A549) fue adquirido a ATCC 
(Estados Unidos). Las células fueron conservadas en un medio Eagle modificado por 
Dulbecco, complementado con suero fetal bovino (10% v/v), L-glutamina (2 mM), penicilina 
(50 U/mL) y estreptomicina (50 µg/mL) (DMEM completo) a 37°C y con CO2 al 5% en un 
incubador humidificado. 
La línea celular procedente del hepatocarcinoma (HepG2) fue adquirida a ATCC (Estados 
Unidos). Las células fueron conservadas en medio Eagle modificado por Dulbecco, 
complementado con suero fetal bovino (10% v/v), L-glutamina (2 mM), penicilina (50 U/mL) 
y estreptomicina (50 µg/mL) (DMEM completo) a 37°C y con un 5% de CO2 en un 
incubador humidificado. 
La línea celular humana derivada de un hepatocarcinoma (HepaRG) fue adquirida ya 
diferenciada como una capa confluente a Biopredic International (Francia). Las células 
fueron conservadas en un medio basal, complementado con una mezcla de recuperación 
durante 24 horas seguido de un medio basal complementado con una mezcla de 
mantenimiento/metabolismo. Los medios y los complementos fueron suministrados por el 
fabricante (Biopredic, Francia). 
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Las células BEAS-2B, A549 y HepG2 fueron cultivadas y expandidas en el laboratorio.  
Los experimentos se llevaron a cabo únicamente entre los pasos 3 y 12. Todos los cultivos 
fueron analizados para descartar la presencia de contaminación por micoplasma, y todos 
resultaron ser negativos. Además, las células fueron autentificadas mediante el análisis de 
repeticiones cortas en tándem para confirmar la naturaleza de los cultivos celulares (LGC 
Standards, Reino Unido) (Nims et al., 2010). 
3.2.- Metodologías 
3.2.1.- Caracterización metabólica de las células BEAS-2B 
Expresión génica: Se examinó un panel de 47 genes con codificación de enzimas de fase I y 
fase II del metabolismo a través del uso de qPCR en las células BEAS-2B, A549 y HepG2, 
tanto en presencia como en ausencia del inductor 2,3,7,8-tetraclorodibenzo-p-dioxina 
(TCDD). La línea celular HepaRG fue analizado en ausencia de inductor. 
Ensayos de actividad enzimática: se generaron perfiles de actividad para cuatro enzimas del 
citocromo P450 implicadas en el metabolismo de algunas sustancias tóxicas del humo de los 
cigarrillos. La actividad de CYP1A1/1B1 se evaluó mediante el ensayo P450-Glo™ después 
de su inducción por TCDD. CYP2A6/CYP2A13, CYP2E1 y CYP1A2 se evaluaron mediante 
UPLC-MS/MS con los sustratos específicos de la enzima: cumarina, clorzoxazona y 
etoxiresorufina. Estos métodos fueron empleados en el capítulo II. 
3.2.2.- Detección y cuantificación de H2AX en células BEAS-2B mediante 
inmunotinción 
Se identificó la H2AX como marcador de la rotura de las dobles cadenas de ADN mediante 
inmunotinción, utilizando un anticuerpo primario específico de la propia γH2AX seguido de 
un anticuerpo secundario acoplado con fluoróforo.  
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La intensidad de la fluorescencia fue detectada y medida a través de la plataforma Cellomics 
Arrayscan® VTi (Thermo Scientific, EE. UU.), y posteriormente analizada con el software 
Target Activation Bioapplication V.6.6.1.4. 
Una vez comprobados los compuestos protóxicos, se empleó la fuente externa de activación 
metabólica el sobrenadante homogeneizado inducido por aroclor-1254 procedente del hígado 
de rata con cofactores (mezcla S9) (Moltox, EE. UU.). La mezcla S9 es uno de los sistemas 
estándar empleados como fuente externa de activación metabólica en los actuales y regulados 
ensayos in vitro.  
Los criterios de aceptación para la citometría de flujo descritos para el ensayo in vitro de la 
H2AX (Smart et al., 2011) fueron aplicados a los resultados del ensayo in vitro de la H2AX 
mediante HCS para evaluar la relevancia de utilizar el mismo enfoque (Tabla 1). 
Tabla 1: Criterios de evaluación de la genotoxicidad para el ensayo in vitro de la H2AX, 
adaptados (Smart et al., 2011). 
Respuesta H2AX Clasificación 
> 1,5 veces H2AX x RCC > 25% Genotóxico (+) 
< 1,5 veces H2AX x RCC 100-0% No genotóxico (–) 
> 1,5 veces H2AX x RCC < 25% “Falso” positivo; genotoxicidad (C) provocada por citotóxico 
= 1,5 veces H2AX x RCC ≥ 25% Equívoco (±) 
 
Esta metodología se aplicó en los capítulos III, IV y V. 
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3.2.3.- Optimización para la exposición a aerosoles 
Para la optimización por la exposición a los aerosoles se empleó la máquina fumadora 
“Borgwaldt RM20S®” (RM20S) para generar el humo directo de los cigarrillos. Las células 
cultivadas en soportes con membrana porosa Transwell™ se mantuvieron expuestas durante 
3 horas a una serie de diluciones del humo directo de los cigarrillos en aire procedentes de 
dos cigarrillos de referencia. El cigarrillo de referencia 3R4F es una mezcla de tabaco “estilo 
EE.UU.” que genera 9,4 mg de alquitrán y 0,7 mg de nicotina cuando se fuma siguiendo las 
condiciones experimentales detalladas por la Organización Internacional de Normalización 
(ISO) sobre el consumo de cigarrillos (ISO 3308:2012). El cigarrillo de referencia M4A es un 
cigarrillo con tabaco curado al aire caliente que genera 10 mg de alquitrán y 1,0 mg de 
nicotina cuando se fuma siguiendo las condiciones experimentales detalladas por la ISO (ISO 
3308:2012). Esta optimización se describe en el capítulo V. 
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4.- RESULTADOS 
4.1.- Capítulo II – Caracterización metabólica de los sistemas celulares in vitro 
empleados en los experimentos toxicológicos: línea celular pulmonar BEAS-2B 
En la introducción, subrayamos la importancia de la actividad metabólica en la bioactivación 
de algunas sustancias tóxicas, aunque no necesariamente en todas. Por este motivo, 
describimos la expresión génica por qPCR de un panel de genes que codifican enzimas 
relacionadas con el metabolismo y la actividad de un grupo seleccionado de enzimas del 
citocromo P450 en células BEAS-2B.  
Expresión génica: el análisis qPCR indicó una expresión génica limitada en las células 
BEAS-2B, con la excepción de CYP1A1, CYP1B1 y CYP1A2, que mostraron una 
importante regulación al alza (25, 5 y 4 veces más, respectivamente) tras una incubación 
previa con TCDD, inductor de algunas enzimas del citocromo P450.  
Actividad enzimática: las células BEAS-2B inducidas por TCDD mostraron una actividad 
CYP1A1/1B1 de 0,2 RLU/mg/min, cantidad baja comparada con otras células 
metabólicamente competentes. En cambio, no se observó ninguna actividad enzimática en las 
células BEAS-2B para CYP1A2, CYP2A6/2A13 y CYP2E1.  
4.2.- Capítulo III – Evaluación del ensayo in vitro H2AX mediante High Content 
Screening (HCS) como nuevo test de genotoxicidad 
Se utilizó un panel de 22 compuestos de referencia, que tenían diferentes mecanismos de 
acción conocidos para llevar a cabo una evaluación preliminar de la sensibilidad y la 
especificidad del ensayo in vitro de la H2AX mediante HCS. También como se había 
previsto en la evaluación se determinaron si los criterios de evaluación de la genotoxicidad 
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descritos por Smart y colaboradores (2011) para el sistema de citometría de flujo podrían 
emplearse con el sistema HCS. 
La evaluación preliminar indica que el ensayo in vitro de la H2AX mediante HCS tiene una 
alta precisión (86%) como consecuencia de su alta sensibilidad y especificidad  
(86-92% y 80-88% respectivamente). Los resultados también confirmaron que los criterios 
empleados para el sistema de análisis por citometría de flujo (Tabla 1) también pueden 
aplicarse al sistema HCS. 
4.3.- Capítulo IV – Evaluación de la genotoxicidad de sustancias tóxicas específicas del 
humo de los cigarrillos empleando el ensayo in vitro de la H2AX mediante High 
Content Screening (HCS) 
A continuación, se aplicó el ensayo de la H2AX mediante HCS sobre las sustancias tóxicas 
conocidas del tabaco, incluyendo hidrocarburos policíclicos aromáticos, nitrosaminas y 
metales pesados, con la finalidad de evaluar el ensayo en el contexto de la toxicología del 
tabaco. El compuesto B[a]P no indujo ningún incremento en la frecuencia de la H2AX por 
encima de los controles tratados con el vehículo (control negativo) después de 3 horas de 
tratamiento en cultivos previamente inducidos por TCDD o no inducidos. Cuando se evaluó 
el B[a]P durante 24 horas, se comprobó que se había producido un incremento significativo 
de la frecuencia de la H2AX en los cultivos tanto inducidos por TCDD como no inducidos, 
en concentraciones superiores a 0,5 µM. 
No obstante, la frecuencia de la H2AX en cultivos no inducidos para concentraciones 
superiores a 4 µM después de un tratamiento de 24 horas, volvió a los niveles tratados con 
vehículo (inducción < 1,5 veces).  
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El cloruro de cadmio produjo una respuesta positiva después de un tratamiento de tres horas 
en concentraciones superiores a 250 µM. Después de las 24 horas de tratamiento, las 
concentraciones por encima de 16 µM mostraban una genotoxicidad generada por efecto 
citotóxico. 
En el caso de las nitrosaminas especificas del tabaco, la NNK y la NNN no mostraron 
incremento estadísticamente significativo alguno en la frecuencia de la H2AX en 
comparación con los controles tratados con vehículo para ningúno del los intervalos de 
tiempo en presencia de mezcla S9. Cuando se evalúan los precursores reactivos NNK-acetato 
y NNN-acetato, ambos produjeron un incremento en la frecuencia de la H2AX en 
comparación con el control tratado con vehículo después de un tratamiento de 3 horas en 
concentraciones por encima de las 16 µM y las 500 µM respectivamente. Después de un 
tratamiento de 3 horas seguido de un período de recuperación de 24 horas, el NNK-acetato 
provocó un incremento significativo en concentraciones superiores a los 125 µM; aunque el 
NNN-acetato provocó un incremento dosis-dependiente en la frecuencia de la H2AX, 
aunque los resultados no alcanzaron el umbral de respuesta positiva.  
Para evaluar el efecto de las mezclas binarias, se llevaron a cabo tratamientos con 5 
permutaciones de mezclas de TSNA con diferentes proporciones de los precursores reactivos 
de NNK y NNN (NNK-acetato y NNN-acetato, respectivamente) durante 3 horas, en 
concentraciones entre 7,8 µM y 1000 µM. El tratamiento con NNK-acetato al 100% provocó 
un incremento significativo en la frecuencia de γH2AX en concentraciones por encima de los 
31,25 µM, mientras que NNN-acetato al 100% generó un incremento importante únicamente 
a la dosis más alta evaluada (1000 µM). Todas las demás combinaciones de mezcla 
comprobadas generaron incrementos importantes en los niveles de H2AX en 
concentraciones por encima de 62,5 µM. La respuesta inducida por diferentes proporciones 
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de nitrosaminas específicas del tabaco sugiere que el NNK-acetato es el principal responsable 
de la respuesta genotóxica cuando se encuentra presente en una mezcla con NNN-acetato. En 
este estudio no se observaron efectos sinérgicos ni antagonistas al utilizar precursores 
reactivos NNK y NNN independientes del citocromo P450 en mezcla binaria. 
4.4.- Capítulo V – Caracterización de un sistema de exposición a aerosoles para la 
evaluación de la genotoxicidad del humo de los cigarrillos usando el ensayo in vitro de la 
H2AX mediante High Content Screening (HCS) 
Algunos productos nuevos derivados del tabaco, como son los cigarrillos “heat not burn” 
(que no necesitan combustión), están apareciendo en el mercado con la ventaja de un 
potencial de una menor exposición a sustancias tóxicas y sugieren por ello un menor riesgo. 
En el contexto regulador del tabaco en constante evolución, las sugerencias relativas a la 
menor exposición y a un menor riesgo tienen o tendrán que corroborarse de acuerdo a las 
legislaciones nacionales específicas. Por este motivo, es interesante desarrollar ensayos 
genotóxicos, como el ensayo de la H2AX sobre la exposición a los aerosoles en 
contraposición a las sustancias tóxicas separadas o en solución. En este capítulo 
comprobamos la respuesta de la H2AX tras la exposición íntegra al humo de dos cigarrillos 
de referencia con una serie de diluciones del propio humo.  
Los cigarrillos de referencia 3R4F y M4A generaron un incremento importante en la 
frecuencia de la H2AX (incremento superior a 1,5 veces) en comparación con el control 
tratado con aire en todas las diluciones comprobadas (de 1:500 a 1:16.000). Mientras que la 
exposición íntegra al humo directo de los cigarrillos del 3R4F produjo una respuesta dosis-
dependiente, no se observó el mismo efecto con el humo directo de los cigarrillos del M4A. 
Los trabajos que se lleven a cabo en un futuro requerirán una caracterización en profundidad 
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del efecto de las variaciones del producto en la inducción de la H2AX para comprender las 
diferencias en la respuesta.  
  
 
 
23 
 
5.- DISCUSIÓN 
Con el paso de los años, el paradigma de la evaluación de riesgos de la toxicología genética 
ha pasado de los métodos de ensayo en animales (in vivo) a los ensayos in vitro (Anadón et 
al., 2014). Por ejemplo, en la industria cosmética, las pruebas en animales están prohibidas 
por la 7.ª modificación de la Directiva de la UE (European Commission, 2003). No obstante, 
en muchos casos, los ensayos in vitro actuales producen un elevado número de “falsos 
positivos”, una respuesta in vitro positiva que no se confirma in vivo. La frecuencia actual de  
estos “falsos positivos” incrementa la necesidad de continuar con los ensayos in vivo, lo cual 
demora mucho el desarrollo de nuevos productos. En consecuencia, durante la última década 
se han realizado multitud de esfuerzos en lo que respecta al desarrollo y la validación de 
nuevos métodos de prueba in vitro por parte de organizaciones como el Centro Europeo para 
la Validación de Métodos Alternativos o el Centro Nacional para el Reemplazo, la Refinación 
y Reducción de Animales de Investigación (Schechtman, 2002). 
En el proceso de desarrollo de nuevos ensayos, tenemos que tomar en consideración todas las 
características relevantes que pueden hacer que el nuevo método de ensayo pueda ser 
utilizado. Lo ideal es que un ensayo sea: 
i. Fisiológicamente relevante: el sistema celular seleccionado para el ensayo tiene que 
ser relevante para la vía de exposición, de origen humano y tiene que tener en cuenta 
las necesidades metabólicas del tejido diana. 
ii. La evaluación de los compuestos debe ser precisa: la sensibilidad (o capacidad de 
detectar compuestos genotóxicos) y la especificidad (o capacidad para discriminar 
compuestos no genotóxicos) tienen que ofrecer una mejora sobre los métodos de 
ensayo existentes. 
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iii. Alto rendimiento: el ensayo tiene que utilizar nuevas técnicas y tecnologías con el fin 
de suministrar un método rápido y en consecuencia barato, que sea fiable y 
reproducible con el paso del tiempo. La automatización o el potencial de 
automatización de la metodología representarían una ventaja, especialmente en lo que 
respecta a la pre-selección. 
iv. Objetivo: la medida de la respuesta será mucho más eficaz si puede llevarse a cabo 
mediante un sistema automático validado en vez de por un operador humano. 
Asimismo, la medida de la respuesta por parte del operador humano se limita a los 
términos cualitativos (sí/no) más que a los cuantitativos (un valor medido). 
v. Aplicable: el ensayo nuevo tiene que poder aplicarse a la investigación actual. 
Se ha utilizado ampliamente la medida de la H2AX como biomarcador de la rotura de las 
dobles cadenas de ADN desde su desde su descubrimiento (Rogakou et al., 1998). En el 
campo de la toxicología genética in vitro, la medida de la H2AX se ha apuntado como un 
posible ensayo complementario a la batería de ensayos existente, especialmente como 
herramienta de pre-evaluación o pre-selección. A pesar de ello, la medida de la H2AX se 
sigue utilizando mucho en la investigación, y son pocos los estudios que se han centrado en el 
desarrollo completo del ensayo investigando las características mencionadas anteriormente. 
Los diferentes capítulos de esta Tesis Doctoral han analizado las características necesarias 
para el desarrollo del ensayo in vitro de la H2AX mediante HCS. 
La línea celular humana BEAS-2B procedente del pulmón fue seleccionada por su naturaleza 
humana y su tejido de origen. No obstante, los resultados de la caracterización metabólica 
mostraron que había ausencia de actividad en la mayoría de las enzimas del citocromo P450 
evaluadas en comparación con el tejido pulmonar normal de una persona. La ausencia de 
competencia metabólica podría mitigarse añadiendo una fuente externa de activación 
 
 
25 
 
metabólica. En los ensayos reguladores rutinarios de genotoxicidad, se utiliza el sobrenadante 
homogeneizado inducido por aroclor-1254 procedente del hígado de rata con cofactores 
(mezcla S9) como fuente externa de activación metabólica. Las mezclas S9 derivadas de 
animales no son representativas de la especie de la línea celular ni del órgano diana, pero 
hasta la fecha son la opción disponible más normalizada. Las mezclas S9 procedentes de 
humanos están disponibles en el mercado, aunque las variaciones fenotípicas y los diferentes 
factores medioambientales hacen que estas fracciones no resulten fiables para ensayos 
rutinarios. En consecuencia, se selecciona el S9 procedente del hígado de rata inducido por 
aroclor-1254 como la fuente externa de activación metabólica para la evaluación de los 
compuestos protóxicos durante el desarrollo del ensayo in vitro de la H2AX mediante HCS. 
El ensayo in vitro de la H2AX mediante evaluación preliminar del HCS mostró una alta 
precisión (86%) en la detección de compuestos genotóxicos y en la discriminación de 
compuestos no genotóxicos; estos resultados coinciden con las evaluaciones llevadas a cabo 
previamente con otras metodologías de análisis (Smart et al., 2011; Tsamou et al., 2012). No 
obstante, se observaron algunas limitaciones durante la fase de desarrollo. La cantidad de 
mezcla S9 empleada para la comprobación de los compuestos protóxicos no alcanzó el 
mínimo recomendado de un 1% v/v como consecuencia de la toxicidad intrínseca observada 
y, por tanto, solo se utilizó un 0,5% v/v. Esta reducción en la cantidad de mezcla S9 utilizada 
podría haber provocado la falta de respuesta positiva del 2-acetilaminofluoreno, uno de los 
cuatro compuestos protóxicos comprobados en esta Tesis Doctoral. Las optimizaciones 
adicionales de ensayos podrían incluir una línea celular humana metabólicamente competente 
para realizar una mejor evaluación de los compuestos protóxicos. En términos generales, las 
líneas celulares hepáticas son conocidas por mantener un cierto nivel de metabolismo, como 
es el caso de HepG2 y HepaRG (Jennen et al., 2010). No obstante, estas líneas celulares 
sacrificarán la relevancia en la vía de exposición en investigaciones donde el órgano diana 
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sea el pulmón. Lo ideal es que se desarrolle una línea celular pulmonar metabólicamente 
competente, con ayuda de la nueva metodología de células madre pluripotentes inducidas se 
puede a largo plazo conseguir un avance en este área.  
Se observó una segunda limitación cuando se comprobaron los compuestos aneugénicos.  
El tratamiento con agentes aneugénicos produjo cambios morfológicos en las células, puesto 
que detiene su ciclo celular. Las células se redondean y la adhesión celular se reduce, lo que 
produce una elevada pérdida de células durante el proceso de inmunotinción. El diseño 
experimental tendrá que ajustarse para comprobar esta familia de compuestos, con el fin de 
asegurar que la adhesión celular quede restablecida antes de que comience el proceso de 
inmunotinción.  
Tras el desarrollo y la optimización adicional del ensayo in vitro de la H2AX mediante HCS, 
se aplica el nuevo ensayo para evaluar el humo de los cigarrillos y una serie de componentes 
presentes en el humo. Los resultados mostraron que el ensayo in vitro de la H2AX mediante 
HCS puede detectar el efecto de la genotoxicidad del humo de dos cigarrillos de referencia, 
con incrementos en la respuesta de hasta 7 veces por encima de los controles tratados con aire. 
El nuevo ensayo también puede detectar y cuantificar el efecto genotóxico de las sustancias 
tóxicas del humo de los cigarrillos, tanto en forma separada como en forma de mezcla binaria, 
lo que muestra el potencial como herramienta para investigar la aportación relativa de cada 
sustancia tóxica a la totalidad de la toxicidad del tabaco asociada al humo en este criterio de 
valoración específico de los daños sobre el ADN. 
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6.- CONCLUSIONES 
 La línea celular BEAS-2B parece no tener actividades en las enzimas del citocromo 
P450 relevantes para la bioactivación de algunos compuestos protóxicos. 
 La H2AX puede detectarse y cuantificarse en las células BEAS-2B mediante un 
sistema automatizado basado en microscopía, conocido como High Content 
Screening. 
 El ensayo in vitro de la H2AX mediante HCS mostró una alta precisión (86%), 
producida por una alta sensibilidad (86-92%) y una alta especificidad (80-88%). 
 El ensayo in vitro de la H2AX mediante HCS puede aplicarse a la evaluación de 
sustancias tóxicas procedentes del humo del tabaco en fase de partículas, tanto 
separadamente como en mezcla primaria. 
 El ensayo in vitro de la H2AX mediante HCS fue optimizado de forma satisfactoria 
para determinar la evaluación de la genotoxicidad de los aerosoles. 
  
 
 
28 
 
7.- REFERENCIAS 
Anadón, A., Martinez, M.A., Castellano, V. and Martinez-Larranaga, M.R., 2014. The role of 
in vitro methods as alternatives to animals in toxicity testing. Expert Opinion on Drug 
Metabolism and Toxicology 10, 67-79. 
Ansteinsson, V., Solhaug, A., Samuelsen, J.T., Holme, J.A. and Dahl, J.E., 2011. DNA-
damage, cell-cycle arrest and apoptosis induced in BEAS-2B cells by 2-hydroxyethyl 
methacrylate (HEMA). Mutation Research 723, 158-164. 
Audebert, M., Riu, A., Jacques, C., Hillenweck, A., Jamin, E.L., Zalko, D. and Cravedi, J.P., 
2010. Use of the H2AX assay for assessing the genotoxicity of polycyclic aromatic 
hydrocarbons in human cell lines. Toxicology Letters 199, 182-192. 
Bickle, M., 2010. The beautiful cell: high-content screening in drug discovery. Analytical and 
Bioanalytical Chemistry 398, 219-226. 
Cunningham, F.H., Fiebelkorn, S., Johnson, M. and Meredith, C., 2011. A novel application 
of the Margin of Exposure approach: segregation of tobacco smoke toxicants. Food and 
Chemical Toxicology 49, 2921-2933. 
European Commission, 2003. Directive 2003/15/EC of the European Parliament and of the 
Council of 27 February 2003 amending Council Directive 76/768/EEC on the approximation 
of the laws of the Member States relating to cosmetic products. Official Journal of the 
European Union L66, 26-35. 
FDA., 2012. Reporting Harmful and Potentially Harmful Constituents in Tobacco Products 
and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act.  
 
 
29 
 
http://www.fda.gov/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformatio
n/UCM297828.pdf 
Garcia-Canton, C., Anadón, A. and Meredith, C., 2012. H2AX as a novel endpoint to detect 
DNA damage: Applications for the assessment of the in vitro genotoxicity of cigarette smoke. 
Toxicology In Vitro 26, 1075-1086. 
Hanahan, D. and Weinberg, R.A., 2000. The hallmarks of cancer. Cell 100, 57-70. 
Hastwell, P.W., Chai, L.L., Roberts, K.J., Webster, T.W., Harvey, J.S., Rees, R.W. and 
Walmsley, R.M., 2006. High-speciticity and high-sensitivity genotoxicity assessment in a 
human cell line: Validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. 
Mutation Research 607, 160-175. 
IARC., 2012a. IARC monographs on the evaluation of carcinogenic risk to humans. A review 
of human carcinogens: chemical agents and related occupations. Benzo[a]pyrene. 100F. 
IARC., 2012b. IARC Monographs on the evaluation of carcinogenic risks to humans. A 
review of human carcinogens:Personal habits and indoor combustions. N'-Nitrosonornicotine 
(NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). International Agency 
for Research on Cancer. 100E. 
ICH., 2011. Guidance on genotoxicity testing and data interpretation for pharmaceuticals 
intended for human use S2(R1). 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/Step
4/S2R1_Step4.pdf 
Jeggo, P.A. and Lobrich, M., 2007. DNA double-strand breaks: their cellular and clinical 
impact? Oncogene 26, 7717-7719. 
 
 
30 
 
Jennen, D.G.J., Magkoufopoulou, C., Ketelslegers, H.B., van Herwijnen, M.H.M., Kleinjans, 
J.C.S. and van Delft, J.H.M., 2010. Comparison of HepG2 and HepaRG by Whole-Genome 
Gene Expression Analysis for the Purpose of Chemical Hazard Identification. Toxicological 
Sciences 115, 66-79. 
Kirkland, D., Kasper, P., Muller, L., Corvi, R. and Speit, G., 2008. Recommended lists of 
genotoxic and non-genotoxic chemicals for assessment of the performance of new or 
improved genotoxicity tests: A follow-up to an ECVAM workshop. Mutation Research 653, 
99-108. 
Lynch, A.M., Sasaki, J.C., Elespuru, R., Jacobson-Kram, D., Thybaud, V., De Boeck, M., 
Aardema, M.J., Aubrecht, J., Benz, R., Dertinger, S.D., Douglas, G.R., White, P.A., Escobar, 
P.A., Fornace, A., Jr., Honma, M., Naven, R.T., Rusling, J.F., Schiestl, R.H., Walmsley, 
R.M., Yamamura, E., van Benthem, J. and Kim, J.H., 2011. New and Emerging Technologies 
for Genetic Toxicity Testing. Environmental and Molecular Mutagenesis 52, 205-223. 
Nims, R.W., Sykes, G., Cottrill, K., Ikonomi, P. and Elmore, E., 2010. Short tandem repeat 
profiling: part of an overall strategy for reducing the frequency of cell misidentification. In 
Vitro Cellular and Developmental Biology.Animal. 46, 811-819. 
Perfetti, T.A. and Rodgman, A., 2011. The complexity of tobacco and tobacco smoke. 
Contributions to Tobacco Research 24, 215-232. 
Phillips, J., Richter, A., Massey, E.D. and Kluss, B., 2005. Exposure of bronchial epithelial 
cells to whole cigarette smoke: Assessment of cellular responses. ATLA Alternatives to 
Laboratory Animals 33, 239-248. 
Reddel, R.R., Ke, Y., Gerwin, B.I., McMenamin, M.G., Lechner, J.F., Su, R.T., Brash, D.E., 
Park, J.B., Rhim, J.S. and Harris, C.C., 1988. Transformation of human bronchial epithelial 
 
 
31 
 
cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via 
strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. 
Cancer Research 48, 1904-1909. 
Redon, C.E., Nakamura, A.J., Martin, O.A., Parekh, P.R., Weyemi, U.S. and Bonner, W.M., 
2011. Recent developments in the use of gamma-H2AX as a quantitative DNA double-strand 
break biomarker. Aging-Us 3, 168-174. 
Rogakou, E.P., Pilch, D.R., Orr, A.H., Ivanova, V.S. and Bonner, W.M., 1998. DNA double-
stranded breaks induce histone H2AX phosphorylation on serine 139. The Journal of 
Biological Chemistry 273, 5858-5868. 
Schechtman, L.M., 2002. Implementation of the 3Rs (refinement, reduction, and 
replacement): validation and regulatory acceptance considerations for alternative 
toxicological test methods. ILAR Journal 43 Suppl, S85-S94. 
Smart, D.J., Ahmedi, K.P., Harvey, J.S. and Lynch, A.M., 2011. Genotoxicity screening via 
the H2AX by flow assay. Mutation Research 715, 25-31. 
Svetlova, M.P., Solovjeva, L.V. and Tomilin, N.V., 2010. Mechanism of elimination of 
phosphorylated histone H2AX from chromatin after repair of DNA double-strand breaks. 
Mutation Research 685, 54-60. 
Tsamou, M., Jennen, D.G., Claessen, S.M., Magkoufopoulou, C., Kleinjans, J.C. and van 
Delft, J.H., 2012. Performance of in vitro H2AX assay in HepG2 cells to predict in vivo 
genotoxicity. Mutagenesis. 27, 645-652. 
 
 
32 
 
Veljkovic, E., Jiricny, J., Menigatti, M., Rehrauer, H. and Han, W., 2011. Chronic exposure 
to cigarette smoke condensate in vitro induces epithelial to mesenchymal transition-like 
changes in human bronchial epithelial cells, BEAS-2B. Toxicology In Vitro 25, 446-453. 
WHO., 2008. The Scientific Basis Of Tobacco Product Regulation. WHO technical report 
series ; no. 951.  
http://www.who.int/tobacco/global_interaction/tobreg/publications/9789241209519.pdf 
 
  
 
 
33 
 
DISSERTATION ORGANISATION 
This PhD dissertation is presented by publications where all the chapters have been submitted 
to peer-reviewed journals included in the Journal Citation Reports (JCR) and are listed below. 
The PhD dissertation starts with a summary that includes a brief introduction to the PhD topic 
together with the objectives, simplified materials and methods followed by the result section 
and a final discussion with conclusions. 
CHAPTER I - H2AX as a novel endpoint to detect DNA damage: Applications for 
the assessment of the in vitro genotoxicity of cigarette smoke: This introduction chapter 
contains a detailed literature review on the H2AX as a biomarker of DNA double strand 
breaks including an overall description of the current endpoints used in in vitro genetic 
toxicology evaluation. 
CHAPTER II - Metabolic characterization of cell systems used in in vitro 
toxicology testing: Lung cell system BEAS-2B as a working example: This chapter is 
focused on understanding the metabolic competency of the cell system BEAS-2B used during 
this PhD project. It also highlights the importance of metabolic activity in in vitro systems in 
the context of toxicant bioactivation. 
CHAPTER III - Assessment of the in vitro H2AX assay by High Content 
Screening as a novel genotoxicity test: This chapter describes the development of the in 
vitro H2AX assay by High Content Screening in BEAS-2B cells. The automated scoring 
system contributes to the high throughput of the assay and eliminates the subjectivity from 
the manual scoring. A preliminary assessment to calculate the sensitivity and specificity of 
the assay by testing a panel of positive and negative controls is described  in this chapter.  
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CHAPTER IV - Genotoxicity evaluation of individual cigarette smoke toxicants 
using the in vitro H2AX assay by High Content Screening: This chapter focuses on the 
application of the novel in vitro H2AX assay by High Content Screening in the evaluation of 
cigarette smoke toxicants from the particulate phase individually and in binary mixture. 
CHAPTER V - Characterisation of an aerosol exposure system to evaluate the 
genotoxicity of whole mainstream cigarette smoke using the in vitro H2AX assay by 
High Content Screening: This chapter describes the optimisation of the novel assay to 
evaluate aerosols, followed by the application of the optimised in vitro H2AX assay by High 
Content Screening in the evaluation of whole mainstream cigarette smoke. 
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1.- SUMMARY INTRODUCTION 
There are multiple forms of DNA damage, one of the most deleterious lesions are double-
strand breaks (DSBs) since no complementary strand is left intact to act as a template during 
DNA repair. This lesion can lead to cell death if the repair mechanism fails, however, if 
repaired incorrectly, the DNA information can be compromised leading to mutation and 
potentially the perpetuating incorrect DNA information (Jeggo and Lobrich 2007). 
Phosphorylation of the histone 2AX resulting in γH2AX occurs as an early response to DNA 
DSBs and was first described in 1998 (Rogakou et al., 1998). The phosphorylation of H2AX 
is a conserved biomarker of DNA damage across eukaryotes and is therefore present in 
humans as well as animals and plants cells (Redon et al., 2011). Since its discovery, this 
biomarker of DNA damage has been used in different disciplines of scientific research such 
as clinical studies, genome integrity research and drug development. The field of pre-clinical 
genetic toxicology testing in the 21st century is experiencing a revolution where new and 
emerging technologies are being used to develop and improve new and existing testing 
methods in genetic toxicology (Lynch et al., 2011).  In this PhD dissertation, H2AX has 
been studied as a novel endpoint of DNA damage focusing on the potential applications in 
the discipline of in vitro genetic toxicology. The measurement of H2AX has been suggested 
as a complementary tool to the existing battery of genetic toxicology tests, more specifically 
as a pre-screening assay based on the high throughput given by scoring systems such as flow 
cytometry, in cell western immunoblotting and High Content Screening (HCS) (Smart et al., 
2011; Audebert et al., 2010; Garcia-Canton et al., 2012). Chapter I of this PhD dissertation 
reviews the mechanisms of H2AX phosphorylation and the relevance of H2AX as a novel in 
vitro genotoxicity assay in the context of current in vitro genotoxicity tests both regulatory 
and non-regulatory. 
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The experimental design for measuring H2AX in vitro requires the selection of a cell system 
taking into consideration route of exposure and metabolic requirements. In this PhD 
dissertation, the in vitro H2AX assay by HCS is planned to be applied to the evaluation of 
cigarette smoke which is known to be a major cause of lung cancer and contributes to other 
diseases including cardiovascular and respiratory related diseases. Some cigarette smoke 
constituents such as Benzo[a]pyrene (B[a]P) are not genotoxic per se, but can be metabolized 
by tissue specific enzymes such as cytochromes P450 (CYPs) into reactive species. These 
compounds are known as pro-toxicants. Therefore, the metabolic capability of the selected 
cell system needs to be characterised to ensure that pro-toxicant compounds are correctly 
evaluated.  
Here, the human lung-derived BEAS-2B cell line was selected as the cell system. This cell 
line was established by Reddel and colleagues from normal bronchial epithelial cells that 
were immortalised by a replication-defective 12-SV40/adenovirus hybrid (Reddel et al., 
1988). When measuring H2AX, cell lines derived from normal tissues, such as BEAS-2B 
cells, are considered to be more reliable than those from pre-malignant and cancer tissues. 
For instance, it has been reported that some tumorigenic cell lines can be defective in key 
functions including DNA damage repair mechanisms and lack normal cell cycle regulation 
(Hanahan and Weinberg 2000). Malignant cell transformation could affect the H2AX 
response, for instance, there have been reports showing significant amount of H2AX in the 
absence of DNA DSBs, possibly as a response to “oncogenic stress” (Svetlova et al., 2010). 
Moreover, the organ of origin of this cell line is of special interest in the evaluation of 
compounds since the primary target is the lung. This is the case of cigarette smoke, pollutants 
and nanomaterials among others (Ansteinsson et al., 2011; Veljkovic et al., 2011). However, 
the metabolic capabilities of the BEAS-2B cell line needed to be further characterised to 
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support robust experimental design for pro-toxicant bioactivation. The metabolic 
characterisation of the BEAS-2B cell line is detailed in Chapter II of this PhD dissertation.  
Following our assessment of the BEAS-2B cells, we concluded that limited cytochrome P450 
enzyme activity could be detected in BEAS-2B cells compared to normal lung-tissue. To 
avoid an incorrect evaluation of pro-toxicants, a standardised external source of metabolic 
activation was incorporated in the experimental design of the in vitro H2AX assay 
development as recommended in testing guidelines (ICH, 2011). The assay development 
included an automated microscopy-based scoring system referred to as High Content 
Screening (Bickle 2010). Other alternative automated screening systems previously used to 
measure H2AX include flow cytometry (Smart et al., 2011) and In Cell Western a multi-
well plate based immunoblotting (Audebert et al., 2010). A panel of 22 positive and negative 
compounds used in previous genotoxicity assay assessments (Hastwell et al., 2006) and 
recommended by the European Centre for the Validation of Alternative Methods (ECVAM) 
were selected. The sensitivity, specificity and accuracy of the assay by HCS were calculated 
following recommendations published by an expert group (Kirkland et al., 2008). The 
selected panel included compounds with different known mechanisms of action, such as pro-
toxicants, aneugens and non-genotoxic compounds. The in vitro H2AX assay by HCS 
development and preliminary assessment is presented in Chapter III of this PhD dissertation. 
Following the completion of the H2AX assay performance evaluation with reference 
toxicants, we applied the H2AX assay to cigarette smoke toxicants and whole smoke 
exposure. Cigarette smoke is a complex mixture consisting of more than 5,600 identified 
compounds (Perfetti and Rodgman 2011). Estimations suggest that the whole mixture 
contains over 150 known toxicants (Cunningham et al., 2011), including compounds 
classified by IARC as “carcinogenic to humans” (Group 1) such as B[a]P and NNK (IARC, 
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2012a; IARC, 2012b). Experimental results obtained from complex mixture testing could be 
difficult to interpret as interactions between single components could affect the final outcome. 
Fractionation of the complex mixture into single components and simple mixtures could 
assist with the determination of key toxic drivers present in the cigarette smoke. The 
regulation of tobacco products from different organisations such as the Food and Drug 
Administration Center for Tobacco Products (FDA CTP) and the World Health Organisation 
Framework Convention on Tobacco Control (WHO FCTC) require sensitive and fast risk 
assessment tools that complement existing knowledge based mainly on in vivo data (WHO 
2008; FDA, 2012). The challenging task of pre-screening the in vitro genotoxicity potential 
of a large number of compounds individually and in simple mixture requires a high 
throughput assay with a simplified experimental design. This approach also supports the 
reduction in the use of animal models as recommended by the 3Rs approach (Schechtman 
2002). In this PhD dissertation, the newly developed in vitro H2AX assay by HCS was 
applied to the evaluation of the genotoxic potential of cigarette smoke toxicants (described in 
Chapter IV) and whole mainstream cigarette smoke (WMCS) (described in Chapter V). 
In Chapter IV of this PhD dissertation, we selected a number of cigarette smoke toxicants 
from the particulate phase to be tested in the novel in vitro H2AX assay by HCS. The 
polycyclic aromatic hydrocarbon B[a]P, the tobacco-specific nitrosamines (TSNAs) 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and  N-nitrosonornicotine (NNN) and 
the heavy metal cadmium were all tested individually whereas the TSNAs were also tested in 
binary mixture. The first three toxicants are recommended for mandated lowering while the 
last one is recommended for monitoring by the WHO FCTC (WHO 2008).     
The in vitro H2AX assay by HCS was also optimised in Chapter V for the evaluation of 
aerosols at the air-liquid interface. This methodology is considered more physiologically 
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relevant for the evaluation of WMCS as cells are directly exposed to the complex mixture of 
combusted tobacco (Phillips et al., 2005).  
In summary, this PhD dissertation describes the development, preliminary assessment and 
application of a novel assay for the detection of DNA damage using new technologies to 
automate the measurement of the response. Furthermore, the novel assay has demonstrated 
the potential to be further optimised and applied in the area of tobacco regulation as a tool to 
pre-screen large numbers of compounds and mixtures including aerosols.  
2.- OBJECTIVES 
 To characterise the metabolic capabilities of the lung-derived cell line BEAS-2B for 
its use in in vitro toxicology testing. 
 To determine whether the H2AX response can be measured in BEAS-2B cells by an 
automated microscopy-based system known as High Content Screening. 
 To assess the sensitivity, specificity and accuracy of the in vitro H2AX assay by 
HCS with a preliminary set of control compounds. 
 To determine whether the in vitro H2AX assay by HCS can be applied to the 
evaluation of cigarette smoke toxicants individually and in binary mixture. 
 To investigate whether the in vitro H2AX assay by HCS can be further developed 
and adapted to aerosol exposure. 
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3.- MATERIALS AND METHODS 
3.1.- Cell Lines 
The human bronchial epithelial cell line (BEAS-2B), was purchased from ATCC (United 
States). Cells were maintained in Bronchial Epithelial Growth Medium (BEGM®) at 37°C 
and 5% CO2 in a humidified incubator (Lonza Group Ltd., Belgium).  
The human type II alveolar adenocarcinoma-derived (A549), was purchased from ATCC 
(United States). Cells were maintained in Dulbecco’s modified Eagle medium  supplemented 
with fetal bovine serum (10% v/v), L-glutamine (2 mM), penicillin (50 U/mL) and 
streptomycin (50 µg/mL) (complete DMEM) at 37°C and 5% CO2 in a humidified incubator. 
The hepatocarcinoma-derived (HepG2) cell line was purchased from ATCC (United States). 
Cells were maintained in Dulbecco’s modified Eagle medium  supplemented with fetal 
bovine serum (10% v/v), L-glutamine (2 mM), penicillin (50 U/mL) and streptomycin (50 
µg/mL) (complete DMEM) at 37°C and 5% CO2 in a humidified incubator. 
The human hepatocarcinoma-derived cell line (HepaRG) was purchased as a differentiated 
confluent monolayer from Biopredic International (France). Cells were maintained in basal 
medium supplemented with recovery mix for 24 hours followed by basal medium 
supplemented with maintenance/metabolism mix. Media and supplements were provided by 
the manufacturer (Biopredic, France). 
BEAS-2B, A549 and HepG2 cells were cultured and expanded in-house. Experiments were 
performed between passages 3 and 12 only. All cultures were negative for mycoplasma. 
Additionally, the cells were authenticated using the short tandem repeat profiling to confirm 
the nature of the cell cultures (LGC Standards, United Kingdom) (Nims et al., 2010). 
 
 
41 
 
3.2.- Methodologies 
3.2.1.- Metabolic characterization of BEAS-2B cells 
Gene expression: A panel of 47 phase I and phase II enzyme-encoding genes was examined 
using qPCR in BEAS-2B, A549 and HepG2 cells in the presence and absence of the inducer 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD). HepaRG was examined in the absence of 
inducer. 
Enzyme activity assays: Activity profiles were generated for four cytochrome P450 enzymes 
involved in the metabolism of some cigarette smoke toxicants. CYP1A1/1B1 activity was 
assessed with the P450-Glo™ assay after induction with TCDD. CYP2A6/CYP2A13, 
CYP2E1, and CYP1A2 were assessed by UPLC-MS/MS with the enzyme-specific substrates; 
coumarin, chlorzoxazone, and ethoxyresorufin respectively. These methods were used in 
Chapter II. 
3.2.2.- Detection and quantification of H2AX in BEAS-2B cells by immunostaining 
H2AX as a marker of DNA DSBs was identified by immunostaining using a fluorophore-
coupled γH2AX-specific antibody. Fluorescence intensity was detected and measured with 
the Cellomics Arrayscan® VTI platform (Thermo Scientific, USA), then analysed with the 
Target Activation Bioapplication software V.6.6.1.4. 
When testing pro-toxicants, the external source of metabolic activation used was Aroclor-
1254 induced rat liver homogenate supernatant with cofactors (S9 mix) (Moltox, USA). S9 
mix is one of the standard systems employed as an external source of metabolic activation in 
current regulatory in vitro assays.  
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The acceptance criteria described for the in vitro H2AX assay by flow (Smart et al., 2011) 
were applied to the results from the in vitro H2AX assay by HCS to evaluate the relevance 
of using the same approach (Table 1). 
Table 1: Genotoxicity evaluation criteria for the in vitro H2AX assay, adapted from (Smart et al., 
2011). 
H2AX response Classification 
> 1.5-fold H2AX @ RCC > 25% Genotoxic (+) 
< 1.5-fold H2AX @ RCC 100-0% Non-genotoxic (–) 
> 1.5-fold H2AX @ RCC < 25% “False” positive; Cytotoxic-driven genotoxicity (C) 
= 1.5-fold H2AX @  RCC ≥ 25% Equivocal (±) 
This methodology was applied in Chapters III, IV and V. 
3.2.3.- Aerosol exposure optimisation 
The aerosol exposure optimisation used the Borgwaldt RM20S® smoking machine (RM20S) 
as the engine to generate WMCS. Cells grown on porous Transwell™ inserts were exposed 
for 3 hours to a range of WMCS dilutions in air from two reference cigarettes. Reference 
cigarette 3R4F is a “US style” blended cigarette that delivers 9.4 mg tar and 0.7 mg nicotine 
under the International Standard Organisation (ISO) conditions for cigarette smoking (ISO 
3308:2012). Reference cigarette M4A is a flue cured cigarette that delivers 10 mg of tar and 
1.0 mg nicotine under ISO smoking conditions (ISO 3308:2012). This optimisation is 
discussed in Chapter V. 
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4.- RESULTS 
4.1.- Chapter II - Metabolic characterization of cell systems used in in vitro toxicology 
testing: Lung cell system BEAS-2B as a working example 
We highlighted in the introduction the importance of metabolic activity in the bioactivation 
of some but not all toxicants. Therefore we profiled the expression of a panel of metabolic 
genes by qPCR and activity of selected cytochromes P450 in BEAS-2B cells.  
Gene Expression: qPCR analysis indicated limited gene expression in BEAS-2B cells, with 
the exception of CYP1A1, CYP1B1 and CYP1A2 which showed a significant up-regulation 
(25-, 5- and 4-fold, respectively) following pre-incubation with the CYP-inducer TCDD.  
Enzyme activity: TCDD-induced BEAS-2B cells showed a CYP1A1/1B1 activity of 0.2 
RLU/mg/min which is low compared to other metabolically competent cells. Conversely, no 
enzyme activity was observed in BEAS-2B cells for CYP1A2, CYP2A6/2A13 and CYP2E1.   
4.2.- Chapter III - Assessment of the in vitro H2AX assay by High Content Screening as 
a novel genotoxicity test 
A panel of 22 compounds with different known mechanisms of action were used to perform a 
preliminary assessment of the sensitivity and specificity of the in vitro H2AX assay by HCS. 
The assessment was also intended to determine if the genotoxicity evaluation criteria 
suggested by Smart and colleagues for the flow cytometry system could be employed with 
the HCS system. 
The preliminary assessment indicates that the in vitro H2AX assay by HCS has a high 
accuracy (86%) as a result of high sensitivity and specificity (86-92% and 80-88% 
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respectively). The results also confirmed that the criteria employed for the flow cytometry 
scoring system (Table 1) can also be applied to the HCS system. 
4.3.- Chapter IV - Genotoxicity evaluation of individual cigarette smoke toxicants using 
the in vitro H2AX assay by High Content Screening 
We next applied the H2AX HCS assay to known tobacco toxicants, including aromatic 
hydrocarbons, nitrosamines, and heavy metals, in order to evaluate the assay in the context of 
tobacco toxicology. B[a]P did not induce any increase in H2AX frequency above the 
vehicle-treated controls after 3 hour treatment in TCDD pre-induced or non-induced cultures. 
When B[a]P was tested for 24 hour, there was a significant increase in H2AX frequency in 
both TCDD-induced and non-induced cultures at concentrations above 0.5 µM. However, the 
H2AX frequency in non-induced cultures at concentrations above 4 µM after 24 hour 
treatment returned to vehicle-treated levels (< 1.5-fold induction).  
Cadmium chloride produced a positive response after 3 hour treatment at concentrations 
above 250 µM. After 24 hour treatment, concentrations above 16 µM showed cytotoxic-
driven genotoxicity. 
Both TSNAs, NNK and NNN, failed to show any statistically significant increase in H2AX 
compared to the vehicle-treated controls at all timepoints in the presence and absence of S9 
mix. When the reactive precursors NNK-acetate and NNN-acetate were tested, both produced 
an increase in H2AX frequency compared to the vehicle-treated control after 3 hour 
treatment,  at concentrations above 16 µM and 500 µM respectively. After a 3 hour treatment 
followed by 24 hour recovery period NNK-acetate induced a significant increase at 
concentrations above 125 µM, although NNN-acetate induced a dose-related increase in 
H2AX frequency, the results failed to reach the positive response threshold.  
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Treatments with 5 TSNA mixture permutations containing different ratios of the reactive 
precursors of NNK and NNN (NNK-acetate and NNN-acetate respectively) were performed 
for 3 hour at concentrations from 7.8 µM to 1000 µM. Treatment with 100% NNK-acetate 
produced a significant increase in γH2AX at concentrations above 31.25 µM while 100% 
NNN-acetate produced a significant increase only at the highest tested dose, 1000 µM. All 
other mixture combinations tested produced significant increases in H2AX levels at 
concentrations above 62.5 µM. The response induced by different ratios of tobacco specific 
nitrosamines suggests that NNK-acetate is the primary driver of the genotoxic response when 
present in a mixture with NNN-acetate. Neither synergistic nor antagonistic effects were 
observed in this study using CYP-independent NNK and NNN reactive precursors. 
4.4.- Chapter V - Characterisation of an aerosol exposure system to evaluate the 
genotoxicity of whole mainstream cigarette smoke using the in vitro H2AX assay by 
High Content Screening 
Novel tobacco products such as “heat not burn” cigarettes are emerging on the market with 
potential reduced toxicant exposure and risk claims. In the evolving tobacco regulatory 
context, claims regarding reduced exposure and risk have or will have to be substantiated 
according to specific national legislations. Therefore it is of interest to develop genotoxic 
assays such as the H2AX assay for aerosol exposure as opposed to single toxicants or 
toxicants in solution. Here, we tested the H2AX response following whole smoke exposure 
to two reference cigarettes with a range of smoke dilutions.  
Both reference cigarettes 3R4F and M4A produced a significant increase in H2AX 
frequency (above 1.5-fold increase) compared to the air-treated control in all the dilutions 
tested (1:500 to 1:16,000). While exposure to 3R4F WMCS produced a slight dose-related 
response, the same effect was not observed with M4A WMCS. Future work will require an 
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in-depth characterisation on the effect of product variations in H2AX induction to 
understand the differences in response.  
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5.- DISCUSSION 
Over the years, the genetic toxicology risk assessment paradigm has been moving away from 
animal based test methods (in vivo) towards in vitro test methods. For instance, in the 
cosmetic industry, the use of animal testing is banned by the EU 7th Amendment Directive 
(European Commission 2003). However, in many cases the current in vitro assays produce an 
elevated number of “false positive” results, a positive response in vitro that is not confirmed 
in vivo. The current frequency of “false positive” increases the need of follow up in vivo tests 
delaying the development of new products. As a consequence, over the last decade multiple 
efforts have been placed on the development and validation of new in vitro test methods by 
organisations such as the European Centre for Validation of Alternative Models (ECVAM) 
and the National Centre for the Reduction, Refinement and Reduction of Animals in 
Research (NC3Rs). 
In the process of new assay development we have to consider all the relevant characteristics 
that can make the novel test method worthy of use. Ideally, an assay has to be: 
i. Physiologically relevant: The cell system selected for the assay has to be relevant to 
the route of exposure, of human origin and needs to take into account the metabolic 
needs of the target tissue. 
ii. Accurate in the evaluation of compounds: The sensitivity (or ability to detect 
genotoxic compounds) as well as the specificity (or ability to discriminate non-
genotoxic compounds) have to provide an improvement over existing testing 
methods. 
iii. High Throughput: the assay has to utilise new techniques and technologies in order to 
provide a fast, inexpensive method that is reliable and reproducible over time. The 
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automation or potential for automation of the methodology would be an advantage, 
especially towards pre-screening. 
iv. Objective: the measure of the response will be more efficient if it can be carried out 
by a validated system rather than human operator. Also, the measure of the response 
by human operator is limited to qualitative (yes/no) rather than quantitative (a 
measured value). 
v. Applicable: the novel assay needs to have applicability in current research. 
Measuring H2AX has been extensively used as a biomarker of DNA DSBs since its 
discovery in 1998 (Rogakou et al., 1998). In the field of in vitro genetic toxicology, 
measuring H2AX has been suggested as a potential complementary assay to the existing 
battery, especially as a pre-screening tool. Even though, measuring H2AX is currently used 
extensively in research, limited studies have focused on the full assay development 
investigating the characteristics afore mentioned. The different chapters of this PhD 
dissertation have explored the characteristics required for the development of the in vitro 
H2AX assay by HCS. 
The human lung-derived BEAS-2B cell line was selected for its human source and tissue of 
origin. However, the results from the metabolic characterisation showed that there was a lack 
of activity in the majority of the cytochrome P450 enzymes evaluated compared to human 
normal lung tissue. The lack of metabolic competency could be mitigated by adding an 
external source of metabolic activation. In routine regulatory genotoxicity testing, Aroclor-
1254 induced rat liver homogenate supernatant with cofactors (S9 mix) is used as an external 
source of metabolic activation. Animal-derived S9 mixes are neither representative of the cell 
line species nor the target organ, but to date they are the most standardised option available. 
Human-derived S9 mixes are commercially available, yet, the phenotypic variations and 
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different environmental factors made these fractions unreliable for routine testing. As a result, 
Aroclor-1254 induced rat liver S9 was selected as the external source of metabolic activation 
for the testing of pro-toxicant compounds during the in vitro H2AX assay by HCS assay 
assessment. 
The in vitro H2AX assay by HCS preliminary assessment showed a high accuracy (86%) in 
detecting genotoxic compounds and discriminating non-genotoxic compounds, these results 
concur with previous evaluations using other scoring methodologies (Smart et al., 2011; 
Tsamou et al., 2012). Nevertheless, some limitations were observed during the 
developmental phase. The amount of S9 mix used for testing pro-toxicants could not reach 
the minimum recommended amount of 1% v/v due to intrinsic toxicity and therefore only 
0.5% v/v was employed. This reduction in the amount of S9 mix used could have caused the 
lack of positive response from 2-acetylaminoflurene, one of the four pro-toxicants tested in 
this study. Further assay optimisations could include a metabolically competent human-
derived cell line to better assess pro-toxicants. Generally, liver-derived cell lines are known 
to maintain a degree of metabolism, this is the case for HepG2 and HepaRG (Jennen et al., 
2010), however, these cell lines will sacrifice the route of exposure relevance in research 
where the target organ is the lung. Ideally, a metabolically competent lung-derived cell line 
needs to be developed, and the novel induced pluripotent stem cell (iPS) methodology may 
help with this issue in the long term.  
A second limitation was observed when aneugenic compounds were tested. Treatment with 
aneugens produced morphological changes in the cells as their cell cycle is arrested. The cells 
become more round and cell adhesion decreases producing an elevated loss of cells during 
the immunostaining process. The experimental design will need to be adjusted for the testing 
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of this family of compounds to ensure the cell adhesion is restored before the immunostaining 
process starts.   
Following the development and further optimisation of the in vitro H2AX assay by HCS, the 
novel assay was applied to the evaluation of cigarette smoke and a number of cigarette smoke 
constituents. The results showed that the in vitro H2AX assay by HCS can detect the 
genotoxicity effect of WMCS from two reference cigarettes with increments in the response 
up to 7-fold increases over the air-treated controls. The novel assay can also detect and 
quantify the genotoxicity effect of cigarette smoke toxicants both individually and in binary 
mixture showing potential as a tool to investigate the relative contribution of each toxicant to 
the whole tobacco smoke-related toxicity in this particular end-point of DNA damage. 
6. - CONCLUSIONS 
 The BEAS-2B cell line appears to lack cytochrome P450 enzyme activities relevant to 
the bioactivation of pro-toxicants. 
 H2AX can be detected and quantified in BEAS-2B cells by an automated 
microscopy-based system known as High Content Screeening. 
 The in vitro H2AX assay by HCS showed a high accuracy (86%) which results from 
a high sensitivity (86-92%) and a high specificity (80-88%). 
 The in vitro H2AX assay by HCS can be applied to the evaluation of cigarette smoke 
toxicants from the particulate phase both individually and in primary mixture. 
 The in vitro H2AX assay by HCS was successfully optimised for the genotoxicity 
evaluation of aerosols. 
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Chapter I 
H2AX as a novel endpoint to detect DNA damage: Applications 
for the assessment of the in vitro genotoxicity of cigarette smoke 
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ABSTRACT 
 
Histone H2AX is rapidly phosphorylated to become H2AX after exposure to DNA-
damaging agents that cause double-strand DNA breaks (DSBs). H2AX can be detected and 
quantified by numerous methods, giving a direct correlation with the number of DSBs. This 
relationship has made H2AX an increasingly utilised endpoint in multiple scientific fields 
since its discovery in 1998. Applications include its use in pre-clinical drug assessment, as a 
biomarker of DNA damage and in in vitro mechanistic studies. 
Here, we review current in vitro regulatory and non-regulatory genotoxicity assays proposing 
the H2AX assay as a potential complement to the current test battery.  
Additionally, we evaluate the use of the H2AX assay to measure DSBs in vitro in tobacco 
product testing. 
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1.- INTRODUCTION 
DNA damage can be caused by products from internal metabolism such as reactive oxygen 
species but also by a range of exogenous agents, from energetic radiations such as UV light to 
chemicals. There are multiple forms of DNA damage; DNA single-strand breaks (SSBs), 
DNA-DNA crosslinks or DNA–protein crosslinks or covalent binding to DNA bases, 
nucleotide substitution, DNA frameshifts, double-strand breaks (DSBs) etc. DSBs are one of 
the most deleterious lesions since they affect both strands of the DNA helix. This lesion can 
lead to cell death by triggering apoptosis but if the lesion fails to repair or it is repaired 
incorrectly, DNA information can be compromised leading to mutation and ultimately cancer 
and/or heritable damage  (Jeggo and Lobrich, 2007).  
Histones are highly conserved proteins which play a role not only in DNA packing but also in 
DNA repair and gene regulation. There are 5 families of histones: 1, 2A, 2B, 3 and 4. Histone 
2AX (H2AX) from the histone 2A family becomes rapidly phosphorylated (H2AX) at 
serine-139 in response to DSBs  (Rogakou et al., 1998). There are mechanisms that get 
activated after DNA damage has occurred to avoid genomic instability; they are known as 
DNA damage response (DDR). One of the earliest DDRs is the activation of H2AX as a 
result of a DSB. This response occurs within minutes of the damage, thus making it a useful 
marker of DNA damage. The description of events involved in this activation in mammalian 
cells leading to H2AX and beyond is a complex process that has been described in detail in 
previous reviews  (Riches et al., 2008; Paull et al., 2000; Fernandez-Capetillo et al., 2004; 
Cann and Dellaire, 2011; Bekker-Jensen and Mailand, 2010; Srivastava et al., 2009; Svetlova 
et al., 2010). 
Briefly, the earliest responding proteins are those of the phosphatidylinositol 3-kinase-like 
family of kinases (PIKK) including ataxia telangiectasia-mutated (ATM), ATM- and Rad3-
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related (ATR) and the catalytic subunit of DNA-dependent protein kinase (DNA-PKc). The 
proteins are activated by DNA damage and are rapidly recruited to the site of damaged 
chromatin. Once there, they phosphorylate the histone 2AX at serine residue 139 located at 
the C-terminal tail resulting in the formation of H2AX. However, to date it is still not fully 
understood how DNA damage is detected by the cellular machinery. Cann et al. suggested 
two models. The first postulates that changes in the chromatin structure following a DSB 
release topological constraints on the DNA helix that ultimately activate ATM. The second 
model, however, postulates that the MRE11-RAD50-NBS1 (MRN) complex in its task of 
keeping both ends of the broken DNA together is the critical DSB sensor but also the initial 
repair force, recruiting ATM to the site where it becomes activated  (Cann and Dellaire, 2011).  
Some investigations with cell lines deficient in DNA-PK and ATM showed a limited increase 
in H2AX phosphorylation after DSB damage  (Paull et al., 2000). The roles played by the 
PI3K enzymes are thought to be different depending on toxic stimulus or cell type  (Yan et al., 
2011; Riches et al., 2008).  
Either way, after the initial H2AX activation, a positive feedback loop is created between 
H2AX and the PIKKs for further DDR. The signal amplification acts as a repair signal 
calling for the repair systems to move to the location of the damage  (Nakamura et al., 2010). 
Within minutes of the damage occurring, H2AX can be detected in high quantities in the 
areas surrounding the DSB  (Rogakou et al., 1999). These areas are known as nuclear foci and 
could extend several megabases of chromatin around the site of damage (Riches et al., 2008). 
Multiple studies  (Cann and Dellaire, 2011; Xu and Price, 2011) suggest that H2AX foci 
formation is mainly limited to euchromatin considered transcriptionally active and moderately 
compacted. Heterochromatin representing the transcriptionally inactive and highly compacted 
chromatin could be inaccessible to phosphorylation or more resistant to DNA damage. One 
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could also hypothesise that DNA damage in the heterochromatin does not lead to genomic 
instability as there is no active transcription. Therefore, repair resources are not invested. 
The formation of nuclear foci in response to DNA DSBs differs from the formation of the 
“apoptotic H2AX ring” (Solier and Pommier, 2009). They demonstrated that H2AX ring 
staining is an early apoptosis indicator that precedes a global nuclear staining or pan-nuclear 
staining and apoptotic body formation. The main driver of this particular phosphorylation is 
DNA-PK in contrast to ATM and ATR associated with H2AX nuclear focus formation. This 
morphology variation could potentially be used to discriminate DNA DSBs from other forms 
of DNA damage. 
H2AX could also act as a cell cycle checkpoint  (Downey and Durocher, 2006). H2AX could 
become phosphorylated at any point during the cell cycle, including during mitosis while 
other DDR proteins are limited to interphase cells  (Nakamura et al., 2010). It has been 
suggested that DSB repair mechanisms may be suspended during mitosis. However, H2AX 
foci continue to form during mitosis. The foci act as indicators to activate the repair 
mechanisms as soon as the cell has finished the division process. If the DNA DSB occurs in 
G1, the cell cycle would stop to prevent the cell moving into S-phase with damaged DNA. 
Likewise, DNA replication could be slowed if the DNA DSB has occurred in S-phase, so that 
the repair mechanisms could act before the DNA polymerase reaches the damaged section. 
Finally, when the damage occurs in G2-phase, the cell is prevented from moving into mitosis, 
avoiding the fracture of chromosomes during anaphase and cytokinesis  (Jackson, 2002). 
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1.1.- Kinetics of phosphorylation  
Following the induction of DSBs, phosphorylation of the serine 139 residue starts within 
minutes, reaching a plateau at around 30 minutes after damage occurs  (Paull et al., 2000). 
The phosphorylation then decreases over a period of hours  (Rogakou et al., 1998).  
The mechanism of H2AX elimination has not been fully unravelled. There are multiple 
phosphatases involved in H2AX dephosphorylation. Dephosphorylation could occur directly 
on the chromatin or could happen after the histone has been displaced from the nucleosomes  
(Chowdhury et al., 2005; Redon et al., 2011a). Both mechanisms could potentially occur 
simultaneously, independent of the location of the H2AX in the foci. Other mechanisms 
mentioned by Bao involve histone chaperone proteins in the process of H2AX elimination  
(Bao, 2011). Experiments carried out by Keogh and colleagues suggest that the loss of 
H2AX could be triggered not only by DSB repair but also by the activation of steps that 
precede DSB repair  (Keogh et al., 2006). However, some of their results seem to indicate that 
H2AX loss is not mediated by single-stranded DNA resection, one of the cellular responses 
to DSBs.  
1.2.- Rationale for measuring γH2AX  
There are several reasons why H2AX is used to detect DSBs. The formation of H2AX is 
proportional to the amount of DSBs, giving a direct 1:1 correlation to existing damage  
(Sedelnikova et al., 2002). This correlation indicates that for every DSB one nuclear focus 
would be created. Moreover, H2AX is distributed throughout the mammalian chromatin and 
when it becomes phosphorylated it covers a large area of the chromatin producing the easily 
detectable nuclear foci  (Rogakou et al., 1999). The foci can be measured by different 
techniques in what is known as the H2AX assay to give an account of the DSBs. In addition, 
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this marker is conserved across eukaryotic evolution, giving the H2AX assay potential use 
not only in human studies but also in other organisms including plants  (Redon et al., 2011b). 
The standard battery of genotoxicity tests measure fixed DNA damage as their endpoint e.g. 
mutations in the Ames test  (OECD, 1997a) or chromosome damage in the in vitro 
micronucleus test  (OECD, 2010). However, measuring total DNA damage could provide a 
complement to the current tests. In general, DNA damage could produce genome instability or 
cell death. Mis-repaired DNA damage could lead to mutation and unrepaired DNA damage to 
chromosome breaks. Moreover, repeat DNA damage could saturate the cell repair system 
leading to accumulation of unrepaired lesions. The H2AX assay can provide an indication of 
DNA damage which can be used as a pre-screening tool or as a complement to the standard 
battery of genotoxicity tests  (Watters et al., 2009). 
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2.- CURRENT GENOTOXICITY TESTS 
2.1.- Regulatory Assays 
From the total number of assays described to measure genotoxicity in vitro, only a small 
number are accepted for regulatory purposes. These are deemed acceptable for estimating the 
genotoxic risks posed by compounds commercially employed for human use and thus are 
required by regulatory authorities. This group includes the Ames test, mouse lymphoma assay 
(MLA), the micronucleus and chromosomal aberration tests. These assays have been 
extensively validated and are accompanied by an Organisation for Economic Co-operation 
and Development (OECD) guideline describing the proper conduct of these tests. There is a 
wealth of literature available on each of these genotoxicity assays. Therefore, this section will 
only briefly describe each assay, its application and limitations.  
2.1.1.- Ames Test 
The Ames test  is a bacterial gene mutation assay widely used for its simplicity, accuracy and 
low cost  (OECD, 1997a). The assay measures the number of colonies formed after exposure 
to the test chemical. If the bacteria have suffered mutations, the frequency of colonies would 
be significantly higher than the frequency of colonies in the negative control cultures. This 
assay detects most tested genotoxic carcinogens with a high sensitivity. However, the Ames 
test sometimes fails to detect genotoxic compounds, primarily those that cause large DNA 
deletions or compounds that are non-DNA reactive (aneugens and carcinogens that have a 
non-genotoxic mechanisms). Other carcinogenic compounds that have a specific target in 
mammalian cells such as the cell division spindle apparatus or DNA polymerases and 
topoisomerases can also be mislabelled by the Ames test. Moreover, compounds such as 
antibiotics or bacteriocides cannot be tested adequately in the Ames test as they are toxic to 
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bacteria per se.  Additionally, false positives (i.e. non-carcinogens detected as mutagens) do 
occur in the Ames test. There are a small number of compounds that are Ames positive 
mutagens due to their bacterium-specific metabolism e.g. sodium azide and some nitro-group 
containing compounds  (Prival, 1983). 
The strains of Salmonella typhimurium used in the Ames test contain different mutations in 
various histidine synthesis genes (Table 1). The mutations carried by the specific strains 
prevent the bacteria from growing in media without histidine. However, if the test chemical 
mutates the defective mutation back to functional status (revert initial mutation), the bacteria 
will acquire the ability to grow in histidine-free media and form colonies. These colonies are 
thus known as revertants  (Ames et al., 1975).  
Table 1: Salmonella typhimurium strains with mutation gene  
Strain Mutated gene (allele) uvrB pKM101 Mutation 
TA97 hisD6610 No Yes Frameshift 
TA1537 hisC3076 No No Frameshift 
TA98 
hisD3052 
No Yes 
Frameshift 
TA1538 No No 
TA100 
hisG46 
No Yes 
Base substitution 
TA1535 No No 
TA102 
hisG428 
Yes Yes 
Base substitution 
TA104 No Yes 
 
All strains except TA102 are missing the uvrB DNA repair gene, thus removing the main 
error-free DNA excision repair pathway, compared to wild-type cells. This will amplify the 
mutations as DNA repair, in the absence of excision repair, occurs by error-prone pathways. 
TA102 bacteria strain maintains the excision repair system to be able to detect DNA cross-
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linking agents such as mitomycin C. Otherwise compounds with DNA cross-link mechanism 
of action will not be detected, as unrepaired cross-links are lethal to the cell.  
In addition, all strains have the mutation known as deep rough or rfa genotype. This is an 
alteration of the phenotype, where the polysaccharide capsule surrounding the cell is no 
longer present. Therefore, larger compounds are able to enter through the cell membrane 
reaching the bacterial DNA. 
Various strains possess the plasmid pKM101 which contains the operon muc. Enzymes 
encoded by this operon allow the damaged DNA to continue its synthesis. The effect of this 
operon is to amplify the translation of DNA damage to mutations. The plasmid also contains a 
gene coding for resistance to the antibiotic ampicillin. This ampicillin-resistant property 
permits the selection of mutants containing the plasmid. 
Alternatively, some Escherichia coli strains can be used to screen for mutagens. These strains 
have base change mutations in one of the tryptophan synthesis operon genes (trpE) instead of 
the histidine operon genes. Strains with and without the uvrA mutation are available as are 
strains with and without the plasmid pKM101. E. coli WP2 strains are equivalent to TA102 in 
terms of types of mutagen detected (including oxidative mutagens). However, if a cross-
linking effect is to be detected, then the E. coli strain must have an intact excision repair 
system. The rfa mutation is not required as E. coli cells are naturally permeable to larger 
molecules. 
Each strain of bacteria used in the Ames test detects a different spectrum of mutagens. 
Compounds are usually tested in multiple bacterial strains to understand the nature of their 
mutagenicity and also to broaden the range of mutagens detected (Table 1).  
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There are two types of mutations, base substitution or frameshift point mutations. A base 
substitution is a type of mutation where one nucleotide is replaced by another. As a 
consequence, a codon that will not code for any amino acid could be produced. This is also 
referred to as a nonsense mutation creating a stop codon which results in a truncated, 
incomplete or non-functional protein, when the relevant mRNA is translated. If the 
substitution leads to a codon that codes for a different amino acid then it is referred to as a 
missense mutation. Missense mutations do not always lead to marked protein changes but can 
give rise to non-functional proteins. Frameshift mutations are typically caused by loss or gain 
of a number of nucleotides that are not evenly divisible by three. As a result, the whole 
sequence will be modified from the point of mutation as the reading frame or sequence of 
codons will be changed. This in turn leads to a completely different translation.  
The bacterial mutation assays are normally carried out in the presence and absence of a 
surrogate for human liver activity such as rat liver S9 fraction. Liver S9 is obtained from 
animals treated with inducers of P450 enzymes required for phase I metabolism. Thus, 
compounds that are innocuous but which have DNA reactive metabolites can be detected. 
2.1.2.- Mouse Lymphoma Assay 
The mouse lymphoma LY5178Y TK assay (MLA) is a gene mutation assay used to assess the 
mutagenicity of chemicals  (OECD, 1997c). The principle of this assay is very similar to the 
Ames test, although in this case forward mutations are induced rather than reverse mutations. 
The selected mutation will cause the cell to be resistant to a toxic chemical.  Thymidine 
kinase-competent (TK+/+ or TK+/-) mouse lymphoma cells are treated with test chemicals, then 
the cells are transferred to selective media containing lethal analogues such as 
trifluorothymidine. Only cells that have mutated to TK-/- survive and form colonies. The loss 
of this specific enzyme does not cause any other deleterious effect to the cell. However, if the 
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mutation results from an extensive deletion causing the loss of essential genes, the cell will 
die and no colonies will form.  There are also genes close to the TK gene that are involved in 
cell growth, thus a deletion that removes these genes will result in a slow growing colony. 
This contrasts with point mutations within the TK gene, where a large mutant colony will be 
formed. By measuring the numbers of small mutant colonies that are induced after exposure 
to a test chemical, an assessment of clastogenicity can be obtained, as chromosome damage 
could result in deletions. By measuring the number of large mutant colonies, an estimate of 
induced point mutations can be obtained.  
In addition to the MLA, rodent cell lines such as Chinese hamster V79 cells, and Chinese 
hamster ovary (CHO) cells have also been used for mammalian cell mutation assays, 
measuring mutations in the hypoxanthine-guanine phosphoribosyl transferase (hprt) gene. 
Moreover, mutation of the TK gene can also be measured in the human lymphoblastoid cell 
line TK6. However, the MLA test is most commonly used as it detects both aneugens (non-
direct effect on DNA) and clastogens (direct effect on DNA). 
The current methodology includes the use of either a plate assay in soft agar or a liquid 
exposure in a 96-well microplate increasing the throughput. However, the scoring of the 
colonies has to be done manually by an operator, adding subjectivity to the process.  
Initially, the MLA assay was conducted using short treatments of 3 to 6 hours. However, the 
genotoxicity testing guideline from the International Conference on Harmonisation (ICH) for 
the registration of pharmaceuticals recommended a continuous treatment (24 hours) when 
there is a negative response in the short treatments in the absence of S9  (ICH, 2008). The 
longer treatments allow the cells to go through 1.5 to 2 normal cell cycles, ensuring that weak 
positive chemicals are readily detectable. Additionally, some evidence suggests that 
aneugenic compounds can also be detected with this longer treatment time  (Moore et al., 
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2002). However, Fellows et al. have recently advised against the use of MLA as a routine test 
to detect aneugens, as some of their tested compounds did not generate a positive response, 
while others only produced positive results at toxic concentrations  (Fellows et al., 2011).  
As with the Ames test, the MLA assay can be conducted in the presence of S9. However, S9 
can only be used in the short treatments as it is toxic per se when the cells are exposed for 
more than 3 hours. 
2.1.3.- Chromosomal Aberration Test 
The in vitro chromosomal aberration test is a cytogenetic assay that has traditionally been 
used to evaluate chromosome abnormalities and stability after chemical treatment  (OECD, 
1997b). The assay evaluates the karyotype in the first metaphase after a short (3-6 hours) and 
long (24 hours) treatment with test compounds. 
This assay is laborious and requires observational skills to score the different chromosome 
aberrations. These include chromosome and chromatid gaps and breaks and more complex 
rearrangements including chromosome fusions to produce dicentric chromosomes and 
exchange figures. Although many of these lesions are lethal to the cell, they are surrogates for 
stable chromosomal exchanges and translocations which are compatible with cell survival and 
are important in activation of oncogenes and, in some cases, deletion of tumour suppressor 
genes. The development of fluorescence in situ hybridization (FISH) has facilitated the 
identification of chromosome abnormalities. 
The in vitro chromosomal aberration test focuses primarily on structural aberrations. For this 
reason, carcinogens with a non-genotoxic potential will not be identified. Several cell types 
have been used routinely for these studies including human peripheral lymphocytes as well as 
various established Chinese hamster cell lines such as V79, CHO and CHL cells. 
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This assay can include an exogenous source of metabolic activation such as S9 for use with 
the shorter exposures. 
This test is not easily automated and the throughput is limited. However, there is imaging 
technology available to find and sort well spread metaphases for scoring, which significantly 
decreases the time needed to score experiments. Although an option in the international 
guidelines for genotoxicity testing, in general, this assay is beginning to be superceded by the 
in vitro micronucleus test, which has the advantage of detecting aneugens as well as 
clastogens more easily  (Lynch and Parry, 1993).  
2.1.4.- In vitro Micronucleus Assay 
The in vitro micronucleus assay is a cytogenetic test that measures genetic damage using the 
formation of micronuclei as an endpoint  (OECD, 2010). Micronuclei are small membrane-
bound structures that contain chromosome fragments or sometimes whole chromosomes that 
are not incorporated into either daughter nucleus. The majority of micronuclei contain DNA 
fragments giving a measure of chromosomal damage or clastogeniticy. The content of the 
micronuclei can be identified by adding an extra step in the standard method: Centromere 
immunostaining gives this assay the ability to identify aneuploidy when the micronucleus 
contains a whole chromosome  (Lynch and Parry, 1993). 
The micronuclei should be present in cells that have undergone at least one mitosis. 
Segregating the populations that have experienced mitosis was initially a challenge. This led 
to the development by Fenech of the cytokinesis-blocked micronucleus assay (CBMN) which 
uses cytochalasin B to inhibit membrane division after mitosis (karyokinesis)  (Fenech, 2007). 
This allows the scorer to identify which cells have undergone mitosis by counting the 
micronuclei present in binucleated cells (cells containing both daughter nuclei). 
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The micronucleus test shows fixed DNA damage in the form of chromosomal breaks or 
chromosomal loss but does not give an indication of total damage as some of the initial 
damage can be repaired or the cell can undergo apoptosis. The micronucleus test does not 
detect point mutations. For this reason, a mutation assay is always needed as a complementary 
test in genotoxicity test batteries. 
This assay can be performed in the presence of S9 to detect promutagens. However, S9 is 
only employed for the short treatments as it is toxic per se to mammalian cells in culture. 
The technique involved in this assay is much simpler than the chromosomal aberration test 
where the analysts require greater skills to prepare the metaphases and score the aberrations. 
However, a degree of subjectivity is associated with the manual scoring which also limits the 
throughput. Over the past few years, some automation methods for scoring micronuclei have 
gained acceptance, in particular flow cytometry (Lynch et al 2011).  
In a recent review,  Dearfield et al. compiled a list of all available genotoxicity assays and 
organised them into 4 categories based on their validation status, strengths and weaknesses  
(Dearfield et al., 2011). Table 2 below details the assays contained in their “category one” 
also known as regulatory assays comprising of assays that are well-characterised and have an 
issued OECD guideline and are currently used for regulatory purposes. 
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Table 2: In vitro genotoxicity regulatory assay. Adapted from (Dearfield et al., 2011). 
Assay Endpoint Strengths Limitations Opportunities 
Ames bacterial 
reverse 
mutation assay 
 
 
 
Gene mutations (point mutations 
including base pair substitutions 
and frameshift mutations) in 
bacterial cells. 
Commonly used, well validated, 
inexpensive, recognized guideline, ability 
to differentiate frameshift and point 
mutations (different bacterial strains). Can 
be conducted both with and without 
metabolic activation. 
Prokaryotic (bacterial specific); does 
not detect clastogens. 
Use as high throughput 
screening test.  
(Jacobson-Kram and 
Contrera, 2007) 
In vitro mouse 
lymphoma 
L5178Y tk+/- 
assay 
 
 
 
Gene mutations (point mutations 
including base pair substitutions 
and frameshift mutations) in 
mammalian cells. Can also detect 
various sizes of chromosome 
deletions, mitotic recombination, 
chromosome rearrangements, and 
some aneugens 
Can detect point mutation inducers, 
clastogens and some aneugens.  
Can be conducted both with and without 
metabolic activation. 
Use of positive controls for colony 
sizing essential for quality control. 
Colony sizing required to distinguish 
between point mutation or clastogen 
endpoints. Evaluation and 
interpretation changed over the years. 
Recent protocol updates recommended. 
Cytotoxicity (necrosis and apoptosis) 
needs to be controlled to avoid false 
positive results 
Recent protocol updates 
recommended (adjusted 
Relative Total Growth 
and Global Evaluation 
Factor), might improve 
data interpretation.  
(Moore et al., 2002; 
Moore et al., 2007) 
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In vitro gene 
mutation assay 
in mammalian 
cells (excluding 
mouse 
lymphoma 
assay) 
 
 
 
Gene mutations (point mutations 
including base pair substitutions 
and frameshift mutations) in 
mammalian cells (e.g. hprt). Can 
also detect various sizes of 
chromosome deletions when 
autosomal gene (e.g., in AS52 
cells) is used; hprt locus assay can 
detect some deletions, though not 
very efficiently. 
Detects gene mutation in mammalian 
cells without confounding chromosome 
damage when non-autosomal genes are 
used 
Can be conducted both with and without 
metabolic activation. 
Currently infrequently used but may be 
used more in future (e.g. REACH, 
interest in in vitro alternatives to in vivo 
testing),  
Chinese hamster cells considered by 
some to be insufficiently sensitive.  
Cytotoxicity (necrosis and apoptosis) 
needs to be controlled to avoid false 
positive results mammalian cells. 
For AS52 cell lines, can 
be used as alternative to 
metaphase analysis.  
In vitro 
chromosome 
aberration assay 
 
 
 
Structural and numerical 
chromosome damage in 
mammalian cells (i.e., 
clastogenicity and polyploidy). 
Detects clastogens and polyploidy 
inducers, including some aneugens.  
Some information on aneugenicity can be 
obtained with extended culture times.  
Applicable to different cell types, able to 
proliferate in culture. Provides 
information on the type of chromosome 
aberrations.  
Analysis made on individual cells.  
Can be conducted both with and without 
metabolic activation. 
Resource intensive and time consuming 
scoring of aberrations. Requires skilled 
scientists.  
Polyploidy provides suboptimal 
predictivity of aneugenicity. Limited 
number of cells evaluated. Cytotoxicity 
(necrosis and apoptosis) needs to be 
controlled to avoid false positive 
results. 
FISH/chromosome 
painting can provide 
additional mechanistic 
information.  
In vitro 
micronucleus 
Structural and numerical 
chromosome damage in 
Can detect both aneugens and clastogens.  
Rapid and easy to conduct.  
Resource intensive and time consuming 
scoring of micronuclei.  
Mechanistic studies: can 
be used with and without 
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assay  
 
 
 
mammalian cells (i.e., 
clastogenicity and aneuploidy). 
Applicable to different cell types that can 
proliferate in culture. Analysis made on 
individual cells.  
Can be conducted both with and without 
metabolic activation. 
Does not distinguish complex 
rearrangements and chromosome 
breaks. Cytotoxicity (necrosis and 
apoptosis) needs to be controlled to 
avoid false positive results. 
FISH analysis of 
centromeres to 
differentiate clastogens 
from aneugens. Can be 
used for screening assay. 
Potential for automation, 
e.g. flow cytometry, 
image analysis.  (Kirsch-
Volders et al., 2011) 
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The Ames test is considered to have high specificity, with a low frequency of false positive 
results with non-carcinogens. However, the sensitivity is limited because some carcinogens 
only show activity with eukaryotic cells. Additionally, compounds such as antibiotics or 
bacteriocides cannot be tested adequately in the Ames test as they are toxic to bacteria per se. 
False positives (i.e. non-carcinogens detected as mutagens) do occur in the Ames test. Those 
include compounds with bacterial-specific metabolism (e.g. sodium azide) and some nitro-
group containing compounds which will not produce a harmful effect in mammalian cells. 
Therefore, in vitro mammalian assays are required to generate a complete safety assessment 
of genotoxicity potential  (Kirkland et al., 2007a). 
Unfortunately, the established in vitro mammalian cell tests produce an unacceptable rate of 
false positives  (Kirkland et al., 2007b). For this reason they are defined as low specificity 
assays, and several causes are thought to be responsible for this lack of specificity. Many of 
the cell systems used for these assays are deficient in DNA repair mechanisms. In addition, 
genetic drift occurring during repeated subculturing can make them artificially prone to 
genetic damage. The high rates of false positives are also increased by the current guidelines 
requiring very high test concentrations of up to 10 mM or 5000 µg/mL. Furthermore, 
guidelines require top concentrations to elicit high levels of cytotoxicity of 50% or even 
higher (90% for the MLA). These conditions can result in the appearance of genetic damage 
that is unrelated to the inherent genotoxicity of the test compounds themselves. Moreover, the 
use of different cytotoxicity measures such as relative cell counts (RCC), relative population 
doubling (RPD), and mitotic index (MI) among others, could lead to different cytotoxicity 
results  (Kirkland et al., 2007b; Greenwood et al., 2004). Kirkland showed that, by using 
different cytotoxicity measures, the same compound could give a positive or negative 
response at the maximum level of toxicity (50%) in the in vitro micronucleus test  (Kirkland, 
2010). 
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Finally, the in vitro assays only have the inherent ability to detect mutagens and carcinogens 
but they cannot detect the metabolites produced by hepatic metabolism from compounds 
known as promutagens or procarcinogens. To cover this deficiency, the majority of the assays 
require an exogenous metabolic source, such as rat liver S9 fraction from animals treated with 
inducers of P450 enzymes. However, S9 is deficient in detoxification phase II enzymes (and 
no co-factors for these enzymes are included in the S9 mix) giving rise to a high level of 
metabolites which may be irrelevant to in vivo systems. Alternatively, some mammalian cell 
tests can use genetically modified cell lines with some degree of metabolic capability like 
engineered Chinese hamster V79 cells or can be co-cultured with primary hepatocytes  
(Kirkland et al., 2007b; Pfuhler et al., 2011; Dearfield et al., 2011). 
2.2.- Non-regulatory Assays 
The current mammalian in vitro genotoxicity assays have a high rate of positive results that do 
not translate into positive rodent carcinogenicity results. This raises the concern that these in 
vitro assays are overly sensitive and therefore generate false positives  (Dearfield et al., 2011; 
Kirkland et al., 2007b). Some companies use non-regulatory assays as early screening tools  
(Jacobson-Kram and Contrera, 2007). 
Recently, Lynch et al. have reviewed the status of new and emerging technologies, comparing 
them with the current battery of genotoxicity tests  (Lynch et al., 2011). These tests do not yet 
have an accompanying OECD guideline, or not enough data has been collected to fully 
establish them (trials, validations). This group of assays includes, for example, the comet 
assay, GreenScreen assay and the H2AX detection assay. These assays are classified as 
replacements or improvements of the traditional genotoxicity assays, forming a new approach 
to replace traditional assays or providing mechanistic understanding complementary to the 
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traditional assays. Subcategories to classify these assays have been defined by experts in the 
field and are described as mature, maturing and emerging  (Lynch et al., 2011).   
Mature refers to methods or technologies that have been in the field for a relatively long time 
and are amongst those tests that are likely to become accepted in the foreseeable future. 
However, these are still not yet fully accepted by regulatory bodies. One reason for this lack 
of acceptance is the need for generating more data by comprehensive validation exercises. 
This category includes, for example, the comet assay, and in silico technologies for 
genotoxicity prediction based on chemical structure-activity relationships (SARs) etc. 
Maturing refers to those methods or technologies that have proved to add value to the existing 
methods but have not yet gone through an extensive validation exercise. Maturing assays are 
the novel GreenScreen assay and yeast DEL assay. Additionally, this category also 
encompasses the automation of existing methods such as, for example, the development of 
flow cytometry to score in vitro micronucleus samples.  
Emerging refers to new technologies that are currently in development, i.e. they show 
interesting capabilities but require further testing/development. While the standard battery of 
genotoxicity assays looks at gene mutation or chromosomal damage and variation in 
chromosome numbers (aneugenicity), there are a number of promising new genotoxicity 
endpoints of interest related to DNA repair-related protein modification as a response to DNA 
damage, such as the histone phosphorylation to form H2AX, subject of this paper. Other 
genotoxicity approaches classified as emerging technologies are toxicogenomics, the use of 
humanised cell lines and Pig-a gene mutation assay among others  (Lynch et al., 2011). 
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2.2.1.- In vitro Comet Assay 
The in vitro comet assay or single cell gel electrophoresis assay is currently considered as a 
mature technology  (Lynch et al., 2011). The assay detects DNA damage in individual cells. 
The methodology employs a microgel electrophoresis technique at alkaline pH (pH>13). The 
measurements of the comet tails (DNA migration) after the cells are lysed gives an indication 
of the amount of DNA damage present in the cells  (Tice et al., 2000; Kumaravel and Jha, 
2006). It is a very sensitive assay. However, in the past the comet assay has shown a high 
variability caused mainly by physical factors such as temperature, and materials that generate 
variation not only in inter-laboratory but also in intra-laboratory comparisons. At this point, 
the method is still not fully optimised or validated, however, further research is still ongoing  
(Zainol et al., 2009).  
The comet assay can take advantage of existing software to score the comets. However, its 
throughput is limited. This assay does not require cell division. Therefore, a parallel 
assessment of the compound cytotoxicity would be needed to ensure the DNA damage is not 
caused by high toxicity  (Dearfield et al., 2011). 
This assay can use any eukaryotic cell or tissue and it has the versatility to be used in vitro 
and in vivo where it may be included in tests being carried out for other purposes such as a 
repeat dose general toxicology study. 
The addition of an external source of metabolic activation in the in vitro comet assay is 
possible if the selected cell system is not metabolically competent. 
2.2.2.- GreenScreen 
The GreenScreen assay, considered to be a maturing assay, is a completely new approach to 
genotoxicity evaluation. It uses the transcriptional response of the human GADD45a gene as a 
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marker of genotoxic stress. The gene for green fluorescent protein (GFP) is fused to the 
GADD45a promoter allowing a fluorescent signal to be generated when the GADD45a gene 
is induced following exposure to genotoxins. The host cell line is the human lymphoblastoid 
line TK6, which has the advantage of being p53-competent. This competency allows the cells 
to maintain genomic stability after genotoxic stress reducing the rate of false positives  
(Kirkland et al., 2007b; Lynch et al., 2011). 
This assay has initially been developed without the use of rat liver S9 in a multi-well 
microplate format, which allowed for a reasonable throughput in use  (Hastwell et al., 2006). 
After the initial development, it was further modified to include the use of S9 with flow 
cytometry scoring  (Jagger et al., 2009), although this resulted in a lower throughput.  
2.2.3.- Yeast DEL assay 
The Yeast DEL assay is another new approach to genotoxicity evaluation and is also 
classified as a maturing assay. The assay uses homologous recombination scoring for DNA 
deletion in the yeast Saccharomyces cerevisiae. The assay can detect carcinogens that act 
directly on the DNA (clastogens)  (Kirpnick et al., 2005). The methodology has been 
modified to support microwell plate use thereby increasing throughput  (Hafer et al., 2010). 
However, there are still concerns about the cell wall permeability of the yeast and the 
perceived relevance of the cell system  (Lynch et al., 2011). 
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3.- H2AX AS A NEW GENOTOXICITY ASSAY 
There are 2 major limitations to the current in vitro mammalian genotoxicity assays: 
o Low throughput: This is mainly linked to the manual scoring that limits large scale 
screening in terms of time. In the last few years, some technologies have been 
developed to increase the throughput. For example, automated flow cytometric 
analysis is used to score in vitro micronucleus samples  (Bryce et al., 2007). This 
methodology could potentially be used as a pre-screening tool while awaiting further 
validation, as detailed in a recent review  (Avlasevich et al., 2011).   
 
o High frequency of false positives: A large proportion of non-carcinogenic compounds 
produced positive results in at least one of the in vitro assays of the standard battery of 
genotoxicity tests  (Kirkland et al., 2007b). The relevance of those in vitro positives 
was not confirmed in the follow-up in vivo genotoxicity tests. This contributes to 
delays in drug development and an increase in animal use. Moreover, for the cosmetic 
industry, where animal testing is banned by the EU 7th Amendment Directive  
(European Commission, 2003), the effect of a false positive has serious consequences 
in potential loss of useful compounds.  
3.1.- Methods 
The H2AX assay could be of potential use in overcoming the 2 major limitations mentioned 
above. There are several methods for detecting H2AX and these have evolved to become 
simpler, quicker and more automated. 
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Initially, H2AX detection employed acetic acid-urea-triton and acid-urea-
cetyltrimethylammonium bromide polyacrylamide gel electrophoresis (aut-aucPAGE), a two-
dimensional gel analysis to detect the level of phosphorylated H2AX. Gels from untreated 
mammalian cell cultures were compared to gels generated using radiated cultures. The gels 
from the treated cells showed an additional shadowed area identified as a region containing 
the H2AX protein which migrates through the gel differently than non-phosphorylated 
H2AX  (Rogakou et al., 1998).  
However, after the initial development of this approach, immunocytochemical detection as 
described by Rogakou et al. became the primary method of detection, as it is several orders of 
magnitude more sensitive and has the potential for quantitation  (Rogakou et al., 1999),  
(Sedelnikova et al., 2002). This method is based on the use of a H2AX-specific monoclonal 
fluorophore-coupled antibody. Once H2AX presence has been detected by the antibody 
based method, the results can be quantified using various methods. These approaches have 
been discussed extensively in a previous review  (Bonner et al., 2008) and are summarised 
briefly below. 
3.1.1.- Immunofluorescence analysis  
A phosphospecific antibody is used to detect H2AX, the antibody does not bind to any non-
phosphorylated H2AX. This antibody can either be directly labelled with a fluorophore 
reporter or detected by addition of a secondary, fluorophore-labelled antibody. The stained 
H2AX can then be analysed by manual or automated scoring. 
Manual scoring: The stained cells are evaluated by eye using a fluorescence microscope. This 
method will only be able to give qualitative results, i.e. presence or absence of fluorescence. 
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Additionally, the number of foci per cell could be counted. This scoring method is considered 
very time consuming and has a high level of subjectivity  (Sedelnikova et al., 2002). 
Automated detection using a cell enzyme-linked immunosorbent assay (cell-ELISA): A 
peroxidase-conjugated secondary antibody substitutes the standard fluorophore-conjugated 
secondary antibody used in immunocytochemistry. The enzymatic reaction carried out by the 
peroxidase generates an amount of product that can be measured by absorbance. This 
absorbance measure would be directly proportional to the amount of H2AX present in the 
cells. This methodology has the advantage of high throughput technology. However, no 
measure of focus number per cell or distribution would be available  (Matsuzaki et al., 2010). 
A variation of this method consists of reading the infrared fluorescence dye from the 
secondary antibody directly on the microwell plate   (Audebert et al., 2010). 
o Automated scoring using flow cytometry: The flow cytometer uses a laser to 
detect the fluorescence per nucleus. This method will generate qualitative 
results based on measures of H2AX antibody present in the sample. However, 
the cells are destroyed in the process and no measure of focus number per cell 
or distribution is available  (Banath and Olive, 2003). 
 
o Automated scoring using high content screening (HCS): This qualitative 
method uses automatic microscopy to acquire cell images and image analysis 
software to measure different endpoints such as brightness, focus number per 
cell, distribution etc. This method generates and stores the images for future re-
scan or quality control check  (Kim et al., 2011; Hou et al., 2009).   
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3.1.2.- Immunoblotting analysis  
Here absolute amounts of H2AX protein are measured and compared to the total H2AX and 
H2A content. However, different cell types have different H2AX/H2AX and H2AX/H2A 
ratios yielding as a result different absolute amounts of H2AX for the same number of DSBs  
(Rogakou et al., 1998). 
Overall, microscopic analysis of H2AX is considered to be more sensitive than other 
methods such as flow cytometry  (Kim et al., 2011). Initial microscopy developments in this 
area were limited to manual scoring of the samples which is restrictive in terms of sample 
generation (slide vs microwell plate), operator time and subjectivity. 
New developments in the area of automated microscopy and image analysis software have 
increased the sensitivity of the results obtained by HCS. Additionally, the use of microplates 
and robotic systems has promoted the development of high throughput assays. Moreover, the 
use of software analysis allows objective quantitative scoring, avoiding operator subjectivity. 
The potential for multiplexing or evaluating various endpoints simultaneously is an attractive 
option as there would be a reduction in experimental time and resources. Therefore, from the 
current methods described above, HCS is considered a strong candidate for routine testing of 
H2AX.  
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4.- ASSESSMENT OF H2AX AS A GENOTOX ASSAY 
In the last decade, the use of H2AX to assess DNA damage has grown exponentially as 
demonstrated by the number of publications (Figure 1A). This growth comes as a 
consequence of the diversification of scientific fields where H2AX is used (Figure 1B). Initial 
studies were carried out in the field of radiation research, but once the relation between the 
phosphorylation of H2AX and DSBs was demonstrated  (Rogakou et al., 1998), the use of 
H2AX soon expanded to other areas.  
The initial methodologies supported experimentation focused on DNA damage and repair 
mechanisms  (Mukherjee et al., 2006; Marti et al., 2006; Celeste et al., 2003; Bassing et al., 
2003) to mention some. Other studies were orientated to assess the DNA damage potential of 
drugs, potency of chemotherapy agents and other medical materials  (Tanaka et al., 2006; 
Ansteinsson et al., 2011; Olive and Banath, 2009).  
Further optimisations in H2AX detection allowed the use of this indicator of DSBs as a 
biomarker  (Muslimovic et al., 2008; Cornelissen et al., 2011). For example, Muslimovic et al. 
used non-fixed blood cells from irradiation patients to develop a biomarker that could 
potentially lead to modulation of radiological treatment  (Muslimovic et al., 2008; Johansson 
et al., 2011). The clinical use of H2AX as a biomarker has been reviewed recently  (Redon et 
al., 2010). 
In the field of genetic toxicology, Albino et al. proposed the use of H2AX as a novel 
genotoxicity assay using flow cytometry  (Albino et al., 2004) and was soon followed by 
Gallmeier et al. recommending immunocytochemistry  (Gallmeier et al., 2005). Since then, 
multiple compounds have been tested in the H2AX assay to assess its utility as a 
genotoxicity assay (Table 3). Overall, H2AX is considered as a good marker of genotoxic 
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damage. Moreover, the large number of compounds tested by Smart et al. has shown the 
H2AX assay to be a sensitive and specific assay for the assessment of genotoxicity  (Smart et 
al., 2011). 
 
Figure 1: [A] Since its discovery as a DNA DSB marker in 1998 (arrow), the number of publications 
containing H2AX in the title/abstract has grown exponentially. Adapted and updated from  (Dickey et 
al., 2009). [B] Areas in which H2AX is studied as a marker of DNA damage. Taken from  (Redon et 
al., 2011b). 
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Table 3: Studies using well-characterised compounds to assess H2AX as a marker of DNA DSB damage. 
Year Detection Method Compounds Reference 
2005 Immunoblotting and Microscopy Norethindrone  (Gallmeier et al., 2005) 
2006 Microscopy Methyl methanesulfonate,  
N-ethyl-N-nitrosourea, benzo[a]pyrene,  
2-acetyl-aminofluorene, azathioprine, cyclosporine A. 
 (Zhou et al., 2006) 
2008 Microscopy Bleomycin  (Rakiman et al., 2008) 
2008 Flow cytometry Etoposide and mitoxantrone  (Smart et al., 2008) 
2009 Flow cytometry Etoposide, methyl methanesulfonate, bleomycin, ampicillin, sodium chloride  (Watters et al., 2009) 
2010 Microscopy and Immunoblotting* Benzo[a]pyrene,  
fluoranthene,  
3-methylcholanthrene 
 (Audebert et al., 2010) 
2010 Cell-ELISA Methyl methanesulfonate,  
N-ethyl-N’-nitro-N-nitrosoguanidine, 
mitomycin C,  
cis-diamminedichloroplatinum II, irinotecan hydrochloride hydrate, etoposide, 
methotrexate hydrate, 
5-fluorouracil, colcemid, 
vincristine sulfate salt,  
paclitaxel, griseofulvin, 
17-allylaminogeldanamycin,  
sodium dodecyl sulfate,  
 (Matsuzaki et al., 2010) 
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sodium chloride 
2011 Microscopy Doxorubicin, cisplatin,  
etoposide, camptothecin,  
bleomycin  
 (Kim et al., 2011) 
2011 Flow cytometry Cyclophosphamide, 
ethyl methane sulphonate, 
methyl methane sulphonate, 
n-butyl chloride, trimethyl ammonium chloride,2-acetylaminofluorene, 
2-aminoanthracene, 
5-chloro-o-toluidine, 
2,4-diaminotoluene, 
p-chloroaniline, 4-nitroquinolineoxide, 
p-nitroaniline, mitomycin C, 
glycidol, 1,2-propylene oxide, 
styrene oxide, benzo[a]pyrene, 
hydrogen peroxide, endrin, 
methyl nitrosourea, ethyl nitrosourea, dimethylbenz(a)anthracene, 
hydroquinone, phenanthrene, 
isobutyraldehyde, ethyl acrylate, D-mannitol, 
cyclohexanone, methyl carbamate, hexachloroethane, 
phthalic anhydride, resorcinol, 
propyl gallate, eugenol 
 (Smart et al., 2011) 
* Score in multi-well plate, no gel required. 
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Some cell systems used in in vitro toxicology testing are reported to have different 
deficiencies in their metabolism leading to incorrect evaluation of test compounds  (Kirkland 
et al., 2007a). These limitations could also affect the predictivity of the H2AX assay. To 
prevent this, study designs need to incorporate a metabolically competent cell system or, 
alternatively, an exogenous source of metabolic activation to detect pro-toxicants. These are 
compounds that have to be metabolically activated before their toxic form is active, a prime 
example being benzo[a]pyrene known as B[a]P (Figure 2). 
 
Figure 2: Activation of Benzo[a]pyrene (B[a]P) to Benzo[a]pyrene diol-epoxide (BPDE) by a Phase I 
enzyme from the cytochrome P450. BPDE binds to the DNA molecule creating DNA-adducts. 
Audebert et al. tested various polycyclic aromatic hydrocarbons (PAHs), such as B[a]P, in 
three different cell lines. They demonstrated that in HepG2, B[a]P can be oxidised and 
conjugated (Audebert et al., 2010), however, the metabolic competency of HepG2 has some 
limitations as discussed previously (Jennen et al., 2010).  The use of cell lines with metabolic 
capabilities has been previously recommended to improve the specificity without 
compromising the sensitivity of the method (Rueff et al., 1996; Kirkland et al., 2007b). 
An alternative approach to the use of cell lines with full or limited metabolic competency, is 
the introduction of an exogenous source of metabolism during the experimentation. The most 
commonly used is the hepatic S9 fraction or S9, liver microsomes from rats pre-stimulated 
with Aroclor1254 or phenobarbital/-naphthoflavone. This methodology is currently applied 
to the entire battery of regulatory tests, where S9 is added for short treatments (3 hours) due to 
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its toxicity  (OECD, 2010; OECD, 1997c). The same approach was followed by Smart et al. 
where mouse lymphoma L5178Y cells were used to assess H2AX induction after exposure 
to a panel of pro-toxicants in the presence of S9  (Smart et al., 2011). Alternatively, other 
sources of metabolic activation could be employed. Hepatic human microsomes could be used 
for a human-specific metabolism or a lung subcellular fraction for a more organ-specific 
metabolism. However, incorporating human material could increase the variability compared 
to the S9 from laboratory animals. 
The use of metabolically competent cell systems like HepaRG or human stem cells has also 
been discussed as an option to reduce the false positives produced by the higher activation 
capacity of the rat S9 fraction  (Kirkland et al., 2007b). 
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5.- APPLICATION OF H2AX AS A GENOTOXICITY ASSAY IN THE EVALUATION 
OF CIGARETTE SMOKE 
Cigarette smoke is a complex mixture consisting of a particulate phase and a vapour phase. It 
is estimated that the whole mixture contains approximately 5600 compounds  (Perfetti and 
Rodgman, 2011). Over 150 known toxicants are present in tobacco smoke (Cunningham et al., 
2011). Some of those compounds are known carcinogens, such as B[a]P, a PAH and 4-(N-
methylnitrosamino)-1-(3-pyridinyl)-1-butanone (NNK), a tobacco-specific N-nitrosamine. 
Both compounds  are classified by IARC as “carcinogenic to humans” (Group 1) (IARC, 
2012a; IARC, 2012b).  
Testing of complex mixtures is problematic as a small number of particular components can 
mask the effects of others, especially if they elicit high cytotoxicities. In addition, 
components can also act synergistically or act competitively, so the testing of mixtures can 
only give a global picture obscured by these factors. Fractionation of the different smoke 
components can assist determining of what the key toxic drivers in smoke may be. A global 
picture can also be used to compare smoke from different tobaccos, which may have different 
toxicities.  
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Table 4: Physical forms of cigarette smoke used in in vitro testing. Taken from  (Breheny et al., 
2011). 
Name Description 
Cigarette smoke condensate 
(CSC) 
Comprises the particulate phase along with some vapour phase 
components.  Generated by cold-trapping and condensation of smoke 
at extremely low temperatures.  The condensed ‘tar’ is then typically 
extracted and diluted using acetone. 
Cigarette smoke total 
particulate matter (TPM) 
Comprises the particulate phase only.  Particulates are collected by 
passing cigarette smoke through a Cambridge filter pad and are 
subsequently eluted using a solvent such as dimethylsulphoxide. 
Cigarette smoke extract 
(CSE) 
Comprises the particulate phase along with some vapour phase 
components.  Generated by bubbling smoke in a liquid (e.g. phosphate-
buffered saline or cell culture medium). 
Whole mainstream cigarette 
smoke (WMCS) 
Cells are directly exposed to smoke at the air-liquid interface.  This is 
the most representative of human exposure conditions, as cells are 
exposed to the gas and vapour phase components in an aerosol  
(Phillips et al., 2005). 
 
There are different mechanisms by which cigarette smoke carcinogens interact with DNA  
(Hecht, 1999). DNA adduct formation and oxidative DNA damage are mechanisms known to 
generate DSBs by acting directly on the DNA. Cigarette smoke has also shown to have 
aneugenic activity  (Van et al., 2008), an indirect-acting mechanism of genotoxicity. However, 
no single compound present in cigarette smoke has been classified as an aneugenic compound.  
Currently, the genotoxic potential of cigarette smoke is measured mostly using methods 
focusing on fixed DNA damage after acute exposures to different forms of cigarette smoke  
(DeMarini et al., 2008; Schramke et al., 2006; Van et al., 2008; Wolz et al., 2002; Nakayama 
et al., 1985; Johnson et al., 2009). There are also multiple clinical studies focusing on the 
genotoxic effects of cigarette smoke in humans  (Hruba et al., 2010; Laubenthal et al., 2011; 
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Chapman et al., 2011; Choudhury et al., 2008; Mondal et al., 2010). However, these clinical 
studies fall out of the scope of this review.  
Recent reviews described the different physical forms of cigarette smoke used in in vitro 
testing (Table 4) and the history of the collection of tobacco smoke for toxicology testing 
(Breheny et al., 2011; Johnson et al., 2009).  
De Marini  conducted a detailed review of the genotoxicity of tobacco smoke and tobacco 
smoke condensate (DeMarini, 2004). Overall, cigarette smoke condensate (CSC) and 
cigarette smoke total particulate matter (TPM) have been the main testing forms of cigarette 
smoke in vitro. The use of CSC or TPM for in vitro genotoxicity testing has the advantage 
that test material can be prepared as a concentrated stock solution in a compatible solvent 
(usually DMSO) and applied at a relatively high top concentration in a range of in vitro test 
systems, thus maximizing the potential to detect and quantify a genotoxic effect.  Resultant 
data can be normalized on a per milligram tar, per cigarette or per milligram nicotine basis, 
facilitating product comparisons (DeMarini et al., 2008).  However, it is also clear that such 
assays cannot assess the contribution that the vapour phase of cigarette smoke may make 
toward toxicity. Moreover, these exposure agents are not fully representative of human 
exposure as cells are not fully exposed to both the particulate and vapour phase components 
of the cigarette smoke. A number of whole smoke exposure systems are being developed to 
address these problems,  but have only recently entered a phase where dosimetric 
comparisons can be made and have not yet been validated.  Whole smoke exerts significant 
cytotoxicity and therefore precise exposure conditions need to be defined in order to detect 
specific genotoxic effects.  Of course the real key to definition of appropriate smoke exposure 
systems for toxicity testing is to understand the contribution of individual tobacco smoke 
constituents to the genotoxic effects (both singly and in combination) and to estimate their 
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concentration in tobacco smoke particulate and vapour phase fractions.  This understanding 
then facilitates the design of appropriate tobacco smoke exposure systems, focusing on key 
drivers of genotoxicity, facilitating product comparisons and providing a scientific rationale 
for any observed differences in genotoxic potential. 
To date, there are a limited number of studies using whole mainstream cigarette smoke 
(WMCS) in in vitro genotoxicity assays. WMCS was first used as a smoke exposure system 
in the in vitro micronucleus assay  (Massey et al., 1998; Okuwa et al., 2010). In addition, 
Aufderheide et al. developed a WMCS method to evaluate the mutagenicity of cigarette 
smoke in various bacterial strains in the Ames test  (Aufderheide and Gressmann, 2007; 
Aufderheide and Gressmann, 2008). To date, there is no published information of this 
exposure system in the MLA assay.  
In the field of non-regulatory assays, WMCS was used by Thorne et al. to measure oxidative 
DNA damage in the in vitro comet assay  (Thorne et al., 2009). Studies to measure the 
activation of H2AX in response to DNA damage in vitro after cigarette smoke exposure have 
also used CSC, TPM or cigarette smoke extract (CSE) as a smoke exposure system  (Albino 
et al., 2004; Albino et al., 2006; Tanaka et al., 2007b; Tanaka et al., 2007a; Luo et al., 2004; 
Albino et al., 2009; Zhao et al., 2009; Jorgensen et al., 2010; Darzynkiewicz et al., 2011). 
The in vitro H2AX assay was originally used to measure DSBs following cigarette smoke 
exposure  (Albino et al., 2004). Human A549 pulmonary adenocarcinoma cells were exposed 
to cigarette smoke and normal human bronchial epithelial (NHBE) cells to CSC. Both cell 
systems showed a dose-related response in H2AX activation. Once the relationship between 
smoke exposure and H2AX activation was confirmed, Albino et al. used the assay to 
evaluate cigarettes with different tar deliveries. The results indicated that the increment in 
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H2AX intensity was proportional to the estimated tar delivery rather than the cigarette type 
or smoking behaviour  (Albino et al., 2009).  
Interestingly, when Kato et al. evaluated the response of CSC in the commonly used CHO 
cell system without metabolic activation, they obtained a negative result  (Kato et al., 2007). 
However, Kato et al. synchronised the cultures to evaluate DSBs only in G1 phase. Direct-
acting genotoxic compounds in CSC may require metabolic activation in order to generate 
DSBs. Other indirectly acting genotoxic compounds in CSC would need the cell to progress 
through cell division to generate DSBs as these compounds interfere with cell division 
mechanisms. Further experiments would be needed to elucidate if the negative result was 
caused by the lack of metabolic activation, the synchronisation or both. 
Cigarette sidestream smoke (CSS) or environmental cigarette smoke has also been reported to 
generate a dose- and time-related H2AX induction in A549 cells (Toyooka and Ibuki, 2009). 
Additionally, a recent publication reported the induction of H2AX in A549 cells after 
exposure to smoke of tobacco- and nicotine-free cigarettes (T&N-free cigarettes) and a 
commercially available control cigarette (2R4F)  (Jorgensen et al., 2010). The results showed 
that T&N-free cigarettes produce a consistently higher induction of H2AX compared to 
2R4F. The results indicated that the driver for the H2AX increase is the tar as T&N-free 
cigarettes produced an average of 30.9 mg of TPM per cigarette while 2R4F generate around 
8.9 mg TPM per cigarette. This result concurs with the conclusions reported by Albino et al. 
that the H2AX intensity was proportional to the estimated tar delivery  (Albino et al., 2009). 
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6.- CONCLUSIONS  
Since its discovery in 1998, the phosphorylation of H2AX to H2AX has been used as a tool 
in multiple scientific fields, from the in vitro assessment of new drugs to a clinical biomarker. 
However, the main focus of this review is to collect the efforts of the last decade to 
demonstrate that the H2AX assay could be a potential complement to the current battery of 
in vitro genotoxicity tests. 
Furthermore, we have reviewed the applications of the H2AX assay in the in vitro evaluation 
of cigarette smoke, showing that the H2AX assay could unravel some of the DNA damaging 
effects of this complex mixture. 
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Chapter II 
Metabolic characterization of cell systems used in in vitro 
toxicology testing: Lung cell system BEAS-2B as a working 
example 
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ABSTRACT  
 
The bioactivation of pro-toxicants is the biological process through which some chemicals 
are metabolized into reactive metabolites. Therefore, in vitro toxicological evaluation should 
ideally be conducted in cell systems retaining adequate metabolic competency and relevant to 
the route of exposure. The respiratory tract is the primary route of exposure to inhaled pro-
toxicants and lung-derived BEAS-2B cell line has been considered as a potentially suitable 
model for in vitro toxicology testing. However, its metabolic activity has not been 
characterized.  
We performed a gene expression analysis for 41 metabolism-related genes and compared the 
profile with liver- and lung-derived cell lines (HepaRG, HepG2 and A549). To confirm that 
mRNA expression was associated with the corresponding enzyme activity, we used a series 
of metabolic substrates of CYPs (CYP1A1/1B1, CYP1A2, CYP2A6/2A13 and CYP2E1) 
known to bioactivate inhaled pro-toxicants. CYP activities were compared between BEAS-
2B, HepaRG, HepG2, and A549 cells and published literature on primary bronchial 
epithelium cells (HBEC).  
We found that in contrast to HBEC, BEAS-2B and A549 have limited CYP activity which 
was in agreement with their CYP gene expression profile. Control cell lines such as HepG2 
and HepaRG were metabolically active for the tested CYPs. We recommend that similar 
strategies can be used to select suitable cell systems in the context of pro-toxicant assessment. 
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1.- INTRODUCTION 
The need for in vitro cell systems as alternatives to animal models for toxicological testing is 
increasing in response to new regulations, such as the EU 7th Amendment Directive 
(European Commission 2003), and to ethical considerations like the 3Rs principle 
(Schechtman 2002). Due to their relative homogeneity and ability to be maintained in culture 
indefinitely, established cell lines have been one of the preferred cell systems employed in 
the development and validation of in vitro toxicology assays. Most continuous cell lines, 
however, have been derived from malignant or transformed tissue and fail to replicate the 
physiology and morphology of normal cells. Historically, hepatic cell lines have been 
thoroughly characterized, as they are the prime systems used for drug metabolism and 
toxicity testing in pre-clinical development (Guguen-Guillouzo and Guillouzo 2010; Brandon 
et al., 2003). For instance, the hepatoma cell line HepG2 lacks normal metabolic activity and 
has been engineered to express hepatic cytochrome P450 (CYP) enzymes (CYP3A4, 
CYP2E1) to study in vitro drug hepatotoxicity caused by compounds such as paracetamol 
(Yoshitomi et al., 2001). CYP3A4 and CYP2E1 catalyze the transformation of paracetamol 
into a highly reactive metabolite responsible for the tissue specific toxicity of the drug. This 
process of metabolic transformation of a chemical (pro-toxicant) into a toxic species is 
defined as bioactivation and is a key element in many toxicity studies. In contrast, many other 
cell lines used in toxicology, and in particular non-hepatic cells, have not been extensively 
characterized for their metabolic competency. The deficiencies in the metabolic capabilities 
of cell lines could lead to inaccurate evaluation of test compounds (Kirkland et al., 2007). 
This is the case for benzo[a]pyrene (B[a]P), a well-known tobacco smoke chemical that is 
ultimately metabolized to a diol-epoxide carcinogen by the inducible lung CYPs, 
CYP1A1/1B1. The formation of B[a]P DNA adducts has been reported in vitro using lung 
carcinoma-derived A549 cells (Feldman et al., 1978) but the role of CYP1A1/1B1 in the 
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formation of such adducts in A549 was not demonstrated at the time. In 2000, Hukkanen and 
colleagues reported the expression and inducibility of CYP1A1/1B1 in the A549 cell line but 
activity was not verified.  In 2008, Quinn established that CYP1A1 was not required in A549 
for the oxidation of B[a]P to its reactive form and that this reaction could be catalyzed by 
AKR1B10 (Quinn et al., 2008). However CYP1A1 activity was reported the same year by 
EROD assay after A549 induction (Billet et al., 2008). In contrast, in a comparison between 
CYP1A1/1B1 activity in A549 and HBECS Newland et al. showed that the CYP1A1 activity 
in A549 was limited when compared to a culture of human primary lung epithelial cells when 
incubated with a luminogenic probe substrate. Thus the mechanism of adduct formation in 
A549 can potentially follow multiple metabolic routes different than what would be expected 
in a normal lung epithelium. CYP2B6 activity has also been reported in A549 together with 
mRNA expression of CYP2D6, 2E1, 3A5, and CYP3A7, the latest is not expected to be 
present in normal adult tissue. Other key lung epithelium CYPs such as CYP2A6, CYP2A13, 
and CYP2F1 involved in the bioactivation of toxicants such as nitrosamines were not 
detected in this cell line. This example highlights the importance of characterizing the 
metabolic enzyme profile in cell lines used for toxicological evaluation, with the possibility 
to restrict such study to enzymes relevant to the metabolic pathway of specific toxicants. 
However, to date, there is no standard approach to metabolic characterization. Where some 
researchers focus on gene expression only (Jennen et al., 2010) others may combine gene 
expression with enzyme activity (Westerink and Schoonen 2007).  
The aim of our investigation was to describe an experimental strategy combining quantitative 
real time PCR (qPCR) and functional enzymatic assays applied to the lung-derived BEAS-2B 
cell line. Initially, we profiled the gene expression of a panel of oxidative and conjugative 
metabolism-related genes involved in xenobiotics metabolism, more specifically related to 
the toxicity of cigarette smoke to human lung (Hecht 2006). Next, we used a series of 
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metabolic substrates and inhibitors to test the enzyme activity of key CYP enzymes. The 
selection was made taking into account the relevance of the target organ and the nature of the 
test article. The human lung-derived BEAS-2B cell line was first described in 1988, when 
normal bronchial epithelial cells obtained from autopsy of non-cancerous individuals were 
isolated, then infected with a replication-defective 12-SV40/adenovirus hybrid and cloned to 
create an immortalized phenotype (Reddel et al., 1988). The non-cancerous phenotype of 
BEAS-2B cells is an advantage in the investigation of carcinogenic processes such as DNA 
damage and cell transformation (Sun et al., 2011). Therefore, BEAS-2B cells have been 
considered as a relevant cell line for in vitro toxicology testing in the field of pollutants, 
tobacco products and nanomaterials (Persoz et al., 2012; Veljkovic et al., 2011; Haniu et al., 
2011). Although, several studies have employed BEAS-2B cells to evaluate the effect of 
some pro-toxicants such as B[a]P and 4-(N-methylnitrosamino)-1-(3-pyridinyl)-1-butanone 
(NNK), the metabolic capacity of this particular cell line has not been fully characterized 
(Ovrevik et al., 2010; Proulx et al., 2005).  
Here, BEAS-2B cells were tested and compared to the lung-derived A549 cells broadly used 
as pulmonary in vitro system but with no cytochrome P450 expression reported for CYP1A2 
and the CYP2A family, and inducibility documented for CYP1A1/1B1 genes (Hukkanen et 
al., 2002; Castell et al., 2005). Cells derived from hepatocarcinomas considered to have a 
more extensive cytochrome P450 enzyme activity (HepG2 and HepaRG) were used as a more 
comprehensive control for our CYP assays (Jennen et al., 2010). Moreover, the results were 
contrasted to those reported in primary human bronchial epithelium culture (Newland et al., 
2011; Courcot et al., 2012). The results of this study are considered to be useful for in vitro 
toxicological testing using the cell line BEAS-2B as cell system. Furthermore, we propose 
that the outlined strategy can be incorporated in the characterization of cell systems used in in 
vitro testing.  
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2.- MATERIALS AND METHODS 
2.1.- Cell culture 
The human bronchial epithelial cell line (BEAS-2B), purchased from ATCC (United States), 
was seeded into culture vessels that had been pre-coated with 0.03 mg/mL PureCol® bovine 
collagen solution (Nutacon, The Netherlands). Cells were maintained in Bronchial Epithelial 
Growth Medium (BEGM®) at 37°C and 5% CO2 in a humidified incubator. BEGM® was 
prepared by supplementing Bronchial Epithelial Basal Medium with growth supplements 
provided in the manufacturer’s BEGM® SingleQuot® kit (Lonza Group Ltd., Belgium) 
containing: bovine pituitary extract, hydrocortisone, human epidermal growth factor, 
epinephrine, insulin, triiodothyronine, transferrin, gentamicin /amphotericin-B and retinoic 
acid. 
The human type II alveolar adenocarcinoma-derived (A549) and hepatocarcinoma-derived 
(HepG2) cell lines purchased from the Global Bioresource Centre (ATCC, USA), were 
maintained in Dulbecco’s modified Eagle medium  supplemented with fetal bovine serum 
(10% v/v), L-glutamine (2 mM), penicillin (50 U/mL) and streptomycin (50 µg/mL) 
(complete DMEM) at 37°C and 5% CO2 in a humidified incubator. 
The human hepatocarcinoma-derived cell line (HepaRG) was purchased as a differentiated 
confluent monolayer from Biopredic International (France). After shipment, the cells were 
maintained in basal medium supplemented with recovery mix for 24 hours followed by basal 
medium supplemented with maintenance/metabolism mix. Media and supplements were 
provided by the manufacturer (Biopredic, France). 
BEAS-2B, A549 and HepG2 cells were cultured and expanded in-house. Experiments were 
performed between passages 3 and 12 only. All cultures were negative for mycoplasma. 
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Additionally, the cells were authenticated using the short tandem repeat profiling to confirm 
the nature of the cell cultures (LGC Standards, United Kingdom) (Nims et al., 2010). 
2.2.- Gene expression assay 
BEAS-2B, A549 and HepG2 cells were plated in 12-well tissue culture plates, at 60% 
confluency. A total of 6 wells per plate were treated for 48 hours with 10nM of the 
CYP1A1/1B1 inducer 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD). HepaRG cells were not 
used as positive control cell line for CYP1A1/1B1, therefore, they were not pre-induced with 
TCDD.  
After 96 hours from seeding, total RNA was isolated from the cells using the RNeasy mini kit 
(Quiagen, United Kingdom). The RNA quantity was measured by using the NanoDrop 
ND1000 spectrophotometer (NanoDrop Technologies, USA) and the quality assessed with 
the Agilent 2100 Bioanalyzer (Agilent, United Kingdom). 
The RNA was converted to cDNA using the high-capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, United Kingdom). 
qPCR was carried out using custom TaqMan® array 96-well plates and TaqMan® Fast 
Universal Master mix (Applied Biosystem, United Kingdom). Each plate contained two 
assays with the probes of 1 manufacturing control, 5 endogenous controls and 41 
metabolism-related genes from both phase I and phase II (Table 1). qPCR amplification 
mixtures (20 µL) contained 2 µL of cDNA and 18 µL of fast master mix and were amplified 
using the fast PCR 7500 (Applied Biosystems, United Kingdom). The cycle conditions 
comprised 2 min at 50°C, 20 seconds at 95°C, then 40 cycles of 3 seconds at 95°C and 30 
seconds at 60°C. 
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Threshold cycle (Ct) values for the genes were normalised to RPLP0, and relative expression 
levels were calculated using the ΔΔCt method (Livak and Schmittgen 2001).  
Table 1: Panel of genes classified by phase of metabolism and function. Standard gene nomenclature 
taken from (HGNC, 2012).  
Controls Phase I 
Manufacturing 
Control 
Endogenous 
control 
Cytochrome P450 
Aldo-keto 
reductases 
Others 
RN18S1 GAPDH CYP1A1 CYP3A4 AKR1B10 EPHX1 
 
HPRT1 CYP1B1 CYP3A5 AKR1C1 CBR1 
 
GUSB CYP1A2 CYP2C9 AKR1C2 DCXR 
 
B2M CYP2A6 CYP2D6 AKR1C3 AOX1 
 
RPLP0 CYP2A13 CYP2E1 AKR7A3 FMO3 
  
CYP2B6 CYP2F1 
 
HSD11B1 
  
CYP2B7P1 
  
NQO1 
Phase II 
glutathione 
S-transferases 
UDP-
glucuronosyltransferase 
Others 
GSTA1 UGT1A4 SULT1A1 
GSTM1 UGT1A6 NAT1 
GSTP1 UGT1A7 COMT 
GSTT1 UGT1A1 
 
 
UGT1A8 
 
 
UGT1A9 
 
 
UGT1A10 
 
 
UGT2B7 
 
 
UGT2B10 
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2.3.- Cytochrome P450 enzyme activity assays 
Range finder experiments were initially carried out to select optimal concentrations for 
substrates, inducer and inhibitors where maximal activity, induction or inhibition were 
obtained without cytotoxicity. 
For the enzyme activity profiling, phenol free Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 0.5 mM L-Glutamine was used as a basal experimental medium. 
CYP1A1/1B1 activity was measured using the specific P450-Glo™ kit (Promega, United 
Kingdom). The probe used was Luciferin 6' chloroethyl ether (luciferin-CEE) (50 µM) added 
directly to the basal medium (0 and 4 hour incubation) of 3 wells per condition. For induced 
conditions, cultures were pre-incubated for 48 hours with 10nM of TCDD. For inhibited 
conditions, α-naphthoflavone (10 µM) was added to the basal medium 30 minutes prior to the 
probe. After the incubation, the luminescence was measured using a LMaxII® luminometer 
(Molecular Devices, United States). HepG2 cells were used as ‘positive control’. 
The measurement of CYP2A6/2A13 activity was based on the methodology described 
previously (Newland et al., 2011). The same methodology was adapted, including probes and 
inhibitors, for the measurement of CYP1A2 and CYP2E1 activities. A549 cells were used as 
‘negative control’ for CYP2A6/2A13 and CYP1A2, the status of CYP2E1 activity is 
unknown in A549. HepaRG cells were used as a positive control for CYP1A2 and 
CYP2A6/2A13. HepG2 cells were used as ‘positive control’ for CYP2E1. 
For the CYP1A2 activity assay, 7-ethoxyresorufin (20 µM) was used as a probe and 
fluvoxamine (100 µM) was used as inhibitor. The metabolite quantified was resorufin.  
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In the case of the CYP2A6/2A13 activity assay, coumarin (200 µM) was used as a probe and 
8-methoxypsoralen (8-MOP) (100 µM) as inhibitor. The metabolite measured was 7-
hydroxycoumarin. 
Finally, the CYP2E1 activity assay used chlorzoxazone (100 µM) as probe and disulfiram (20 
µM) as inhibitor. 6-hydroxychlorzoxazone was the metabolite quantified.  
After the probe incubations, 250 µL of basal medium was adjusted to pH 5.0 with 
hydrochloric acid and treated with 2.5 µL of β-glucuronidase from Helix pomatia for 18 
hours at 37°C while shaking. Once the glucuronidase treatment finished, 250 µL of methanol 
and the internal standard 4-methylumbelliferon (5 µM) was added to the solution. The 
metabolites where then quantified using an UPLC- AB SCIEX/API 4000 Q-Trap® mass 
spectrometer using the column Phenomenex Kinetex 2.6µm PFP, 100Å (Applied Biosystems, 
United States). 
Once all basal medium was removed, cells were lysed using Mammalian Protein Extraction 
Reagent (M-PER) lysate buffer (Thermo Fisher Scientific Inc., United Kingdom) and protein 
content was measured employing the bicinchoninic acid protein assay (BSA) together with a 
Multiskan Ascent® spectrophotometer (Thermo Fisher Scientific Inc., United Kingdom). 
Lactate dehydrogenase (LDH) release was used as a measure of cytotoxicy during the 
enzyme activity assays. The CytoTox-ONE® homogeneous membrane integrity assay 
(Promega, United Kingdom) was used following manufacture recommendations and analysed 
with a Fluoroskan Ascent® fluorometer (Thermo Fisher Scientific Inc., United Kingdom). 
The percentage LDH release is inversely proportional to the cell viability which was >85% 
for all treatments and timepoints. 
 
 
 
122 
 
2.4.- Gene expression data analysis   
After completion of the qPCR, the threshold cycle (Ct) values were visually inspected using 
the fast PCR 7500 software v.2.0.5. When required, the threshold setting default (0.2) was 
manually adjusted to ensure optimal sensitivity was maintained. All Ct > 36, indicative of the 
plateau phase of qPCR, were considered non-expressed genes.  
The Ct values were then normalized against the selected endogenous control gene to generate 
Ct values (Ctgene of interest – Ctendogenous control gene). 
2.5.- Statistical analysis 
All the experiments were repeated three times containing three replicates per condition and 
timepoint. 
GeneSpringTM GX11.5.1 (Agilent, United Kingdom) was used to perform the gene 
expression graphical and statistical analysis. Principal Component Analysis (PCA) and 
hierarchical clustering were selected for graphical representations. For the hierarchical 
clustering algorithm, Euclidean distance measured with average linkage was selected for 
interpretation of the normalized gene expression data (Ct). One-way ANOVA was used to 
analyse the effect of the TCDD induction on the expression of each gene. 
The enzyme activity data are represented by the arithmetic mean of three experiments + 
standard deviation (SD). Minitab v.16 was used to perform Student’s t-test. Difference was 
significant when p<0.05.   
 
 
123 
 
3.- RESULTS 
3.1.- Gene expression 
The first stage in the metabolic characterization was to quantify the mRNAs of a panel of 
enzyme-encoding genes involved in oxidative (phase I) and conjugative (phase II) 
metabolism. 
The endogenous control gene RPLP0 showed the most stable expression across the different 
samples and treatments (data not shown). Furthermore, RPLP0 has been reported as being 
highly conserved across tissues and species (Akamine et al., 2007). Therefore, RPLP0 was 
chosen for normalisation of data, generating Ct values (Ctgene of interest – CtRPLP0). 
PCA was used to visualise the dataset in a 3D scatter plot graph shown in Figure 1. This 
analysis demonstrated the segregation of cell lines based on their gene expression profile. The 
graph shows a clear separation of the different cell lines (represented by colours) indicating 
that the expression profile differs from cell line to cell line. In addition, only HepG2 cells 
show a variation between the induced (triangle shaped icon) and non-induced samples 
(rectangle shaped icon), while there is no apparent separation of the induced from the non-
induced BEAS-2B and A549 samples. HepaRG cells were not induced so Figure 1 only 
represents the basal gene expression levels. 
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Figure 1: 3D scatter plot representing principal component analysis (PCA) of qPCR data. Cell type is 
represented by colour - A549 (red), BEAS-2B (blue), HepG2 (maroon) and HepaRG (grey). Shaped 
icons represent induction status, triangle (▲) represents induced cultures and square () represents 
non-induced cultures. (Note: HepaRG gene expression was only measured in non-induced cultures). 
The hierarchical cluster shown in Figure 2 was generated to visualise the gene expression and 
induction profiles of each individual cell line. This graphical representation contained the 
expression value for each individual gene normalised (Ct values); red, blue and yellow 
indicate increased (positive Ct), reduced (negative Ct) and undetectable (Ct close to or 0), 
respectively. The details contained in the hierarchical cluster allowed a gene by gene 
comparison between induced and non-induced treatments but also, between different cell 
lines. This cluster analysis confirms the observations made above by PCA. Gene expression 
profiles in BEAS-2B and A549 cells do not show a significant difference between induced 
and non-induced samples. In contrast, the HepG2 profile shows some changes between 
induced and non-induced samples. However, there are many genes that are not differentially 
expressed. HepaRG cells show a high expression in the majority of the tested genes.  
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Figure 2: Hierarchical cluster representing the gene expression profiles of all four cell lines 
dependent on treatment (induced or non-induced). (Note: HepaRG gene expression was only 
measured in non-induced cultures). Columns represent individual samples and rows represent genes. 
Red, blue and yellow indicate high signal intensity, low signal intensity or no signal in normalised 
gene expression data (Ct), respectively. 
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To allow fine observations between TCDD-induced and non-induced samples, Ct data 
representing fold-changes in gene expression for BEAS-2B, A549 and HepG2 are detailed in 
Table 2. 
As expected, CYP1A1/1B1 were inducible across the three cell lines. In BEAS-2B cells, 
CYP1A2 also showed a degree of inducibility. However, no other gene studied in BEAS-2B 
cells shows a relevant up- or down-regulation.  
Table 2: Gene expression data represented as fold change comparing TCDD- induced with non-
induced cells. In red: genes with at least 2-fold increase in gene expression after induction (up-
regulated). In blue: genes with at least 2-fold decrease in gene expression after induction (down-
regulated). 
Gene ID BEAS-2B A549 HepG2 
Ph
as
e 
I 
CYP1A1 25.35  256.99  389.97  
CYP1B1 5.79  13.69  154.52  
CYP1A2 4.47  1.02  124.64  
CYP2A6 -1.06  1.05  -1.02  
CYP2A13 -1.05  -1.42  1.02  
CYP2B6 -1.05  -2.11  -1.22  
CYP2B7P1 -1.05  -2.11  1.18  
CYP3A4 1.02  -1.11  3.60  
CYP3A5 -1.62  1.36  20.43  
CYP2C9 1.02  -1.52  1.23  
CYP2D6 1.28  1.14  1.96  
CYP2E1 1.37  1.32  18.18  
CYP2F1 -1.05  -1.06  1.18  
AKR1B10 1.25  1.55  4.33  
AKR1C1;AKR1C2 1.21  -1.14  1.67  
AKR1C2 -1.05  1.44  1.10  
AKR1C3 1.63  1.04  -1.04  
AKR7A3 -1.15  1.28  -1.72  
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EPHX1 -1.01  -1.10  1.29  
CBR1 -1.02  -1.05  1.017  
DCXR -1.11  1.43  1.54  
AOX1 1.18  -5.51  1.34  
FMO3 -1.05  -1.35  1.18  
HSD11B1 1.02  -3.08  1.18  
NQO1 1.54  1.30  3.30  
Ph
as
e 
II 
GSTA1 -1.05  -1.35  -8.38  
GSTM1 -1.09  -1.06  1.18  
GSTP1 1.03  -1.02  87.66  
GSTT1 -1.05  -1.06  1.71  
UGT1A4 1.41  1.13  1.05  
UGT1A6 1.94  -1.15  8.17  
UGT1A7 -1.93  -1.34  1.05  
UGT1A1 1.29  1.82  8.51  
UGT1A8 -1.05  1.04  1.18  
UGT1A9 -1.12  -1.03  1.62  
UGT1A10 -1.47  1.31  1.72  
UGT2B7 -1.01  1.16  -1.26  
UGT2B10 -1.05  -1.28  -5.73  
SULT1A1 -1.17  1.09  1.13  
NAT1 -1.02  1.10  -1.72  
COMT -1.28  1.39  1.40  
 
3.2.- Enzyme activity 
The enzymatic activities of four cytochrome P450s enzymes involved in the oxidative 
metabolism of smoke toxicants were further evaluated in BEAS-2B, HepG2, HepaRG, and 
A549 cells to complement the gene expression data.  
Data represent the rate of metabolite formation in pmol/mg protein/minute, normalised to 
soluble protein, except for CYP1A1/1B1 where the metabolite is represented as a measure of 
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luminescence (RLU). Each experiment included data for the cell line intended for 
characterization (BEAS-2B), A549 and the ‘positive control’ cell line (Hep-G2 or HepaRG). 
Results in Figure 3A represent CYP1A1/1B1 enzyme activity. In the absence of TCDD, only 
background activity was detected for BEAS-2B (0.0470 RLU/mg/min±0.0082). In TCDD-
induced BEAS-2B, the activity levels increased 3.7-fold compared to non-induced cells 
(0.1740 RLU/mg/min±0.0317) and were inhibited in the presence of the CYP1A1/1B1 
inhibitor α-naphthoflavone. The activity increase in TCDD-treated cells was statistically 
significant with a p value <0.0001 and was consistent with the CYP1A1/1B1 mRNA 
induction observed in our gene expression data.  
HepG2 cells gave a high level of enzyme activity as expected from the positive control cell 
line following induction with TCDD. In contrast, A549 cells produced only background 
activity both in the presence and absence of the inducer TCDD (0.0284 and 0.0121 
RLU/mg/min respectively). 
The results observed for CYP2E1 enzyme activity (Figure 3B) showed no statistically 
significant difference in the levels of enzyme activity between BEAS-2B or A549 cultures 
treated in the absence or presence of inhibitor disulfiram (p=0.793 and p=0.222 respectively). 
The positive control cell line (HepG2), on the other hand, showed a significant reduction of 
enzyme activity in the presence of inhibitor (p=0.022).  
CYP2A6/2A13 oxidises coumarin to 7-hydroxycoumarin. The results presented in Figure 3C 
showed no statistically significant difference (p=0.741) in BEAS-2B CYP2A6/2A13 activity 
in the presence and absence of inhibitor 8-MOP. A similar profile was observed for A549 
cells. These results are in agreement with the lack of CYP2A6/2A13 mRNA expression 
(Ct>36). HepaRG cells (positive control cell line) showed a reduction in enzyme activity in 
the presence of inhibitor (p<0.0001).  
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Figure 3D represents the enzyme activity levels measured for CYP1A2. The results showed 
that the levels of activity detected in BEAS-2B cells were equivalent to those observed when 
the CYP1A2 inhibitor fluvoxamine was present in the cultures. These results concurred with 
the results obtained for CYP1A2 gene expression that indicate that without induction there is 
no expression of the CYP1A2 gene in BEAS-2B cells based on a Ct>36. HepaRG cells 
(positive control cell line) showed a reduction in enzyme activity (1.6-fold) in the presence of 
inhibitor, however, this reduction was not statistically significant (p=0.127). 
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Figure 3: Enzyme activity represented by metabolite formation. [A] Luciferin formation measured in 
BEAS-2B (a), A549 (c) and Hep-G2 (b) with and without induction with TCDD in the presence and 
absence of a specific inhibitor (α-naphthoflavone). Luciferin rate of formation is indicative of 
CYP1A1/1B1 activity when luciferin-CEE was used as a substrate. [B] 6-hydroxychlorzoxazone 
formation measured in BEAS-2B (a), A549 (c) and Hep-G2 (b) in the presence and absence of a 
specific inhibitor (disulfiram). 6-hydroxychlorzoxazone rate of formation is indicative of CYP2E1 
activity when chlorzoxazone was used as a substrate. [C] 7-hydroxycoumarin formation measured in 
BEAS-2B (a), A549 (c) and HepaRG (d) in the presence and absence of a specific inhibitor (8-MOP). 
7-hydroxycoumarin rate of formation is indicative of CYP2A6/2A13 activity when coumarin was 
used as a substrate. [D] Resorufin formation measured in BEAS-2B (a), A549 (c) and HepaRG (d) in 
the presence and absence of a specific inhibitor (fluvoxamine). Resorufin ratio of formation is 
indicative of CYP1A2 activity when 7-ethoxyresorufin was used as a substrate. CYP activities are 
expressed as the mean + SD of three independent experiments with triplicate samples. The asterisk (*) 
indicates a p<0.001.   
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4.- DISCUSSION 
The lung-derived cell line BEAS-2B has been identified as a cell line of interest in the in 
vitro toxicological testing of inhaled toxicants (Veljkovic et al., 2011; Ansteinsson et al., 
2011). However, to date the metabolic capabilities of this cell line have not been thoroughly 
investigated. In this study, we employed high throughput technology to provide a rapid 
screening for gene expression and inducibility for a panel of 41 metabolism-related genes, 
producing a profile of gene expression and gene inducibility. Then, four key CYP enzymes 
involved in the bioactivation of some smoke pro-toxicants were selected for functional 
enzyme activity assay. The data obtained from both analysis would confirm if enzyme 
activity was consistent with gene expression. The scientific approach used in this study is a 
working example of our proposed strategy for the metabolic characterization of cell systems 
used in the context of in vitro toxicology testing.  
Our gene expression results show that non-induced BEAS-2B cells have high and moderate 
mRNA expression for, GSTM1 and SULT1A1 respectively, both related to conjugative 
reactions which mainly act as detoxification mechanisms (Castell et al., 2005). As expected, 
when cultures were pre-induced with TCDD, CYP1A1, CYP1B1 and CYP1A2 genes showed 
an up-regulation of 25-fold, 6-fold and 4-fold respectively compared with non-induced 
cultures. The up-regulation of CYP1A1 and CYP1B1 genes after pre-incubation with TCDD 
has also been reported in normal human primary bronchial epithelium (NHBE) cells 
(Newland et al., 2011). Surprisingly, in a recent publication Courcot and colleagues report 
high levels of CYP1B1 gene expression in non-induced cultures of BEAS-2B cells and high 
levels of CYP1A1/1B1 gene expression in non-induced cultures of human primary bronchial 
epithelium cells (HBEC), among other lung cell systems (Courcot et al., 2012). This contrasts 
with our gene expression results and other published results (Newland et al., 2011; Castell et 
 
 
132 
 
al., 2005). It is possible that the high levels of CYP1A1 and CYP1B1 reported in HBEC by 
Courcot and colleagues could be as a result of the smoking habit of the donor; cigarette 
smoke is known to activate these enzymes in the lung (Nishikawa et al., 2004; Anttila et al., 
2011). However, this information is not disclosed in their methodology. In order to confirm 
the relevance of the gene expression, activity assessment is generally recommended as a 
follow up experiment. 
The gene expression results we obtained were compared with the enzyme activity data 
obtained for the tested CYPs (CYP1A1/1B1, CYP1A2, CYP2A6/2A13 and CYP2E1). When 
BEAS-2B cells were pre-incubated with TCDD, CYP1A1/1B1 activity showed a statistically 
significant increase compared to non-treated cultures (Figure 3A). This concurs with the gene 
up-regulation described earlier. TCDD-induced BEAS-2B cells showed an activity of 0.2 
RLU/mg/min while HBEC cultures have been reported to show an enzyme activity level 
between 4.3 and 7.3 RLU/mg protein/min (Newland et al., 2011). No activity was observed 
in BEAS-2B cells for the other three CYPs analysed (CYP2E1, CYP2A6/2A13 and CYP1A2) 
which confirms the findings from our gene expression analysis. Previous studies have also 
reported no detectable CYP1A2 activity in BEAS-2B cells and lung microsomes (Van Vleet 
et al., 2002; Shimada et al., 1992), however, CYP1A2 activity could be induced by 
environmental factors and specific CYP1A2 gene polymorphisms increasing lung cancer risk 
as recently reviewed (Pavanello et al., 2012). The activity related to CYP2A and CYP2E1 
has not been previously reported in BEAS-2B cells, but has been detected in human lung 
(Hukkanen et al., 2002). Newland et al. also reported that HBEC cultures from three different 
donors showed a CYP2A6/2A13 activity between 0.15 and 1.33 pmol/mg/min (Newland et 
al., 2011) a similar study by Runge and colleagues showed that CYP2E1 activity in HBEC 
(0.6 pmol/mg/min), however substantial inter-individual variability was reported as only two 
out of the four donors showed CYP2E1 activity (Runge et al., 2001).  
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Overall, the relative enzyme activity level in BEAS-2B cells appears limited compared with 
normal tissue. For instance, immunobloting of human lung microsomes have been used to 
detect CYP1A1, 1B1, 2A6, 2B6, 2C9, 2D6, 2E1, 2F1 and 3A4/5 in normal airway tissue 
(Hukkanen et al., 2002; Bernauer et al., 2006). In HBEC, these CYPs have been reported to 
show both gene expression and enzyme activity, however, high interindividual variability 
between different donors was also noted (Runge et al., 2001; Newland et al., 2011; Anttila et 
al., 2011; Castell et al., 2005). The lack of gene expression for the majority of metabolizing 
enzyme-encoding genes tested, with or without induction by TCDD, and the lack of activity 
for three out of the four selected P450 enzymes indicates that BEAS-2B cells might not be 
suitable to study the toxicity of some inhaled pro-toxicants without an external source of 
metabolic activation (S9 fractions, microsomes, co-cultures or in vitro liver-like cell lines 
amongst others) (Brandon et al., 2003). Alternatively to an external source of metabolic 
activation, Macé and colleagues developed a series of cell lines, derived from BEAS-2B cells, 
expressing one single human cytochrome P450 cDNA, CYP1A2, 2A6, 2B6, 2C9, 2D6, 2E1, 
2F1, 3A4 and 3A5 (Mace et al., 1997a; Mace et al., 1997b). These cell lines have been 
mainly used for the toxicological assessment of single compounds (Mace et al., 1994; Van 
Vleet et al., 2002; Nichols et al., 2003). Although useful for the toxicity evaluation of single 
compounds, genetically engineered cell lines have toxicity testing limitations with complex 
mixtures and compounds with unknown metabolic pathway. The complex mixture could 
contain various pro-toxicants bioactivated by multiple CYPs. Nevertheless, pro-toxicants 
which are metabolised by CYP1A1/1B1 enzymes such as PAHs could be bioactivated in pre-
induced BEAS-2B cultures. In this study CYP1A1/1B1 gene expression and enzyme activity 
were induced using TCDD, however, other xenobiotics such as B[a]P have been used 
previously to induce these isoforms (Nebert et al., 1993; Tsuji and Walle 2006). 
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It is important to consider that the BEAS-2B cell line has a wider application for biological 
endpoint assessment such as DNA damage and repair mechanisms in vitro. The non-
cancerous phenotype and wild-type p53 status of the BEAS-2B cell line makes them an ideal 
cell system in cell transformation research (Reddel et al., 1988; Petitjean et al., 2007; IARC-
TP53 2013). Moreover, the “oncogenic stress” exhibited by pre-malignant and cancer tissues 
could affect the measure of certain biomarkers of DNA damage such as the H2AX (Svetlova 
et al., 2010). The BEAS-2B cell line has also been selected as a cell system in the study of 
nanomaterials cellular transport and intracellular response (Gilbert et al., 2012; Ekstrand-
Hammarstroem et al., 2012).  
During this study a number of well-characterised cell lines were used in parallel with the 
same treatment conditions. The A549 cell line was selected as a lung carcinoma-derived cell 
system for comparison purpose while the HepG2 and HepaRG cell lines were used as 
‘positive control’ with a more extensive cytochrome P450 enzyme activity. A549 cells 
showed a small number of up-regulated genes in basal cultures such as AKR1B10 and 
AKR1C2 known to be associated with the cell line’s tumorigenic origin (Quinn et al., 2008). 
As expected, in pre-induced cultures CYP1A1 and CYP1B1 genes were up-regulated (260-
fold and 14-fold increase respectively). Interestingly, in our study the up-regulation of these 
genes was not translated into enzyme activity. The lack of CYP1A1/1B1 enzyme activity has 
been observed previously (Newland et al., 2011). With respect to the results obtained for 
HepG2 and HepaRG cells, we observed that HepaRG express more genes involved in phase I 
and phase II metabolism than HepG2. Our results concur with data published previously 
(Gerets et al., 2012; Jennen et al., 2010).  
Our data on BEAS-2B have shown a different profile to the data published recently by 
Courcot et al. They recommended BEAS-2B cells as a surrogate for metabolism and 
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bioactivation of toxicants in the lung, based on gene expression similarities between these 
cells and primary cultured cells (Courcot et al., 2012). Although, our functional experiments 
include a subset of metabolic enzymes, our results suggest that BEAS-2B cells do not have 
significant phase I metabolism capabilities. The different results could be explained by 
variations in the culture conditions and cell origin. These protocol variations have been 
reported as causes of differences in phase I and phase II activities (Hewitt and Hewitt 2004). 
Nevertheless, while qPCR is a sensitive method to measure gene expression, not all mRNAs 
are translated into active proteins. There are multiple processes that could interfere with the 
translation and activation of proteins from mRNA one example is the emerging field of 
microRNA research which has shown the ability to modify the regulation of both gene 
expression and translation (Lee and Vasudevan 2013). Thus, mRNA level is not always 
correlated with protein or activity. For instance, Halladay and colleagues studied the 
induction of various hepatic cytochrome P450 at the mRNA, protein and activity level from 
different donors. For CYP1A2, the inducer rifampicin did not increased mRNA and protein 
levels (1.00 and 1.03-fold induction respectively), however, the activity was induced by an 
average of 2.55-fold (one donor’s activity reaching above 4-fold induction). On the contrary, 
CYP3A4/5 inducer ritonavir (5 µM) increased mRNA expression by 2.5-fold but protein and 
activity levels were not induced (<0.3-fold induction) (Halladay et al., 2012). In our study, 
we observed that the HepG2 cell line showed enzyme activity for both CYP1A1/1B1 and 
CYP2E1 (Figure 3A and 3B) but a low mRNA expression was detected in un-induced HepG2 
cultures (Figure 2). The lack of correlation between activity and mRNA could be caused by 
post-transcriptional factors and is also a function of the protein stability. Also, it is worth 
noting that the mRNA expression of both CYP1A1/1B1 and CYP2E1 was upregulated in 
induced HepG2 cultures, the substrates used during the enzyme activity assays could have 
had an inducibility effect. For these reasons, key enzymatic activities should be included in 
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any metabolic characterization to confirm the gene expression results prior the use of the cell 
line for further in vitro toxicological testing. 
In summary, we would like to outline an experimental strategy that benefits from the high 
throughput of qPCR but includes key functional assays (i.e. enzymatic activity).  
i. Define an experimental design considering the nature of the test article, route of 
exposure and metabolic pathways. In our study, the experimental design was 
orientated towards toxicological studies on cigarette smoke toxicants.  
ii. Obtain the cell systems from an established supplier such as the European Collection 
of Cell Cultures (ECACC) to avoid the propagation of misidentified cultures (Lacroix 
2008). Furthermore, whenever the cell line is expanded in-house, simple 
authentication methods will confirm the authenticity of the cells (Nims et al., 2010).  
iii. Select a panel of pathway-relevant metabolism genes to carry out expression analysis.  
iv. Assess corresponding enzyme activity.  
The metabolic characterization of the cell line BEAS-2B carried out in this study will support 
future experimental designs, taking into account the cell system limitations. Moreover, we 
propose that this strategy can be applied to unravel the metabolic capabilities of other cell 
systems considered for in vitro toxicology testing.  
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Chapter III 
Assessment of the in vitro H2AX assay by High Content 
Screening as a novel genotoxicity test 
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ABSTRACT 
 
The γH2AX assay is widely used as a marker of DNA damage in multiple scientific fields 
such as cancer biomarker, clinical studies and radiation biology. In particular, the in vitro 
H2AX assay has been suggested as a novel in vitro genotoxicity test with potential as a pre-
screening tool. However, to date, limited assessments have been carried out to evaluate the 
sensitivity, specificity and accuracy of the in vitro H2AX assay.  
In this study, the microscopy-based system combining automated cellular image acquisition 
with software quantification for High Content Screening (HCS) has been used for the first 
time to evaluate the in vitro H2AX assay. A panel of well-characterised genotoxic and non-
genotoxic compounds was selected to assess the performance of the in vitro γH2AX assay in 
the human bronchial epithelial cell line BEAS-2B.   
The results obtained during this preliminary assessment indicate that the in vitro H2AX 
assay has a high accuracy (86%) as a result of high sensitivity and specificity (86-92% and 
80-88% respectively). Our data highlight the potential for H2AX detection in HCS as a 
complement to the current regulatory genotoxicity battery of in vitro assays. We therefore 
recommend more comprehensive assessments to confirm the performance of the in vitro 
H2AX assay by HCS with a more extensive set of compounds.  
 
  
 
 
148 
 
1.- INTRODUCTION 
The field of genetic toxicology testing in the 21st century faces two challenges recently as 
described by (Mahadevan et al., 2011); “The first challenge is to take full advantage of new 
technologies to improve our ability to assess the impacts of chemically induced genetic 
damage. The second is to use these technologies to reliably assess new and existing 
chemicals for genetic toxicity potential more efficiently, cost-effectively and with less reliance 
on animal models”. 
In particular, current advisory bodies such as the Committee of Mutagenicity (COM) and the 
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH), recommend two options for pre-clinical genotoxicity 
testing (COM, 2011; ICH, 2011) : 
Option 1 
i. A test for gene mutation in bacteria 
ii. A cytogenetic test for mammalian chromosomal damage (in vitro metaphase 
chromosome aberration test or in vitro micronucleus) or an in vitro mouse 
lymphoma Tk gene mutation assay 
iii. An in vivo test for genotoxicity, generally a test for chromosomal damage using 
rodent hematopoietic cells. 
Option 2 
i. A test for gene mutation in bacteria 
ii. An in vivo test for genotoxicity assessment with two different tissues. 
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The recommended in vitro mammalian tests are very laborious, especially due to their manual 
scoring requirements. Additionally, they have the limitation of reporting a large number of 
“false positives” (Kirkland et al., 2007b). For pharmaceuticals, both options require the 
addition of an in vivo test. However, this generates an increase in animal use and might lead 
to delays in product development. Moreover, in the cosmetic industry, the use of animal 
testing is banned by the EU 7th Amendment Directive (European Commission 2003). In order 
to avoid unnecessary in vivo testing, alternative in vitro assays could be used as part of the 
weight of evidence to support non-relevant in vitro positives that could be negative in vivo, 
also known as “false positive” (Kirkland et al., 2007a). Alternative in vitro assays could also 
become part of a pre-screening high throughput filter tool to discard potential genotoxic 
compounds early on during development. Some of these alternative or “non-core” in vitro 
assays have been reviewed and classified into mature, maturing or emerging technologies 
(Lynch et al., 2011). A number of emerging technologies are related to the understanding of 
the mechanisms of DNA damage. One novel endpoint of DNA damage is the 
phosphorylation of the histone 2AX at serine-139 named H2AX, in response to double-
strand breaks (DSB). This early event in the DNA damage response (DDR) mechanism is 
triggered when DNA damage occurs to avoid genome instability and was first described by 
(Rogakou et al., 1998). Since then, the measurement of H2AX has increasingly been used as 
a biomarker of DNA damage in multiple scientific fields such as in vitro mechanistic studies 
and drug development, in vivo DNA damage and repair studies and clinical trials (Dickey et 
al., 2009; Redon et al., 2011). In recent years, the automation of microscopy in cellular-based 
assays and the potential for higher throughput have increased its applicability as a 
complement to the existing battery of in vitro genotoxicity assays (Bickle 2010). However, 
the main efforts have been focused on measuring H2AX by flow cytometry (Smart et al., 
2011; Tsamou et al., 2012), even though such methodologies have been described to be less 
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sensitive than microscopic analysis (Banath and Olive 2003). The sensitivity of the 
microscopy-based method is based on the possibility to identify single foci within the cell’s 
nucleus (Sedelnikova et al., 2002). Other technical benefits include the ability to score 
attached cells directly from the micro-well plate instead of adding an extra step in the 
methodology to generate a cell suspension. Moreover, the cell sample is not destroyed during 
scoring, allowing cell distribution, morphology and other quality control checks to be carried 
out post-scoring.  
In this study, microscopy has been selected as an alternative to flow cytometry for the 
detection of H2AX in vitro. The Cellomics ArrayScan® VTI platform (ThermoScientific, 
USA) is an automated microscopy system that combines cellular image acquisition from 
multi-well microplates with software quantification analysis for High Content Screening 
(HCS) (Taylor 2010). The sensitivity and specificity  of the in vitro H2AX assay to detect 
genotoxic potential was assessed by testing a panel of 22 compounds that had been 
recommended by the European Centre for the Validation of Alternative Methods (ECVAM) 
and used in previous assessments of in vitro genotoxicity tests (Kirkland et al., 2008; 
Hastwell et al., 2006). The compounds selected represent different mechanism of action that 
could lead to the formation of DNA damage in the form of DSB directly or indirectly as 
previously described (Bonner et al., 2008). Bleomycin sulphate, for example, was used as 
reactive oxygen species generator known to directly produce DSBs in the DNA. Etoposide, 
on the other hand, is a topoisomerase II inhibitor that increases the number of topoisomerase-
DNA complexes causing an increase in collisions between the complexes and the replication 
forks. The collisions result in DSB by an indirect mechanism. 
Selecting an appropriate cell line could also affect the sensitivity of the assay. Recently 
published recommendations on cell line selection suggest the use of human p-53 competent 
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cell lines to reduce the incidence of “false positives” (Fowler et al., 2012). To develop the 
assay, we selected the normal phenotype-derived BEAS-2B cells obtained from non-
cancerous lung epithelium cells and immortalised by (Reddel et al., 1988). When measuring 
H2AX, cell lines derived from normal tissues, such as BEAS-2B cells, are considered to be 
more reliable than those from pre-malignant and cancer tissues. Tumorigenic cell lines have 
an impairment to functions such as the DNA damage repair mechanisms and cell cycle 
regulation (Hanahan and Weinberg 2000). The phosphorylation of H2AX is an early event in 
DNA damage response and is also involve in cell cycle progression (Fernandez-Capetillo et 
al., 2004; Downey and Durocher 2006), therefore, malignant transformation could affect the 
H2AX response. For instance, there have been reports showing significant amount of 
H2AX in the absence of DSB, possibly as a response to “oncogenic stress” (Svetlova et al., 
2010). BEAS-2B cells, however, have been reported to have limited metabolic capabilities 
reducing its ability to detect compounds that require metabolic activation i.e. pro-toxicants 
(Garcia-Canton et al., 2013). Therefore, this study included the addition of a standard rat-
derived subcellular fraction as external source of metabolic activation.  
The preliminary results obtained were used to define the sensitivity and specificity of the 
assay using previously recommended criteria (Kirkland et al., 2008). The results were also 
compared with existing in vitro H2AX relevant data published in the scientific literature. 
Overall, the in vitro H2AX assay by HCS has shown potential as an in vitro genotoxicity 
assay that could be included as a complementary tool to the existing battery of in vitro 
regulatory genotoxicity assays. Moreover, the high throughput technology and reproducibility 
of the in vitro H2AX assay by HCS could be a very useful tool in pre-screening for in vitro 
genotoxicity. 
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2.- MATERIALS AND METHODS 
2.1.- Chemicals 
All compounds were of the highest purity available from Sigma-Aldrich (United Kingdom) 
except MNNG (Toronto Research Chemicals, Canada). They were dissolved in an 
appropriate vehicle and further dilute to a final concentration of 1% v/v vehicle in cell culture 
medium. Selection of doses and treatment times followed current ICH regulatory guidelines 
(ICH, 2011). Therefore, the maximum concentration tested was 1mM unless precipitation 
was observed.  
2.2.- Cell culture 
The human bronchial epithelial cell line BEAS-2B, purchased from ATCC (USA), was 
seeded into culture vessels that had been pre-coated with 0.03 mg/mL PureCol® bovine 
collagen solution (Nutacon, The Netherlands). Cells were maintained in Bronchial Epithelial 
Growth Medium (BEGM®) at 37°C and 5% CO2 in a humidified incubator. BEGM® was 
prepared by supplementing Bronchial Epithelial Basal Medium with growth supplements 
provided in the manufacturer’s BEGM® SingleQuot® kit (Lonza Group Ltd., Belgium) 
containing: bovine pituitary extract, hydrocortisone, human epidermal growth factor, 
epinephrine, insulin, triiodothyronine, transferrin, gentamicin /amphotericin-B and retinoic 
acid. BEAS-2B cells were cultured and expanded in-house. All cultures were negative for 
mycoplasma. Additionally, the cells were authenticated using the short tandem repeat 
profiling to confirm the nature of the cell cultures (LGC Standards, United Kingdom) (Nims 
et al., 2010). 
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2.3.- Treatments 
The day before the treatment, BEAS-2B cells were seeded into 96-well, black, clear-bottom 
microplates (PerkinElmer, United Kingdom) at a concentration of 8x104 cells/mL.  
Cells were maintained at 37°C in an atmosphere of 5% CO2 in air and tested with compounds 
for either 3 hour or 24 hour. For compounds that required metabolic activation, the treatment 
was for 3 hour with and without the metabolic activation system. Since  some of these 
compounds are known to bind DNA, a 24 hour recovery period treatment was also included 
in the experimental design to quantify potentially delayed DNA damage (3+24 hour). 
The external source of metabolic activation used in this study was rat hepatic S9 (Aroclor 
1254-induced animals) (Moltox, USA), used as the standard system for metabolic activation 
in regulatory in vitro assays.  
The preparation of the S9 mix (0.5% v/v final concentration in medium) was carried out in 
accordance with the suppliers’ instructions. The concentration of subcellular fraction used 
was below the typically used range (1-10% v/v) due to an intrinsic cytotoxicity observed in 
BEAS-2B cells. Briefly, Reagent A (Moltox, USA) a mixture of phosphate-buffered salt 
solution and glucose-6-phosphate and Reagent B (Moltox, USA) containing NADP were 
mixed at a proportion of 1:3.4 creating a clear solution named co-factor mix. The co-factor 
mix was then used to dilute the rat S9 to a 10% v/v intermediate solution (S9 mix). The 
intermediate solution was further diluted in BEGM® media to prepare the treatment solution 
containing the test compound. 
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2.4.- Immunostaining 
Following treatment, the compound or recovery media was aspirated from the cells and the 
plates were processed for H2AX immunostaining following manufacturer’s 
recommendations (ThermoScientific, USA). Briefly, cells were fixed with 4% 
paraformaldehyde (100 µL/well) and incubated for 15 minutes at room temperature. After 
fixation, plates were washed twice with 100 µL/well phosphate buffered saline (PBS) (0.14 
M sodium chloride, 0.003 M potassium chloride, 0.002 M potassium phosphate and 0.01 M 
sodium phosphate). The cells were then permeabilised for 15 minutes by incubating them at 
room temperature with 100 µL/well of permeabilisation buffer (PBS with 1% Triton X-100). 
After permeabilisation, the cells were washed twice with 100 µL/well of PBS. Blocking 
buffer (ThermoScientific proprietary formulation supplemented with 2% fetal bovine serum) 
(100µL/well) was then added for 15 minutes at room temperature to avoid unspecific 
antibody binding. The blocking buffer was aspirated and 50 µL primary antibody solution 
(0.1% H2AX primary antibody in PBS) was added to each well and plates were incubated 
for 1 hour at room temperature. After the incubation, the primary antibody solution was 
aspirated and plates washed twice with PBS II (PBS with 1% Tween-20) followed by one 
wash with PBS. Then, 50 µL secondary antibody (DyLightTM 549 conjugated goat anti-
mouse IgG) containing Hoechst dye DNA staining solution (0.2% secondary antibody and 
0.01% Hoechst in PBS) was added to each well and plates were incubated for 45 minutes at 
room temperature in the dark. After the incubation, the wells were washed twice with PBS II 
followed by one wash with PBS. Finally, the wells were filled with 200 µL of PBS and sealed 
for scanning. Plates were stored at 4°C after the scan or while awaiting the scan. 
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2.5.- Imaging analysis 
Images from the wells at 20x magnification were taken using the Cellomics Arrayscan® VTI 
platform (Thermo Scientific, USA) and analysed with the Target Activation Bioapplication 
software V.6.6.1.4. 
The algorithm parameters for object selection was set to count a minimum of 250 cells per 
well, giving a minimum of 1500 cells per concentration tested. Two different nuclear stains 
were measured. Nuclear DNA fluorescence intensity (Hoechst dye) was assessed in channel 1 
to identify viable cells. Micrographies were obtained with a fixed exposure time of 0.04 
seconds. Object area and shape parameters were defined during the algorithm set up to fit the 
specific nuclei morphology of the cell line, generating the criteria to define valid nuclei. The 
valid nuclei from channel 1 showed a green overlay that served as the target to measure the 
fluorescence intensity of channel 2. Rejected nuclei from channel 1 showed an orange 
overlay and no further measures are taken from them. No cell rejection in channel 1 was 
based on fluorescence intensity. 
Channel 2 measures whole nuclei fluorescence intensity of the secondary antibody 
(DyLightTM 549) in valid nuclei. Micrographies were obtained with a fixed exposure time of 
0.06 seconds. All intensities are automatically calculated by the software per pixel in the 
identified target area of every valid object. 
With all the micrographies parameters quantified, the software generated a number of 
measurements to report, in this study we selected two for their relevance to the H2AX 
endpoint: 
“Selected Object Count per Valid Field” is the average number of objects (viable cells) 
selected for analysis per valid field in the well. These data were obtained from the identified 
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nuclei in channel 1. Untreated wells would have a higher number of nuclei per field while 
toxic doses would have lower number of nuclei per field. These data were converted into cell 
viability data. The vehicle treated counts were defined as 100% cell viability. The cell counts 
in the compound treated wells were then compared to those in the vehicle-treated wells, and 
the percentage cell viability was calculated. This comparison against the vehicle control data 
is referred to as Relative Cell Counts (RCC) and expressed as percentage. 
“Mean average intensity in channel 2” is the average intensity in channel 2 of all pixels 
within the overlay mask identified in valid nuclei in channel 1. The mean average intensity is 
measured in intensity units and was reported as H2AX frequency (intensity units) in this 
study. This measurement relates to the number of DSBs present in the cells.  
2.6.- Data analysis and criteria 
All experiments were repeated at least 3 independent times. The results for both H2AX 
intensity and RCC for all tested compounds were graphically represented using GraphPad 
Prism software v.6 
The evaluation criteria for the in vitro H2AX assay selected in this study is described in 
Table 1 and was previously presented by Smart et al. (Smart et al., 2011). 
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Table 1: Genotoxicity evaluation criteria for the in vitro H2AX assay, adapted from (Smart et al., 
2011). 
H2AX response Classification 
> 1.5-fold H2AX @ RCC > 25% Genotoxic (+) 
< 1.5-fold H2AX @ RCC 100-0% Non-genotoxic (–) 
> 1.5-fold H2AX @ RCC < 25% “False” positive; Cytotoxic-driven genotoxicity (C) 
1.5-fold H2AX @  RCC ≥ 25% Equivocal (±) 
  
The in vitro to in vivo predictivity of the assay was defined by the calculation of the 
“Sensitivity”, “Specificity” and “Accuracy” defined previously by Kirkland et al. (Kirkland 
et al., 2005). The sensitivity is defined as the ability of the assay to detect in vitro genotoxic 
compounds. These compounds should give a positive response in in vitro mammalian cell 
genotoxicity tests. They are also in vivo genotoxic compounds and are often classified as 
carcinogenic compounds (Kirkland et al., 2008). 
Specificity, on the other hand, is defined as the ability of the assay to discriminate non-
genotoxic compounds. These compounds should give a negative response in in vitro 
mammalian cell tests. When there is data available in in vivo genotoxicity testing, the results 
are usually negative. They are often non-carcinogenic or if carcinogenicity is observed in vivo, 
the mode of action assumed is non-mutagenic (Kirkland et al., 2008). 
Some of the compounds tested are classified as artifactual in vitro genotoxic positives (false 
positive). These compounds should give a negative response in in vitro mammalian cell tests 
but often have been reported to produced positive genotoxicity, especially at high cytotoxic 
concentrations. They are commonly negative in in vivo gentotoxicity tests (Kirkland et al., 
2008). 
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Sensitivity = A/B 
Specificity = C/D 
Accuracy = (A+C)/(B+D) 
where A is the number of in vivo genotoxic compounds that tested positive in the in vitro 
H2AX assay evaluated in this study, B is the total number of in vivo genotoxic compounds 
tested. C is the number of in vivo non-genotoxic compounds that tested negative in the in 
vitro H2AX assay, and D is the total number of in vivo non-genotoxic compounds tested. 
  
 
 
159 
 
3.- RESULTS 
The assessment of the in vitro H2AX assay by HCS was performed by treating BEAS-2B 
cells with different control compounds. The increase of histone 2AX phosphorylation 
(H2AX) labelled by immunostaining and detected by automated fluorescence microscopy 
was used as an indication of DNA double strand breaks. An illustration H2AX detection is 
given in Figure 1 after 3 hour treatment of the cells with etoposide.  
 
Figure 1: Example of H2AX detection after 3 hour treatment with one of the genotoxic compounds, 
etoposide. The nuclei of the cells were stained with Hoechst and H2AX with a combination of 
primary anti-H2AX and secondary fluorophore-conjugated antibody. Hoechst micrographs indicate 
with a green overlay the scored nuclei (green arrow) and orange overlay the rejected nuclei (orange 
arrow).  
Etoposide 
250 µM 
Etoposide 
8 µM  
Vehicle-treated 
control 
Hoechst H2AX  Merge 
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For this study, we selected a series of genotoxic compounds with different mechanisms of 
action in order to have a comprehensive selection of DNA-damaging agents. Direct DNA-
damaging compounds interact directly with the DNA causing different degree of DNA 
damage ranging from point mutations to crosslinks. Ethyl methanesulfonate, mitomycin C 
and methylnitronitrosoguanidine (MNNG) were used in this study as they interact directly 
with the DNA. Similarly, reactive oxygen species (ROS) generators such as bleomycin 
sulphate, also used here, generate ROS molecules that have the potential to oxidise DNA. 
Some direct DNA-damaging compounds have to be metabolically activated before their toxic 
form is active, these compounds are known as pro-toxicants. The limitations of some cell 
systems used in in vitro toxicological testing to activate these compounds implies that 
external sources of metabolic activation would be required to carry out subsequent endpoint 
analysis. Benzo(a)Pyrene, cyclophosphamide, 2-acetylaminofluorene and aflatoxin B1 were 
used as pro-toxicant models during this study.  
Indirect DNA-damaging compounds interfere with cellular functions involved in DNA repair, 
synthesis or mitosis. Damage in these fundamental functions could ultimately translate into 
DNA damage. In this assessment, amsacrine and etoposide were used as topoisomerase 
inhibitors while aphidicolin and zidovudine were used as DNA synthesis inhibitors.  
Aneugenic compounds affect mitosis mechanisms such as microtubules synthesis and 
cytoeskeleton morphology. These changes could lead to aneuploidy in daughter cells 
(abnormal chromosomal number), cell cycle deregulation and so on, rather than actual DNA 
damage. These compounds are included here in the non-genotoxic carcinogenic class. In this 
study, colchicine and nocodazole were used as model compounds. 
Artifactual in vitro compounds typically show a positive response in some in vitro 
genotoxicity assays but are not genotoxic in vivo. False positive responses are commonly 
 
 
161 
 
produced when toxic concentrations are tested (Kirkland et al., 2007b; Kirkland et al., 2008). 
Here, 2,4-dichlorophenol and D,L-menthol were used as examples. Negative in vitro 
genotoxic compounds selected have been extensively tested, consistently giving negative 
results for genotoxicity or carcinogenicity both in vitro and in vivo (Kirkland et al., 2008; 
Hastwell et al., 2006). Acetonitrile, 3-amino-1,2,4-triazole, dimethyl formamide, ethylene 
glycol, D-mannitol and sodium chloride were chosen as model negative compounds for this 
work. 
The sensitivity and specificity of the in vitro H2AX assay has been calculated by the number 
of in vitro genotoxic and non-genotoxic compounds that the assay could discriminate during 
this assessment as previously defined (Kirkland et al., 2008; Kirkland et al., 2005).  
3.1.- In vitro H2AX assay assessment 
Table 2 summarised the results obtained during the assessment of the in vitro H2AX assay 
by HCS performed in this study on BEAS-2B cells using Smart et al. evaluation criteria 
(Table 1) (Smart et al., 2011). For comparison purposes we have included published data 
available on regulatory in vitro genotoxicity tests as well as other H2AX studies where these 
control compounds have been used.  
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Table 2: Control compounds tested in the in vitro H2AX assay by High Content Screening in 96-
well plates, and data from published data on regulatory in vitro genotoxicity assays and other H2AX 
studies. Positive results (+), negative (–), equivocal (±), cytotoxic (C).  
Compound 
(CAS number) 
IARC 
Group 
Regulatory in vitro 
tests (refs)* 
Other H2AX H2AX by HCS 
Ames 
In vitro 
mammalian 
test 
Direct DNA-damaging compounds 
Ethyl methanesulfonate 
(62-50-0) 2B + + 
+ 
 (Smart et al., 2011)  + (500 µM) 
Mitomycin C 
(50-07-7) 2B ± + 
+ 
 (Smart et al., 2011)  + (0.47 µM) 
MNNG 
(70-25-7) 2A + + 
+  
(Staszewski et al., 2008) + (0.49 µM) 
Pro-toxicant compounds 
Benzo[a]pyrene 
(50-32-8) 1 + + 
+  
(Smart et al., 2011)  + (7.8 µM) 
Cyclophosphamide 
(6055-19-2) 1 + + 
+  
(Smart et al., 2011) + (1000 µM) 
2-Acetylaminofluorene 
(53-96-3) N/A + + 
+  
(Smart et al., 2011) – 
Aflatoxin B1        (1162-
65-8) 1 + + 
+  
(Gursoy-Yuzugullu et 
al., 2011) 
+ (4 µM) 
Reactive Oxygen Species Generator 
Bleomycin 162ulphate 
(9041-93-4) 2B + + 
+  
(Kim et al., 2011) + (0.019 µM) 
Topoisomerase inhibitors 
Amsacrine (m-AMSA) 
(54301-15-4) 2B + + N/A + (0.2 µM) 
Etoposide 
(33419-42-0) 1 – + 
+  
(Matsuzaki et al., 2010) + (0.24 µM) 
Nucleotide/DNA synthesis inhibitors 
Aphidicolin 
(38966-21-1) N/A – + 
+  
(Tanaka et al., 2007) + (1.56 µM) 
Zidovudine 
(30516-87-1) 2B + + N/A + (125 µM) 
Aneugen compounds 
Colchicine 
(64-86-8) N/A – ± N/A + (7.8 µM) 
Nocodazole 
(31430-18-9) N/A  + 
+  
(Dalton et al., 2010) C 
Artifactual in vitro genotoxic positives (false positive) 
2,4-Dichlorophenol 
(120-83-2) N/A ± ± N/A + (1000 µM) 
D,L-menthol 
(15356-70-4) N/A – ± N/A – 
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In vitro genotoxic negatives 
Acetonitrile 
(75-05-8) N/A – ± N/A – 
3-Amino-1,2,4-triazole 
(61-82-5) 3 – – N/A – 
Dimethyl formamide 
(68-12-2) 3 – – N/A – 
Ethylene glycol 
(107-21-1) N/A – – N/A – 
D-Mannitol 
(69-65-8) N/A – – 
–  
(Smart et al., 2011) – 
Sodium chloride 
(7647-14-5) N/A – – 
–  
(Matsuzaki et al., 2010) – 
* (United State National Library of Medicine, 2013; Department of Health and Human Services, 2013;  
IARC, 2000; IARC, 1987) 
 
Figure 2 illustrates a summary of the graphical results obtained during the assessment of the 
in vitro H2AX assay. The data represented is expressed as mean fluorescence (H2AX 
frequency) ± Standard Deviation (SD) of three separate experiments to show the 
reproducibility between experiments. The RCC is expressed as a percentage of the vehicle-
treated control calculated for the three separate experiments. The X-axis represents the 
compound concentration (µM) in logarithmic scale, the left Y-axis represents the H2AX 
frequency in absolute units (intensity units) and the right Y-axis represents the cell viability 
as RCC in percentage relative to vehicle-treated control. In those selected examples, the 
direct-DNA damaging compound, Ethyl methanesulfonate (Figure 2A) produced a 
statistically significant increase in the H2AX frequency compared to vehicle-treated control 
at concentrations above 500 µM after treatment for 24 hour without a reduction in cell 
viability below 80%. Ethyl methanesulfonate is typically used in DNA damage and repair 
studies for its mutagenic activity (Munroe and Schimenti 2009). In contrast, the treatment 
with the pro-toxicant B[a]P in the presence of aroclor-induced rat S9 mix (Figure 2B) 
produced a significant increase in H2AX frequency at concentrations above 8 µM at 3 hour 
(RCC > 80%) and concentrations above 16 µM at 3 hour followed by 24 hour recovery 
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period (RCC > 60%). In the absence of S9 mix B[a]P did not produce any increase in H2AX 
frequency above vehicle-treated controls at either timepoint.  
B[a]P is a polycyclic aromatic hydrocarbon present in cigarette smoke which is oxidised by 
cytochrome P450 enzymes, primarily CYP1A1 but also CYP1A2 and CYP1B1. 
Treatment for 3 hour with ROS generator, bleomycin sulphate (Figure 2C), produced a 
statistically significant increase in H2AX frequency at concentrations above 0.3 µM without 
a reduction in cell viability (RCC > 95%). However, treatment for 24 hour produced an 
increase in H2AX frequency above 1.5-fold at concentrations above 0.02 µM with a dose-
related decrease in cell viability (RCC from 65% to 33%). 
Both, topoisomerase and DNA synthesis inhibitors, etoposide and zidovudine, produced a 
gentoxic response in the in vitro H2AX assay. Etoposide treatment (Figure 2D) produced a 
positive response after 3 hour at concentrations above 7.8 µM without a reduction in cell 
viability below 80%. The range of concentrations used for the 24 hour treatments was lower 
as high cytotoxicity was observed in the initial range finder (data not shown). Treatment with 
etoposide for 24 hour produced a positive response at concentrations above 0.24 µM with a 
cell viability of 75%. A dose-related decrease in cell viability was observed after 24 hour 
treatment when etoposide concentration increased (supplementary data). Contrarily, only 
treatment for 24 hour with zidovudine (Figure 2E) produced a significant increase in H2AX 
frequency at concentrations above 125 µM with a cell viability above 65%. 
The aneugenic compound, colchicine (Figure 2F), produced a significant increase in H2AX 
frequency compared to vehicle-treated controls after 24 hour continuous treatment at 
concentrations above 7.8 µM (RCC > 25%). However, as the concentration increased, there 
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was a reduction in H2AX frequency and at concentrations above 250 µM the H2AX 
frequency was equivalent to background response (< 1.5-fold).  
The artifactual genotoxic compound 2,4-dichlorophenol generated a significant increase in 
H2AX frequency at the highest dose tested (1000 µM) after both 3 and 24 hour treatments 
(Figure 2G). There was no significant reduction in cell viability after the 3 hour treatment 
(RCC > 95%), however, after 24 hour treatment, there was a dose-related reduction in cell 
viability from 100% to 40% RCC. 
Treatments with the non-genotoxic D-mannitol (Figure 2H) did not produce any significant 
increase in H2AX frequency compared to vehicle-treated controls at any timepoint. The cell 
viability was also maintained at around 100% RCC at all timepoints. 
Overall, the majority of tested compounds, both in vitro genotoxic and non-genotoxic, 
produced the expected increment in H2AX frequency (above and below 1.5-fold increase 
respectively). All the results are graphically represented in the supplementary data and 
discussed in more detail in the in vitro H2AX assay performance section. 
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Figure 2: Example data from the assessment of the in vitro H2AX assay. Left Y-axis represents 
H2AX frequency (continuous line) and right Y-axis represents RCC (% control) (dotted line). 
Compounds: [A] Ethylmethane sulfonate, [B] B[a]P, [C] bleomycin sulphate, [D] etoposide, [E] 
zidovudine, [F] colchicine, [G] 2,4-dichlorophenol and [H] D-mannitol. Triangle (-▲-) represents 
short treatment and circle (-●-) represents long treatment. Asterisk (*) indicates the minimum 
concentration that shows genotoxicity compared to the vehicle treated control after short treatment. 
Hash (#) indicates the minimum concentration that shows genotoxicity compared to the vehicle 
treated control after long treatment.  
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3.2.- In vitro H2AX assay performance 
The results obtained in the in vitro H2AX assay assessment were used to calculate the 
sensitivity, specificity and accuracy of this single assay to predict in vivo genotoxicity 
(Kirkland et al., 2005).  
The sensitivity (or ability to detect genotoxic compounds) calculated for this preliminary 
assessment showed that 91.6% of genotoxic compounds could be detected if aneugenic 
compounds are considered non-genotoxic. When aneugenic compounds were considered as 
indirect-acting genotoxic compounds, the sensitivity fell to 85.7%.  For specificity (or ability 
to discriminate non-genotoxic compounds), this preliminary assessment indicated an 80% 
specificity if aneugenic compounds are considered non-genotoxic or 87.5% if aneugenic 
compounds are considered to have genotoxic potential. 
The accuracy of the in vitro H2AX assay by HCS in this preliminary assessment is therefore, 
calculated to be 86.4%, independent of the aneugenic compound classification.  
To put our performance results in context with existing in vitro regulatory genotoxicity tests, 
we have evaluated previously published data for the 22 compounds tested in this study (Table 
2) to calculated the sensitivity, specificity and accuracy of the current regulatory in vitro tests.  
The results in Table 3 have been calculated considering aneugens as both genotoxic and non-
genotoxic compounds. 
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Table 3: Performance results based on the 22 compounds tested in this study. 
Results Ames test In vitro Mammalian test H2AX by HCS 
Aneugens considered genotoxic compounds 
No. of genotoxic compounds 
clearly positive (A) 
9 13 12 
No. of genotoxic compounds tested 
(B) 
14 14 14 
Sensitivity (%) 64% 93% 86% 
No. of non-genotoxic compounds 
clearly negative (C) 
7 5 7 
No. of non-genotoxic compounds 
tested (D) 
8 8 8 
Specificity (%) 88% 63% 88% 
Accuracy (%) 73% 82% 86% 
Aneugens considered non-genotoxic 
No. of genotoxic compounds 
clearly positive (A) 
9 12 11 
No. of genotoxic compounds tested 
(B) 
12 12 12 
Sensitivity (%) 75% 100% 92% 
No. of non-genotoxic compounds 
clearly negative (C) 
8 5 8 
No. of non-genotoxic compounds 
tested (D) 
10 10 10 
Specificity (%) 80% 50% 80% 
Accuracy 77% 77% 86% 
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4.- DISCUSSION AND CONCLUSIONS  
The in vitro H2AX assay has been previously proposed as a potential complement to the 
existing battery of in vitro genotoxicity assays (Garcia-Canton et al., 2012). Although, 
measuring H2AX as a biomarker of DNA damage is commonly used in current scientific 
research, there is a limited number of studies focused on assessing the sensitivity and 
specificity of the in vitro H2AX assay (Matsuzaki et al., 2010; Smart et al., 2011; Tsamou et 
al., 2012). More data is needed to support its move from emerging to maturing technology in 
genetic toxicology testing as described previously (Lynch et al., 2011). To date, the main 
system employed to measure H2AX has been flow cytometry (Smart et al., 2011; Tsamou et 
al., 2012). Here, we present the first study where automated microscopy-based HCS in multi-
well microplates has been used to assess the sensitivity, specificity and accuracy of the in 
vitro H2AX assay.  
Although flow cytometry incorporates high throughput qualitative scoring, the sensitivity of 
detection for H2AX has been described to be lower than in microscopy (Banath and Olive 
2003). Additionally, flow cytometry scoring requires cells to be in suspension; however, the 
majority of cell lines used in in vitro toxicology testing are adherent cells. The requirement 
for a cell suspension increases the time and complexity of the methodology as a trypsin-
mediated detachment step will be required. Moreover, the use of trypsin have been shown to 
affect the cell viability and can cause DNA damage during detachment (Wischermann et al., 
2007). In contrast, HCS applies the sensitivity of microscopy with an automated high-
throughput system for acquiring cellular images and software to aid with the qualitative 
scoring. Other benefits include the scoring of samples in situ in multi-well plates, elimination 
of the detachment step and storage of images as raw data for quality control purposes. HCS 
methods could also incorporate cell cycle information if required by measuring DNA content 
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or multiplexing nuclei dyes (Lyman et al., 2011; Chan et al., 2013). An overview of the 
technology with current capabilities, limitations and potential developments has been 
published by Bickle (Bickle 2010).  
The genotoxicity assessment of the in vitro H2AX assay performed in this study involved 
the treatment of the phenotypically-normal cell line BEAS-2B to a panel of genotoxic and 
non-genotoxic compounds following ICH guidelines (ICH, 2011). One of the major 
limitations of current in vitro assays is the rate of “false” or misleading positives, non-
carcinogenic compounds that produce a positive response in vitro (Kirkland et al., 2007b). In 
this study, all the well-established in vitro genotoxic negative compounds tested produced a 
negative response at both treatment timepoints (3 and 24 hour). Of the two previously 
reported artifactual in vitro genotoxic positive compounds, D,L-menthol produced a clear 
negative result. By contrast, 2,4-dichlorophenol produced a positive response at the highest 
concentration tested after both 3 and 24 hour treatments, however, this statistically significant 
increase in H2AX frequency was only achieved in one experiment. The same inconsistent 
response has been reported for 2,4-dichlorophenol in other in vitro genotoxicity studies and 
summarised recently (Fowler et al., 2012). Although there is no evidence for carcinogenicity 
of 2,4-dichlorophenol in vivo, there have been some studies indicating endocrine disruption in 
the zebra fish model (Ma et al., 2012). The hormonal imbalance caused by 2,4-
dichlorophenol could potentially elevate the levels of estrogens, an endogenous genotoxic 
agent. These events suggest that 2,4-dichlorophenol have an indirect DNA-damage effect 
caused by hormonal imbalance (Cavalieri et al., 2000; Amer and Aly 2001).  
The acceptance criteria described for the H2AX assay by flow cytometry (Smart et al., 2011) 
were applied to our data to evaluate the relevance of using the same approach for the H2AX 
assay by HCS. Our data showed that all increments in H2AX frequencies over the vehicle-
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treated control observed were also identified by the 1.5-fold increase “cut off” criterion 
defined by Smart and colleagues. The RCC levels selected as a measure of cytotoxicity was 
the second criterion employed to monitor that increases in H2AX frequencies were not 
caused solely by a toxic effect. 
The performance of the in vitro H2AX assay by HCS to detect direct-acting genotoxic 
compounds showed a high sensitivity. Only the pro-toxicant 2-acetylaminofluorene (2AAF) 
failed to show a positive response. 2AAF is an aromatic amine not classified by IARC 
regarding its carcinogenicity. However, the IARC monograph describing some aromatic 
amines refers to its mechanism of action as formation of DNA-adducts by different 
metabolites (IARC, 2010). 2AAF is mainly activated by CYP1A2 present in the standard rat 
S9 mix. Although, in this study 2AAF show a dose-related increase in H2AX frequency, the 
response was never greater than 1.5-fold. In a previous study, Zhou and colleagues reported 
that the ability of 2AAF to induce DSBs depends on the cell type tested (Zhou et al., 2006). 
They obtained a positive response at 90 µM in Chinese hamster CHL cells after short 
treatments only, while no positive response was observed in human ambion FL cells at any 
timepoint. Similarly, Tsamou et al. report a positive response at 50 µM after 24 hour 
treatment in HepG2 cells, known to have a degree of metabolic competency (Tsamou et al., 
2012). Smart et al. report a positive response at a concentration above 125 µM after 3 hour 
treatment in the presence of 1% v/v of rat S9 mix (Smart et al., 2011). In our experiments, we 
tested 2AAF up to a concentration of only 125 µM as precipitation was observed at higher 
doses. However, in our experimental design for the testing of pro-toxicants, the limiting 
factor was the inherent toxicity produced by the rat S9 to the cells. At the minimum 
concentration of 1% v/v S9, typically used in vitro, the cell viability fell below 55%, which is 
not compatible with robust testing for DNA damage. The reduction in concentration to 0.5% 
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v/v S9 maintained the cell viability above 80% but could have compromised the metabolic 
activation of 2AAF.  
In the case of indirect-acting genotoxic compounds, the in vitro H2AX assay performance 
was also highly sensitive. The cellular targets affected by these compounds are essential for 
the DNA synthesis and repair, both functions are intrinsic of the cell cycle. All the indirect-
acting genotoxic compounds tested in this study produced a positive response in the in vitro 
H2AX assay.   
During the in vitro H2AX assay assessment, we also tested two aneugenic compounds. We 
define these as non-genotoxic carcinogens as they can cause aneuploidy (Aardema et al., 
1998). Aneugenic compounds do not damage DNA directly, instead, they affect cellular 
mechanisms involve in the cell cycle process to the point of forcing the cell to programmed 
death i.e. apoptosis (Yamada and Gorbsky 2006). In this assessment, nocodazole produced a 
genotoxic response at highly cytotoxic concentrations (RCC < 25%) after 24 hour treatment. 
This effect is considered an artifactual genotoxic positive result (Scott et al., 1991). 
Colchicine, on the other hand, produced a genotoxic response after 24 hour treatment with 
cell viability around 40%. These contrasting results could be influence by the different levels 
of cytotoxicity exerted by the compounds. In general, treatments with aneugenic compounds 
could lead to DNA damage by products liberated to the culture media during cell death and 
other mechanisms of toxicity (Scott et al., 1991). Therefore, a small degree of clastogenicity 
could be observed after treatment with aneugenic compounds. This effect could lead to an 
increase in H2AX frequency above the vehicle-treated control when aneugens are tested, 
and potentially an additional mechanism of indirect DNA damage. Increases in H2AX have 
been associated to other mechanisms such as apoptosis (Mukherjee et al., 2006; 
Darzynkiewicz et al., 2012). Briefly, during a late-stage event of apoptosis, fragmentation of 
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cellular DNA could produce an increase in the frequency of H2AX followed by a reduction 
of both H2AX levels and cell viability as a result of the programmed cell death. Thus, it is 
considered important to report both H2AX frequency and cell viability data. 
The performances of other in vitro regulatory assays calculated from the panel of compounds 
tested in this study (Table 3), showed that the Ames test is better at discriminating negative 
compounds (specificity). Other in vitro mammalian tests (i.e. Micronucleus test, mouse 
lymphoma test etc.) are better at detecting positive compounds (sensitivity). Our observations 
concur with more extensive assessments such as the evaluation carried out by Kirkland et al. 
with over 800 compounds (Kirkland et al., 2005). The performance of the in vitro H2AX 
assay by HCS obtained in this preliminary assessment shows a consistently high level of both 
sensitivity and specificity giving as a result a greater accuracy than the other in vitro tests. It 
is as yet not possible to compare the sensitivity and specificity of the in vitro H2AX assay 
by HCS with previously reported methods such as flow cytometry. Only a limited subset of 
the reference compounds have been used across all studies (Table 2). However, it would be 
interesting for future studies to perform a parallel comparison between HCS and flow 
cytometry using the same experimental conditions e.g. cell lines.  
 Overall, the in vitro H2AX assay by HCS results obtained during this preliminary 
assessment are in line with previously published evaluations (Smart et al., 2011; Tsamou et 
al., 2012; Audebert et al., 2010). However, we believe that the use of HCS for the scoring of 
micro-well plates and detecting H2AX may offer advantages in terms of higher throughput 
and sensitivity. Initially, the reproducibility and accuracy of the data gathered supports the 
use of the in vitro H2AX assay as a complementary tool to the existing battery of 
genotoxicity assays, principally as a pre-screening assay. Nevertheless, a more 
comprehensive assessment including a more extensive set of compounds would be required 
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to confirm the performance of the in vitro H2AX assay by HCS and to provide further 
support for future validation trials. 
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Chapter IV 
Genotoxicity evaluation of individual cigarette smoke toxicants 
using the in vitro H2AX assay by High Content Screening 
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ABSTRACT 
 
Cigarette smoke is a complex mixture consisting of more than 5600 identified chemical 
constituents of which approximately 150 have been identified so far as “tobacco smoke 
toxicants”. Proposals made by the World Health Organisation Framework Convention on 
Tobacco Control mandate the lowering of nine tobacco smoke priority toxicants, including 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK),  N-nitrosonornicotine (NNN), and 
benzo[a]pyrene (B[a]P) and monitoring the levels of a further nine including cadmium.  
Here, we evaluated the genotoxic potential in human bronchial epithelial BEAS-2B cells of 
four cigarette smoke toxicants; NNK, NNN, B[a]P and cadmium using the novel in vitro 
H2AX assay by High Content Screening (HCS). We also examined the genotoxicity of 
binary mixtures of NNK and NNN reporting their relative contribution to the genotoxic end-
point. 
The results of this preliminary assessment showed that the in vitro H2AX assay by HCS 
could be used as a pre-screening tool to detect and quantify the genotoxicity effect of 
cigarette smoke toxicants individually and in binary mixture. Moreover, the data produced 
could contribute to the prioritisation of toxicant reduction research in modified tobacco 
products. 
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1.- INTRODUCTION 
Cigarette smoke is a complex mixture consisting of more than 5,600 identified compounds 
(Perfetti and Rodgman 2011), of which over 150 are known toxicants (Cunningham et al., 
2011). In 2008, the World Health Organisation Framework Convention on Tobacco Control 
(WHO FCTC) published “The scientific basis of tobacco product regulation” a report 
containing recommendations on tobacco product regulation from a group of international 
experts (TobReg) (WHO 2008). From the initial report, Burns and colleagues summarised the 
proposal in a paper where a list of 18 priority toxicants was shortlisted based on evidence of 
their direct toxicity and their hazard indices as described by Fowles and Dybing (Burns et al., 
2008; Fowles and Dybing 2003). Of these 18 toxicants, 9 were proposed for mandated 
lowering, including NNK, NNN, and B[a]P and 9 were proposed for monitoring (Table 1). 
Similarly, the Food and Drug Administration (FDA) Center for Tobacco products (CTP) has 
recently drafted a guideline for reporting Harmful and Potentially Harmful Constituents 
(HPHCs) in tobacco products. From the list of 93 established HPHCs (FDA, 2012a), 20 are 
initially shortlisted for reporting in the draft guideline (FDA, 2012b). The WHO FCTC 
priority toxicants list and the abbreviated HPHC list contain 14 toxicants in common as 
detailed in Table 1.   
Burns and colleagues further discussed the limitation of the prioritisation model used which 
was established based on individual toxicant exposure, as opposed to complex mixture, and is 
mostly based on animal data. In this context, it is of interest to characterise the toxicity of 
smoke toxicants and mixtures using relevant human target tissue to prioritise toxicant 
reduction. However, the level of characterisation proposed along with ethical considerations 
like the 3Rs principle (Schechtman 2002) requires a high throughput in vitro method to 
overcome lengthy and expensive testing as well as being an alternative to animal models.  
 
 
187 
 
Table 1: Cigarette smoke toxicants. Cigarette smoke is an aerosol composed of condensed-phase 
particle in a gaseous medium. Compounds with low volatility have been found to be exclusively in the 
particulate phase, in the gas phase or partitioned between both phases (vapour). 
Priority toxicants 
(Burns et al., 
2008) 
Abbreviated 
HPHCs 
(FDA, 2012a) 
Chemical Family Smoke Phase  
Recommended 
for lowering 
by FCTC 
Acetaldehyde Carbonyls Vapour Yes 
Acrolein Carbonyls Vapour Yes 
Acrylonitrile Organic Compounds Vapour No 
4-Aminobiphenhyl Aromatic Amines Particulate No 
- 1-Aminonaphthalene Aromatic Amines Particulate No 
2-Aminonaphthalene Aromatic Amines Particulate No 
- Ammonia Inorganic Compound Gas No 
- Arsenic Metal/Metalloid Particulate No 
Benzene Volatile Hydrocarbons Vapour Yes 
Benzo[a]pyrene - B[a]P 
Polyaromatic 
hydrocarbons 
Particulate Yes 
1,3-Butadiene Volatile Hydrocarbons Vapour Yes 
Cadmium Heavy Metal Particulate No 
Carbon Monoxide Organic Compounds Gas Yes 
Catechol - Phenol Particulate No 
Crotonaldehyde Carbonyls Vapour No 
Formaldehyde Carbonyls Vapour Yes 
- Isoprene Volatile Hydrocarbons Vapour No 
- Nicotine Aza-arenes Particulate No 
Hydrogen cyanide - Organic Compounds Vapour No 
Hydroquinone - Phenol Particulate No 
Nitrogen Oxides – 
various 
- Nitrogen Oxides Gas No 
NNK * 
Tobacco Specific 
Nitosamines 
Particulate Yes 
NNN ** 
Tobacco Specific 
Nitrosamines 
Particulate Yes 
- Toluene Volatile Hydrocarbons Vapour No 
* 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone 
** N´-nitrosonornicotine 
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The aim of this study was to utilise the recently developed in vitro H2AX assay by High 
Content Screening (HCS) to evaluate the genotoxicity effect, in human lung-derived cells, of 
a group of cigarette smoke toxicants shown to cause genotoxicity in vitro in the battery of 
assays described in regulatory guidelines, such as International Conference on Harmonisation 
of Technical Requirements for Registration of Pharmaceuticals for Humans (ICH) (ICH, 
2011; IARC, 2012a; IARC, 2012b; IARC, 2012c). The high throughput scoring system 
employed was the Cellomics ArrayScan® VTI platform (ThermoScientific, USA), an 
automated microscopy system that combines cellular image acquisition from multi-well 
microplates with software quantification analysis (Taylor 2010). HCS could provide 
simplified experimental design that allows a larger number of toxicants and mixtures to be 
pre-screened for genotoxicity effects compared to established regulatory in vitro tests. 
The novel in vitro H2AX assay HCS in human lung-derived BEAS-2B cells has been 
recently described (Garcia-Canton et al., 2013b). Briefly, the phosphorylation of the histone 
2AX named H2AX has been demonstrated to be a sensitive marker of DNA damage in the 
form of double strand breaks in different scientific fields since its discovery in 1998 
(Rogakou et al., 1998). In the field of regulatory genotoxicity, the in vitro H2AX assay has 
been suggested as a complementary tool to the existing battery of in vitro assays based on its 
sensitivity, specificity and automated scoring (Garcia-Canton et al., 2012; Watters et al., 
2009; Smart et al., 2011). Moreover, the use of the human-derived BEAS-2B cells as the in 
vitro cell system could provide a more physiologically relevant testing system than existing 
assays where rodent-derived cell lines are used routinely. The BEAS-2B cell line was first 
described by Reddel and colleagues in 1988 (Reddel et al., 1988). BEAS-2B cells have a 
non-cancerous phenotype and wild-type p53 status, both of which are important advantages 
in the measurement of DNA damage response such as H2AX (Petitjean et al., 2007; 
Svetlova et al., 2010; IARC, 2013). However, the cell line BEAS-2B lacks normal metabolic 
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activity for the majority of the cytochrome P450 family (Garcia-Canton et al., 2013a). The 
lack of metabolic activation could cause some pro-toxicants to produce a “false negative” 
response in vitro (Kirkland et al., 2007). To solve the BEAS-2B metabolic competency 
limitation, the standardised Aroclor-1254 induced rat S9 mix was included in our 
experimental design as an external source of metabolic bioactivation.  
In this study, we have selected 3 chemicals recommended for mandated lowering by the 
FCTC, namely B[a]P, NNK and NNN. We also tested cadmium, a toxicant recommended for 
monitoring by the FCTC. The toxicants belong to polyaromatic hydrocarbons (PAH), 
Tobacco-Specific Nitrosamines (TSNAs), and heavy metals, respectively. B[a]P, NNK, NNN 
and cadmium can be found in the particulate phase of cigarette smoke and are all classified  
by the international agency for research on cancer (IARC) as Group 1 – carcinogenic to 
humans (IARC, 2012a; IARC, 2012b; IARC, 2012c). 
The PAH B[a]P is found in tobacco smoke but also in barbequed foods, polluted air (both 
outdoor and indoor) and coal tar-based pharmaceuticals. The toxic effects associated with 
B[a]P exposure are caused by the diol-epoxide metabolite (BPDE) formed as a result of the 
CYP1A and CYP1B1 metabolism. This metabolism-mediated toxicity designates B[a]P as a 
pro-toxicant. The principal mechanism of action is the formation of DNA-adducts that could 
ultimately lead to mutation and DNA breaks (Alexandrov et al., 2010). B[a]P was previously 
evaluated in the presence of S9 mix during the assessment of the in vitro H2AX assay by 
HCS (Garcia-Canton et al., 2013b). In this study B[a]P was tested in BEAS-2B cultures 
where CYP1A1/1B1 were pre-induced using 2,3,7,8-Tetrachlorodibenzodioxin (TCDD) as 
previously described (Garcia-Canton et al., 2013a). 
The heavy metal Cadmium is absorbed from soil by the tobacco plant which can accumulate 
relatively high amounts in its leaves (Lugon-Moulin et al., 2006). Different in vivo and in 
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vitro studies defined cadmium as a weak mutagenic compound with various mechanisms of 
action such as causing DNA strand breaks, inducing oxidative stress and acting as a co-
mutagen that increases the mutagenicity of other compounds by inhibition of DNA-repair 
mechanisms (Waisberg et al., 2003; Hartwig 2010). Cadmium also has the potential to be a 
spindle poison in vivo i.e. an aneugenic compound (Watanabe et al., 1979). However, in vitro 
studies have shown conflicting results that could be caused by the use of different cell lines 
and differing ranges of tested concentrations (Seoane and Dulout 2001; Lynch and Parry 
1993). In this study, the soluble form of cadmium tested was cadmium chloride as it has been 
widely used both in vivo and in vitro (IARC, 2012c; Fowler et al., 2010; Forti et al., 2010).    
The TSNAs NNK and NNN are present in all tobacco products as a result of the curing 
process. The toxicity of NNK and NNN is mainly caused by their metabolites, formed as a 
result of the CYP2A6/2A13 metabolism (Hecht and Tricker 1999). Their mechanism of 
action is to bind covalently to DNA producing mutations and strand breaks (Liu et al., 1990; 
Hecht 1999). Here we tested both TSNAs in the presence and absence of S9 mix. We have 
also tested NNK-acetate and NNN-acetate as CYP-independent reactive forms of NNK and 
NNN respectively. The acetate forms are stable intermediates that do not require cytochrome 
P450 activity to become activated, instead they are activated by esterase enzyme activity 
which are ubiquitous in mammalian cells (Peterson et al., 2001). 
Here, we report and discuss the results obtained from the in vitro H2AX assay by HCS 
applied to the selected cigarette smoke toxicants tested individually or for the TSNAs as a 
binary mixture. The results obtained support the use of the in vitro H2AX assay by HCS as a 
high throughput tool to investigate the genotoxicity effect of cigarette smoke toxicants.  
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2.- MATERIALS AND METHODS 
2.1.- Chemicals 
All compounds were of the highest available grade. Etoposide (positive control) (CAS 
33419-42-0), B[a]P (CAS 50-32-8) and cadmium chloride (CAS 10108-64-2) were purchased 
from Sigma-Aldrich (United Kingdom). NNK (CAS 64091-91-4), NNK-acetate (CAS 
127686-49-1), NNN (CAS 80508-23-2) and NNN-acetate (CAS 68743-65-7) were purchased 
from Toronto Research Chemicals (Canada). Dimethyl sulfoxide (DMSO) was used as a 
vehicle at a final concentration of 1% v/v in cell culture medium. Current guidelines for the 
genotoxicity testing of pharmaceuticals were followed to define doses and treatment times 
(ICH, 2011). As a result, the maximum concentration tested was 1 mM except for B[a]P 
where the maximum concentration was 15 µM due to poor solubility and precipitation after 
treatment. 
NNK-acetate and NNN-acetate mixture assessment followed simple binary mixture 
experimental design. Five different permutations containing a different ratio of each TSNA 
were prepared and each permutation contained 8 separate concentrations. 
1.- 100% NNK-acetate 
2.- 25% NNK-acetate and 75% NNN-acetate 
3.- 100% NNN-acetate 
4.- 50% NNK-acetate and 50% NNN-acetate 
5.- 75% NNK-acetate and 25% NNN-acetate 
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For example, to prepare 1 mL final volume of the binary mixture 25% NNK-acetate and 75% 
NNN-acetate at a concentration of 1000 µM, 0.25 mL of NNK-acetate solution at a 
concentration of 1000 µM was mixed with 0.75 mL of NNN-acetate solution at a 
concentration of 1000 µM. The same approach was followed for the rest of the binary 
mixtures. 
2.2.- Cell culture 
The human bronchial epithelial cell line BEAS-2B, purchased from ATCC (United States), 
was seeded into culture vessels that had been pre-coated with 0.03 mg/mL PureCol® bovine 
collagen solution (Nutacon, The Netherlands). Cells were maintained in Bronchial Epithelial 
Growth Medium (BEGM®) at 37°C and 5% CO2 in a humidified incubator. BEGM® was 
prepared by supplementing Bronchial Epithelial Basal Medium with growth supplements 
provided in the manufacturer’s BEGM® SingleQuot® kit (Lonza Group Ltd., Belgium) 
containing: bovine pituitary extract, hydrocortisone, human epidermal growth factor, 
epinephrine, insulin, triiodothyronine, transferrin, gentamicin /amphotericin-B and retinoic 
acid. BEAS-2B cells were cultured and expanded in-house. All cultures were negative for 
mycoplasma. Additionally, the cells were authenticated using the short tandem repeat 
profiling to confirm the nature of the cell cultures (LGC Standards, United Kingdom) (Nims 
et al., 2010). 
2.3.- Treatment, immunostaining and imaging analysis 
The methodology to detect and quantify H2AX by HCS has been previously described 
(Garcia-Canton et al., 2013b). Here we introduced a minor variation for the testing of B[a]P 
where 2,3,7,8-Tetrachlorodibenzodioxin (TCDD) was used as CYP1A1/1B1 inducer. Briefly, 
72 hours before B[a]P treatment, cells were seeded into collagen pre-coated 96-well, black, 
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clear bottom microplates (PerkinElmer, United Kingdom) at a concentration of 6x104 
cells/mL and maintained overnight at 37°C in an atmosphere of 5% CO2 in air. Then, TCDD 
was added to the culture media (10nM final) for a further 48 hour. Then, the media 
containing TCDD was removed and cells washed with pre-warmed phosphate buffered salt 
solution prior to treatment with B[a]P.  
Aroclor-induced rat S9 and NADPH cofactor (Moltox United States) (0.5% v/v final 
concentration in medium) were used as the exogenous source of metabolic activation for the 
pro-toxicants NNK and NNN. Preparation of the S9 mix was carried out following suppliers’ 
instructions and as detailed in (Garcia-Canton et al., 2013b). 
In this study compounds were tested for either 3 hour or 24 hour. For compounds that 
required an external source of metabolic activation compounds were tested with and without 
metabolic activation system for 3 hour and 3 hour followed by a 24 hour recovery period. 
2.4.- Data analysis and criteria 
All experiments were repeated at least 3 times and results were graphically represented using 
GraphPad Prism software v.6 
H2AX frequency (response) is reported as fluorescence intensity units. Our methodology 
scores whole nuclei fluorescence instead of foci numbers; Counting foci numbers will 
decrease the throughput of the assay reducing its potential application as a pre-screening tool. 
In addition, the length of our treatments, i.e. minimum of 3 hour, would have an effect in the 
heterogeneity of foci size (overlapping of foci) compromising the sensitivity of the results. 
 Relative Cell Counts (RCC) as a percentage of the vehicle-treated control are used as the 
measure of cell viability. The vehicle treated cell counts were defined as 100% cell viability. 
The cell counts in the compound treated wells were then compared to those in the vehicle-
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treated wells, and the percentage cell viability was calculated. This comparison against the 
vehicle control data is referred to as Relative Cell Counts (RCC).  
The evaluation criteria for this study is described in Table 2, it was initially presented by 
Smart et al. for the analysis of H2AX by flow cytometry (Smart et al., 2011) and recently 
employed by Garcia-Canton et al. for the analysis of H2AX by HCS (Garcia-Canton et al., 
2013b). 
Table 2: Genotoxicity evaluation criteria for the in vitro H2AX assay, adapted from (Smart et al., 
2011) 
H2AX response Classification 
> 1.5-fold H2AX @ RCC > 25% Genotoxic (+) 
< 1.5-fold H2AX @ RCC 100-0% Non-genotoxic (–) 
> 1.5-fold H2AX @ RCC < 25% “False” positive; Cytotoxic-driven genotoxicity 
=1.5-fold H2AX @  RCC ≥ 25% Equivocal (±) 
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3.- RESULTS 
The novel in vitro H2AX assay by HCS was used to evaluate the genotoxicity effect of four 
cigarette smoke toxicants and the binary mixture of two TSNAs. Automated fluorescence 
microscopy was selected as the scoring system to detect and quantify the specific H2AX 
immunostaining, used as a marker of DNA double strand breaks. The graphical 
representations below show the H2AX response obtained after BEAS-2B cells were treated 
with the positive control etoposide (Figure 1), different cigarette smoke toxicants (Figures 2 
to 5) and the TSNAs binary mixture (Figure 6). The X-axis represents the compound 
concentration (µM) on a logarithmic scale while the Y-axis represents the H2AX frequency 
in absolute units (intensity units). RCC representing cell viability are graphically represented 
in the supplementary data for clarity. 
A range of etoposide concentrations up to 1mM was used in this study as a positive control in 
all experiments conducted. A sample dose response is graphically represented in Figure 1. 
 
Figure 1: Etoposide positive control dose response example after 3 hour treatment. 
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B[a]P was tested in both TCDD-induced and non-induced cultures for 3 hour and 24 hour. 
Initial range finder experiments testing up to 1mM showed that B[a]P precipitated at high 
concentrations (data not shown). Therefore, the maximum concentration tested in this study 
was 15 µM. B[a]P did not produce any increase in H2AX frequency above the vehicle-
treated controls after 3 hour treatment in the presence and absence of the inducer TCDD 
(Figures 2A and 2B). When B[a]P was tested for 24 hour, there was a significant increase in 
H2AX frequency in both TCDD-induced and non-induced cultures at concentrations above 
0.5 µM without any significant reduction in cell viability (RCC > 80%). However, the 
H2AX frequency in non-induced cultures at concentrations above 4 µM after 24 hour 
treatment returned to vehicle-treated levels (< 1.5-fold induction) as illustrated in Figure 2B.  
1 10
0
20
40
60
80
100
Ve
hic
le
B(a)P concentration (µM)
#
1 10
0
20
40
60
80
100
B(a)P concentration (µM)V
eh
icl
e
# a
A B
 
Figure 2: H2AX frequency after treatment with B[a]P. [A] B[a]P treatment in TCDD-induced 
cultures [B] B[a]P treatment in non-induced cultures. Triangle (-▲-) represents short treatment (3 
hour) and circle (-●-) represents long treatment (24 hour). Hash (#) indicates the minimum 
concentration that shows genotoxicity (1.5 fold increase) compared to the vehicle treated control after 
long treatment. (a) indicates the minimum concentration where H2AX frequency reverts to non-
genotoxic range (< 1.5 fold-induction). 
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Both tobacco-specific nitrosamines NNK and NNN failed to show any statistically significant 
increase in H2AX compared to the vehicle-treated controls at all timepoints in the presence 
and absence of aroclor-induced rat S9 mix. Figure 3 illustrates the results obtained for NNK 
in the presence of S9 mix, the same profile was obtained for NNN in the presence and 
absence of S9 mix (data not shown).  
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Figure 3: H2AX frequency after treatment with NNK. [A] NNK in the presence of S9 mix and [B] 
NNK in the absence of S9 mix. Triangle (-▲-) represents short treatment (3 hour) and circle (-●-) 
represents short treatment (3 hour) followed by a recovery period (24 hour). 
The results represented in Figure 4 show that both NNK-acetate and NNN-acetate produced 
DNA damage in the form of DSBs. NNK-acetate (Figure 4A) produced a significant increase 
in H2AX frequency compared to the vehicle-treated control at concentrations above 16 µM 
after a 3 hour treatment, without reduction in cell viability (RCC > 90%), at 3 hour followed 
by 24 hour recovery period concentrations above 125 µM showed an increase in H2AX 
above 1.5-fold with a high reduction in cell viability (RCC ~ 40%). The highest concentration 
tested (1000 µM) produced almost total cell death after a 3 hour treatment followed by 24 
hour recovery period, this could explain the high variability observed in the data.  
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When NNN-acetate was tested at 3h there was a positive response at concentrations above 
500 µM without a reduction in cell viability below 90%. NNN-acetate did not produce a 
positive response after 3 hour treatments followed by 24 hour recovery time, although, a 
dose-related increase in H2AX frequency and reduction in cell viability were observed 
(Figure 4B). 
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Figure 4: H2AX frequency after treatment with the active form of NNK and NNN. [A] NNK-acetate 
treatment, [B] NNN-acetate treatment. Triangle (-▲-) represents short treatment (3 hour) and circle (-
●-) represents short treatment (3 hour) followed by a recovery period (24 hour). Asterisk (*) indicates 
the minimum concentration that shows genotoxicity compared to the vehicle treated control after short 
treatment. Hash (#) indicates the minimum concentration that shows genotoxicity compared to the 
vehicle treated control after long treatment. 
Figure 5 illustrates the results obtained after BEAS-2B cells were treated for 3 hour and 24 
hour with cadmium chloride. A positive response was observed after 3 hour treatment at 
concentrations above 250 µM (RCC > 40%). After 24 hour treatment, concentrations above 
16 µM showed cytotoxic-driven genotoxicity with RCC < 25%.  
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Figure 5: H2AX frequency after treatment with Cadmium chloride. Triangle (-▲-) represents short 
treatment (3 hour) and circle (-●-) represents long treatment (24 hour). Asterisk (*) indicates the 
minimum concentration that shows genotoxicity compared to the vehicle treated control after short 
treatment. (a) Indicates the minimum concentration that shows cytotoxic-driven genotoxicity after 
long treatment (RCC < 25%). 
The results obtained after BEAS-2B cells were treated for 3 hour with binary mixtures of 
NNK-acetate and NNN-acetate are graphically represented in Figure 6. The binary mixture 
involved the testing of 5 different permutations containing different percentages of both 
NNK-acetate and NNN-acetate. All permutations tested showed a significant increase in the 
H2AX frequency compared to the vehicle-treated control without a reduction in cell 
viability to levels below 60%. NNK-acetate (100%) produced a more potent genotoxic 
response than NNN-acetate (100%) as the positive response with NNK-acetate is observed at 
lower concentrations than NNN-acetate. The mixtures tested do not suggest any compound-
to-compound interaction such as synergistic or antagonistic effects.  
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Figure 6: H2AX frequency after 3 hour treatments with different ratios of TSNA mixtures. Circle (-
●-) represents 100% NNK-acetate, rhomb (--) represents 75% NNK-acetate and 25% NNN-acetate, 
square (--) represents 50% NNK-acetate and 50% NNN-acetate, down-pointing triangle (--) 
represents 25% NNK-acetate and 75% NNN-acetate and up-pointing triangle (-▲-) represents 100% 
NNN-acetate. Asterisk (*) indicates the minimum concentration that shows genotoxicity compared to 
the vehicle treated control after treatment with 100% NNK-acetate. Dagger (†), section sign (§) and 
double dagger (‡) indicate the minimum concentration that shown genotoxicity compared to the 
vehicle treated control after treatment with 75% NNK-acetate and 25% NNN-acetate, 50% NNK-
acetate and 50% NNN-acetate and 25% NNK-acetate and 75% NNN-acetate respectively. Hash (#) 
indicates the minimum concentration that shows genotoxicity compared to the vehicle treated control 
after treatment with 100% NNN-acetate. 
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4.- DISCUSSION 
The objective of this study was to evaluate the applicability of the novel in vitro H2AX 
assay by HCS for the in vitro genotoxicity assessment of cigarette smoke toxicants in a high-
throughput approach. Additionally, we assessed the genotoxicity effect of a mixture of two 
TSNAs (Acetylated NNK and NNN reactive precursors) developing further understanding of 
their relative contribution to the genotoxic response.  
Traditionally, the in vitro genotoxic effect of tobacco cigarette smoke has been widely 
evaluated by testing the particulate matter collected on Cambridge filter pads in animal-
derived cell lines such as CHO or V79. A thorough review on the evaluation of in vitro 
assays used for assessing cigarette smoke was published by Johnson and colleagues in 2009 
(Johnson et al., 2009). Although these methods are useful when comparing products, it is not 
possible to determine which compounds in the mixture are causing the response or “driving” 
the toxicity. Fractionation of the different components present in tobacco cigarette smoke has 
supported the segregation of the toxicants from other compounds present in the mixture as 
described by (Burns et al., 2008) and the FDA CTP (FDA, 2012a). Nonetheless, mixture 
testing is still required to understand potential toxicant interactions and relative contributions. 
The information obtained from single toxicant and mixture testing would be essential to 
prioritise the reduction of cigarette smoke toxicants in modified tobacco products as 
recommended by the WHO FCTC (WHO 2008). To date, the information existing on 
cigarette smoke toxicants are mainly derived from animal models (in vivo) or current 
regulatory in vitro genotoxicity assays such as Ames, micronucleus or mouse lymphoma 
assay (MLA). Existing regulatory in vitro genotoxicity assays have two main limitations, low 
throughput and high frequency of false positives, for these reasons newer technologies and 
end-points are currently taken into consideration in the genetic toxicology field (Lynch et al., 
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2011). The in vitro H2AX assay has been described as a potential complementary tool to the 
current battery of genotoxicity assays, especially as a pre-screening assay, using scoring 
systems such as manual microscopy, flow cytometry and in cell western (Watters et al., 2009; 
Smart et al., 2011; Audebert et al., 2010). Automated microscopy in the form of High 
Content Screening (HCS) has recently been proposed as an alternative to flow cytometry in 
the in vitro H2AX assay and offer the advantage of a high accuracy (86%), which results 
from a high sensitivity (86-92%) and a high specificity (80-88%) (Garcia-Canton et al., 
2013b). The use of the in vitro H2AX assay by HCS would facilitate the analysis of large 
number of compounds and of mixtures.  
Here, our results indicate that the in vitro H2AX assay by HCS has the ability to detect the 
genotoxicity response from cigarette smoke toxicants in different chemical families such as 
PAHs (B[a]P), heavy metals (Cadmium) and CYP-independent forms of TSNAs (NNK-
acetate and NNN-acetate). The in vitro H2AX assay by HCS has also shown the potential to 
detect and quantify the genotoxicity effect of binary mixtures supporting the assessment of 
complex chemical to chemical interactions and the relative contribution to the toxicological 
end-point. In some cases, an elevated response in H2AX levels was observed at 
concentrations with low cell viability. This effect has been associated to mechanisms such as 
apoptosis as a result of the fragmentation of cellular DNA that is part of the programmed cell 
death sequence (Mukherjee et al., 2006; Darzynkiewicz et al., 2012). 
During this study some limitations were observed when aroclor-induced rat S9 mix was used 
as an external source of metabolic activation for TSNAs. Both NNK and NNN produced a 
negative response in the presence of the S9 mix but a positive response was later obtained 
when the active intermediates were tested. The S9 mix is a standardised hepatic product used 
routinely in in vitro testing. However, not all the relevant cytochrome P450s are present in 
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this external source of metabolic activation as described by Easterbrook et al (Easterbrook et 
al., 2001). They performed a comparison between aroclor-induced rat S9 and human liver 
microsomes finding that the rat S9 lacks 7-hydroxylation activity (equivalent to human 
CYP2A6). In addition, CYP2A13 enzyme activity is mostly restricted to the respiratory tissue 
and therefore not expected in liver S9 mix (Su et al., 2000; Zhang et al., 2007). Both 
CYP2A6 and CYP2A13 enzymes are required for the activation of NNK and NNN (Hecht 
1999), explaining why our experiments did not show any response for these TSNAs in the 
presence of S9 mix. Engineered BEAS-2B cells expressing human cytochrome P450 (Mace 
et al., 1997; Grosse et al., 1997), human- and animal-derived lung fractions or purified CYPs 
could also be employed as alternatives to standard rat S9. The pros and cons of some of these 
methodologies in vitro have been thoroughly reviewed by Brandon and colleagues (Brandon 
et al., 2003). Cell lines with a more comprehensive expression of CYP enzymes such as the 
human hepatoma-derived HepaRG cells could be considered as cell systems (Antherieu et al., 
2010). However, these “metabolically competent” cell lines are derived from the liver which 
in this case is not an appropriate surrogate for the target organ of exposure.          
In summary, the in vitro H2AX assay by HCS can be used as a pre-screening tool for the 
genotoxicity evaluation of cigarette smoke toxicants both individually and in mixtures 
supporting the ranking of priority toxicants, defined by the WHO FCTC, and the HPHCs, 
defined by the FDA CTP (WHO 2008; FDA, 2012a). The data produced could scientifically 
support the prioritisation of toxicant reduction in modified tobacco products. Furthermore, 
the in vitro H2AX assay by HCS can be further developed to be adapted to aerosol exposure 
and this could become a more physiologically relevant model in the evaluation of toxicants in 
the form of gases and vapours as well as whole cigarette smoke.  
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ABSTRACT 
 
The genotoxic effect of cigarette smoke is routinely measured by treating cells with cigarette 
Particulate Matter (PM) at different dose levels in submerged cell cultures. However, PM 
exposure cannot be considered as a complete exposure as it does not contain the gas phase 
component of the cigarette smoke. The in vitro H2AX assay by High Content Screening 
(HCS) has been suggested as a complementary tool to the standard battery of genotoxicity 
assays as it detects DNA double strand breaks in a high-throughput fashion. The aim of this 
study was to further optimise the in vitro H2AX assay by HCS to enable aerosol exposure of 
human bronchial epithelial BEAS-2B cells at the air-liquid interface (ALI). Whole 
mainstream cigarette smoke (WMCS) from two reference cigarettes (3R4F and M4A) were 
assessed for their genotoxic potential. During the study, a further characterisation of the 
Borgwaldt RM20S® aerosol exposure system to include single dilution assessment with a 
reference gas was also carried out. 
The results of the optimisation showed that both reference cigarettes produced a positive 
genotoxic response at all dilutions tested. However, the correlation between dose and 
response was low for both 3R4F and M4A (Pearson coefficient, r = -0.53 and -0.44 
respectively). During the additional characterisation of the exposure system, it was observed 
that several pre-programmed dilutions did not perform as expected.  
Overall, the in vitro γH2AX assay by HCS could be used to evaluate WMCS in cell cultures 
at the ALI. Additionally, the extended characterisation of the exposure system indicates that 
assessing the performance of the dilutions could improve the existing routine QC checks. 
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1.- INTRODUCTION 
Cigarette smoke is a complex aerosol mixture consisting of more than 6,000 identified 
compounds that can be divided between the particulate phase, accounting for 4.5% of the 
total aerosol mixture mass, and the gas phase, accounting for 95.5% of the total aerosol 
mixture mass (Rodgman and Perfetti 2013). 
Testing and understanding the toxicity of cigarette smoke in vitro is a key step in the 
characterisation of modified tobacco products with potentially reduced harm. Adopting such 
strategies are in line with recommendations published by the Institute of Medicine “Clearing 
the Smoke” (Stratton et al., 2001) and the World Health Organisation Framework convention 
on Tobacco Control (WHO FCTC) “The scientific basis of tobacco product regulation” 
(WHO 2008).  
Johnson and colleagues published a thorough review on the in vitro systems used to evaluate 
the toxicity of cigarette smoke (Johnson et al., 2009). In this review, the authors highlighted 
that the majority of tobacco-related in vitro toxicology studies are carried out in non-human 
cell models which are poorly validated for tobacco product comparison. They also concluded 
that better methods are needed, especially in relation to regulation and health claims. In the 
field of in vitro genotoxicity, the authors described that the evaluation of cigarette smoke has 
been carried out using mainly cigarette smoke condensate (CSC). However, CSC contains 
primarily particulate phase components compared to whole mainstream cigarette smoke 
(WMCS) which contains both particulate and gas phase components. We consider WMCS a 
more comprehensive exposure system to study toxicological effects in vitro (Table 1). 
Moreover, the in vitro genotoxicity data has been mainly obtained from animal-derived cell 
systems which are functionally very different from human-derived cells.  
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Table 1: Physical forms of cigarette smoke used in in vitro testing. Adapted from  (Breheny et al., 
2011). 
 
There are different in vitro genotoxicity assays that have been widely used in the assessment 
of tobacco products (Johnson et al., 2009). Some of the assays described such as the 
micronucleus or the mouse lymphoma assay focus on fixed DNA damage like chromosomal 
damage and mutations, their strengths and limitations have been previously summarised 
(Garcia-Canton et al., 2012). The comet assay is the only assay described by Johnson and 
colleagues that specifically detects DNA strand breaks. Although the assay is widely 
accepted and considered a mature method (Lynch et al., 2011), it does not discriminate 
between single or double strand breaks and has shown high inter- and intra-experimental 
variation (Zainol et al., 2009). The in vitro H2AX assay, on the other hand, is an emerging 
method for DNA damage detection. The phosphorylation of H2AX (named H2AX) in 
response to DNA double strand breaks (DSB) was first described in 1998 (Rogakou et al., 
Name Description 
Cigarette smoke condensate 
(CSC) 
Comprises the particulate phase along with some vapour phase 
components.  Generated by cold-trapping and condensation of smoke 
at extremely low temperatures.  The condensed ‘tar’ is then typically 
extracted and diluted using acetone. 
Cigarette smoke particulate 
matter (PM) 
Comprises the particulate phase only.  Particulates are typically 
collected by passing cigarette smoke through a Cambridge filter pad 
and are subsequently eluted from the filter pad using a solvent such as 
dimethylsulphoxide. 
Cigarette smoke extract 
(CSE) 
Comprises the particulate phase along with some vapour phase 
components.  Generated by bubbling smoke through a liquid (e.g. 
phosphate-buffered saline or cell culture medium). 
Whole mainstream cigarette 
smoke (WMCS) 
Cells are directly exposed to smoke at the air-liquid interface.  This is 
more representative of human exposure conditions, as cells are 
exposed to the gas and vapour phase components in an aerosol  
(Phillips et al., 2005). 
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1998) and has since been extensively investigated (Fernandez-Capetillo et al., 2004). Some 
applications in which H2AX has been used as a biomarker of DNA damage are pre-clinical 
drug development and clinical studies (Dickey et al., 2009). More recently, H2AX has been 
suggested as a potential complement to the current battery of in vitro genotoxicity assays with 
applications in the assessment of cigarette smoke (Smart et al., 2011; Garcia-Canton et al., 
2012). 
The aim of this study was to optimise the novel in vitro H2AX assay by High Content 
Screening (HCS) that we had previously developed (Garcia-Canton et al., 2013a), in order to 
adapt it for the assessment of aerosols and to evaluate the genotoxic effect of two reference 
cigarettes in human lung-derived BEAS-2B cells at the air-liquid interface (ALI). The 
optimisation employs the Borgwaldt RM20S® smoking machine (RM20S®) as part of the 
exposure system that delivers WMCS to cells at the ALI (Phillips et al., 2005). 
The in vitro H2AX assay has been previously used in the assessment of cigarette smoke 
using mainly CSC and indirect exposure to WMCS i.e. cell cultures that had a layer of media 
covering the cells continuously or intermittently during smoke exposure and therefore not 
considered true ALI exposure (Albino et al., 2004; Albino et al., 2006; Albino et al., 2009; 
Tanaka et al., 2007; Zhao et al., 2009). In general, flow cytometry has been the main method 
for H2AX detection and analysis. In this study, we selected a microscopy-based automated 
scoring system known as HCS to acquire and quantify the H2AX response after WMCS 
exposure to BEAS-2B cells at the ALI. WMCS was tested from two different cigarettes, 
3R4F a reference cigarette from the University of Kentucky (University of Kentucky, 2013) 
and M4A a historical control used as internal reference in genotoxicity studies by British 
American Tobacco (Combes et al., 2012). 
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Overall, the results show that the in vitro H2AX by HCS can be used as a high throughput 
tool to assess the genotoxic effect of WMCS in cultures exposed at the ALI. The results can 
be used to compare the genotoxic responses of different tobacco products. Furthermore, the 
optimised in vitro H2AX assay for aerosol exposure could be a useful high content 
screening tool to assess the genotoxic potential of toxicants in gaseous form. 
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2.- MATERIALS AND METHODS 
2.1.- Cell culture 
The human bronchial epithelial cell line BEAS-2B was purchased from ATCC (United 
States). Normal bronchial epithelium cells obtained from autopsy of non-cancerous 
individuals had been isolated, then infected with a replication-defective 12-SV40/adenovirus 
hybrid (Ad12SV40) and cloned to create an immortalised phenotype (Reddel et al., 1988). 
Cells were seeded into culture vessels that had been pre-coated with 0.03 mg/mL PureCol® 
bovine collagen solution (Nutacon, The Netherlands). Cells were then maintained in 
Bronchial Epithelial Growth Medium (BEGM®) at 37°C and 5% CO2 in a humidified 
incubator. BEGM® was prepared by supplementing Bronchial Epithelial Basal Medium with 
growth supplements provided in the manufacturer’s BEGM® SingleQuot® kit (Lonza Group 
Ltd., Belgium) containing: bovine pituitary extract, hydrocortisone, human epidermal growth 
factor, epinephrine, insulin, triiodothyronine, transferrin, gentamicin /amphotericin-B and 
retinoic acid. BEAS-2B cells were cultured and expanded in-house, the cells were used 
between passages 3 and 12 only. All cultures were negative for mycoplasma. Additionally, 
the cells were authenticated using the short tandem repeat profiling to confirm the nature of 
the cell cultures (LGC Standards, United Kingdom) (Nims et al., 2010). 
2.2.- Smoking system 
The selection of the RM20S® 8-syringe smoking machine as the WMCS exposure system 
was based on previous in vitro studies (Massey et al., 1998; Phillips et al., 2005) and 
thorough evaluations of precision, accuracy, repeatability and reproducibility (Kaur et al., 
2010; Adamson et al., 2011). The smoking exposure system is schematically represented in 
Figure 1. The RM20S® employs a dilution system that mixes WMCS with different 
proportions of air to generate a dilution ratio represented as 1 : X (smoke volume : air 
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volume). Cigarettes are automatically loaded into cigarette holders (Figure 1A) where 
WMCS is drawn directly into the glass syringe and diluted with air taken from the laboratory 
environment (Figure 1B) following a multi-step process operated by a plunger (Figure 1C). 
The diluted WMCS is then delivered to an exposure chamber (Figure 1D) containing four 
Transwell® inserts with BEAS-2B cells seeded on top of the insert’s membrane (Figure 1E). 
At the time of the exposure the cells are directly exposed to WMCS at the air-liquid interface 
(ALI). 
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Figure 1: Schematic representation of a single RM20S® syringe combined with British American 
Tobacco’s exposure chamber (UK patent publication WO 03/100417/ A1) (not to scale). The 
RM20S® can smoke up to eight cigarettes simultaneously. [A] Cigarette holder with cigarette in place; 
[B] 150mL glass syringe where cigarette smoke dilution in air is prepared; [C] Plunger; [D] Exposure 
chamber containing porous membrane inserts with cells seeded on top at the ALI [E] Transwell® 
insert representation. Figure adapted from (Adamson et al., 2011). 
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2.3.- Dilution performance evaluation 
A range of dilutions were selected for this study from 1:25 to 1:20000 (smoke volume : air 
volume) (Table 2). The methodology employed by Kaur and colleagues used methane (CH4) 
as a reference gas standard with known parts per million (PPM) to compare syringe 
performance and has been adapted here to assess dilution performance (Kaur et al., 2010). 
For our experiments, three different methane reference standards in nitrogen were purchased 
from Air Products PLC (United Kingdom), 10% containing 100,000 PPM methane, 50% 
containing 500,000 PPM methane and 99.95% containing 1,000,000 PPM methane. The 
relevant reference gas was loaded into a sealed bag and connected directly to the smoking 
machine cigarette holder (Figure 1A). The dilution to be tested was then programmed into the 
RM20S® and then gas diluted following International Standard Organization (ISO) 
3308:2012 puffing profile consisting of 35 mL puff volume, 2 sec puff duration, and 60 sec 
puff interval (ISO, 2012). A second empty sealed bag was connected to the exhaust position 
in the place of the exposure chamber to collect the diluted gas (Figure 1D). Quantification of 
methane in PPM was performed with a 3010 MINIFID portable heated flame ionization 
detector total hydrocarbon analyser (Signal Group Ltd, United Kingdom) as per 
manufacturer’s instructions. Table 2 summarises details about dilutions, reference gas 
standard used per dilution and expected PPM. The laboratory environment was conditioned at 
22±2°C and 60±5% Relative Humidity (RH). 
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Table 2: Range of dilutions, details of methane reference gas and expected PPM. 
Dilutions Expected PPM with 10% methane 
Expected PPM with 
50% methane 
Expected PPM with 
100% methane 
1:25 4000     
1:50 2000     
1:100 1000     
1:250 400     
1:500 200     
1:1000 100     
1:1500 67     
1:2000   250   
1:3000   167   
1:4000   125   
1:6000   83   
1:8000   63   
1:16000     63 
1:20000     50 
 
2.4.- Smoke exposure 
Cigarettes were conditioned for a minimum of 48 hours prior to use (60±3% relative 
humidity, 22±1°C according to ISO 3402:1999) (ISO, 2010) and smoked continuously 
throughout the exposure on a RM20S® smoking machine (Borgwaldt KC, Germany) using a 
35 ml puff volume drawn over 2 seconds, once every minute according to ISO 3308:2012 
(ISO, 2012). The smoking environment was conditioned at 22±2°C and 60±5% RH.  
In this study two reference cigarettes were used to test whether the in vitro H2AX assay by 
HCS could discriminate between products. The reference cigarette 3R4F supplied by the 
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University of Kentucky, is a “US style” blended cigarette that delivers 9.4 mg tar and 0.7 mg 
nicotine under ISO conditions for cigarette smoking (ISO 3308:2012) (ISO, 2012). Internal 
reference cigarette M4A is a flue cured cigarette that delivers 10 mg of tar and 1.0 mg 
nicotine under ISO conditions for cigarette smoking (ISO 3308:2012) (ISO, 2012).  
2.5.- Controls 
Etoposide (1mM final) was used as a positive control during the experimentation (Sigma-
Aldrich, United Kingdom). Etoposide is a well-known DNA-damaging compound and has 
previously been used in the in vitro H2AX assay by HCS as a reference compound and 
positive control respectively (Garcia-Canton et al., 2013a; Garcia-Canton et al., 2013b). Two 
different negative controls were used in this study; air control and incubator control. The air 
control was generated by the smoking machine to evaluate the quality of the air used to dilute 
the WMCS and mimic the exposure conditions. The incubator control evaluated the 
incubation conditions used to generate the positive controls. 
2.6.- WMCS treatment, H2AX immunostaining and imaging analysis 
The methodology used during this study to detect and quantify H2AX by HCS was 
previously described (Garcia-Canton et al., 2013a) with variations for the ALI exposure. In 
this study, cells were seeded on top of the membrane of collagen pre-coated 24-Transwell® 
plate (Corning Incorporated Life Sciences, Unites States) at a concentration of 1.2x105 
cells/mL and 500 µL of BEGM® were added underneath to keep the cells hydrated. The 
plates were then incubated overnight at 37°C in an atmosphere of 5% CO2 in air. At the time 
of treatment, the culture media was removed from the Transwell® membrane so the cells 
could be exposed directly at the ALI. Then, four inserts were transferred to each exposure 
chamber containing 25 mL of Dulbecco's Modified Eagle Medium supplemented with 1% L-
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Glutamine and 0.5% penicillin/streptomycin (10000 IU/mL – 10000uG/mL). The exposure 
chambers were then placed in an incubator at 37°C and connected with plastic tubing to the 
smoking machine as represented in Figure 1D (smoke in/smoke out connectors). The 
smoking machine pre-programmed with the appropriate dilutions was set for a 3 hour 
exposure. We selected a 3 hour exposure as it is the minimum recommended in the 
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH guidelines) (ICH, 2011). Following exposure, the 
inserts were placed in clean pre-labelled 24-well plates where the cells were fixed with 4% 
paraformaldehyde (100 µL/insert) and incubated for 15 minutes at room temperature. The 
fixed samples were processed for H2AX immunostaining following manufacturer’s 
recommendation (ThermoScientific, United States).  
Image acquisition was performed using the Cellomics ArrayScan® VTI platform 
(ThermoScientific, USA). Image analysis used the Target Activation Bioapplication software 
v.6.6.1.4. The protocol was set to count a minimum of 500 cells per insert, giving a minimum 
of 2000 cells per concentration tested. Nuclear DNA staining (Hoechst dye) was used to 
identify viable cells nuclei. These nuclei were used as the target areas for the measurement of 
H2AX specific fluorescence intensity represented as absolute intensity units. Viable cell 
counts from negative controls were defined as 100% cell viability. The viable cell counts in 
the WMCS and etoposide treated samples were then compared to those in the negative 
control, and the percentage cell viability was calculated and referred to as Relative Cell 
Counts (RCC). 
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2.7.- Data analysis and criteria 
o Dilution performance evaluation 
1-sample t-test was used to compare the results obtained in PPM for each dilution with the 
expected PPM. A variability of ±10% over the expected PPM was included afterwards as 
accepted measurement variation (Supplier Quality Requirements Taskforce 2002). 
Repeatability and Reproducibility statistics were computed for all data points according to 
ISO 5725 -2:1994 (ISO, 2013). Experiments were replicated 3 times, with 6 repeats per 
dilution per experiment. Data analysis and graphical representations were performed with 
Minitab software v.16. 
o WMCS genotoxicity evaluation 
The evaluation criteria used in this study (Table 3) was first described by Smart et al. for the 
analysis of H2AX by flow cytometry (Smart et al., 2011) and recently applied by Garcia-
Canton et al. for the analysis of H2AX by HCS (Garcia-Canton et al., 2013a). Experiments 
were replicated at least three times and graphical representation was performed using 
GraphPad Prism software v.6.01. 
Table 3: Genotoxicity evaluation criteria for the in vitro H2AX assay by HCS, adapted from (Smart 
et al., 2011). 
H2AX response Classification 
> 1.5-fold H2AX @ RCC > 25% Genotoxic (+) 
< 1.5-fold H2AX @ RCC 100-0% Non-genotoxic (–) 
> 1.5-fold H2AX @ RCC < 25% “False” positive; Cytotoxic-driven genotoxicity (C) 
1.5-fold H2AX @  RCC ≥ 25% Equivocal (±) 
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3.- RESULTS 
The Borgwaldt RM20S® smoking machine combined with British American Tobacco’s 
chamber were used as an exposure system during the optimisation of the novel in vitro 
H2AX assay by HCS for the evaluation of aerosols. 
The initial steps in this optimisation included extending the QC checks of the RM20S® to 
include 14 dilution performance evaluations (Table 2). From the 10 dilutions generating 
accurate deliveries, 6 smoke dilutions were selected for further experiments based on range 
finder experiments (data not shown). The tested smoke dilutions covered a wide range of 
WMCS dilutions to assess the genotoxicity effect of two reference cigarettes (3R4F and 
M4A). 
3.1.- Dilution performance evaluation 
An initial range of 14 dilutions from 1:25 to 1:20,000 were selected to evaluate the actual 
dilution delivery in PPM units using reference methane gases (Table 2). The data in Figure 2 
graphically represents the results from the statistical 1-sample t-test analysis performed 
comparing PPM obtained per dilution (box plot) against the expected PPM (red dot), the 
analysis did not incorporate the ±10% tolerance accepted for machinery measurement 
variation and was, therefore, added to the expected PPM value afterwards (Supplier Quality 
Requirements Taskforce 2002). Results indicate that in the majority of the cases (10 out of 14 
dilutions) the dilution delivery was as expected when the ±10% tolerance was included in the 
analysis. There were four dilutions where the statistical analysis (1-sample t-test) showed a 
statistically significant difference between measured and expected PPM (including ±10% 
measurement variation), those dilutions are identified in Figure 2 with a hash (#) (1:1,000, 
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1:6,000, 1:8,000 and 1:20,000) and were not taken into consideration for the assessment of 
WMCS in the in vitro H2AX assay. 
 
Figure 2: Test dilutions t-test boxplots. Expected PPM (red dot), 95% confidence interval from PPM 
results (blue line). The asterisk (*) indicates outliers while hash (#) indicates dilutions producing a 
significant different PPM than expected (confidence interval includes the 10% machinery 
measurement variability). 
Figure 3 represents the repeatability and reproducibility results indicating the precision of the 
smoking machine dilution performance within the same experiment and in different 
experiments respectively. The repeatability and reproducibility increased linearly with 
concentration as expected. 
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Figure 3: Scatterplot of repeatability (r) (-○-) and reproducibility (R) (--). 
3.2.- WMCS genotoxicity assessment 
Initial range finder experiments showed that 3 hour exposures to WMCS from 3R4F 
cigarettes at dilutions more concentrated than 1:500 produced tar depositions, this effect was 
considered equivalent to precipitation. Only dilutions greater than 1:500 were included in 
further experiments. Both reference cigarettes 3R4F and M4A produced a significant increase 
in H2AX frequency (above 1.5-fold increase) compared to the air-treated control in all the 
dilutions tested (Figure 4). In all experiments the positive control etoposide produced an 
increase greater than 1.5-fold compared to the air-treated control (Figure 4A and 4B). 
Relative Cell Counts (RCC) for all results presented were above the acceptance limit of 
toxicity (RCC > 25%) and therefore no cytotoxic-driven genotoxicity was observed (Table 3). 
Figure 4A illustrates the response produced after 3 hour exposure to 3R4F WMCS. A 
variation in the response can be observed between the most concentrated WMCS (1:500) and 
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the most diluted WMCS dilution (1:16,000). However, the linear regression model indicates a 
low correlation between the dose and the response (Pearson coefficient, r = -0.53). Figure 4B 
showed the results obtained after 3 hour exposure to M4A WMCS. In this case, a variation in 
the response can only be observed at the most diluted WMCS dilution tested (1:16,000). The 
linear regression model produced a low correlation between the dose and the response 
(Pearson coefficient r = -0.44). Figure 4C graphically represents the fold-induction results 
from both reference cigarettes. In general, 3R4F WMCS exposure seems to have a more 
potent genotoxic effect compared to M4A WMCS exposure, especially at the most 
concentrated dilution 1:500. 
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Figure 4: H2AX frequency mean ±SD after 3 hour exposure to WMCS from reference cigarette [A] 
3R4F, [B] M4A. Circle (-●-) represents WMCS results, square (--) represents positive control 
etoposide (1mM final), triangles (-- and -▲-) represents negative controls, air and incubator 
controls respectively and dotted red line represents the 1.5-fold increase over the air control indicating 
the threshold of genotoxic response. [C] H2AX fold-induction for both reference cigarettes 3R4F 
(blue) and M4A (red), dotted line indicates genotoxic level (>1.5-fold H2AX response).  
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4.- DISCUSSION 
The main objective of this study was to optimise the novel in vitro H2AX by HCS for the 
genotoxicity assessment of aerosols. During the optimisation, the genotoxic potential in the 
form of H2AX induction from various dilutions of WMCS of two reference cigarettes were 
tested and differences in the response evaluated. 
The cell system selected was the BEAS-2B cell line, a human-derived cell line from the lung, 
the first target tissue of inhaled aerosols. The non-tumorigenic human-derived BEAS-2B cell 
line was isolated from normal human epithelium and immortalised by virus infection (Reddel 
et al., 1988). The normal phenotype and wild-type p53 status support the use of this cell line 
in DNA damage studies (Svetlova et al., 2010; Petitjean et al., 2007; IARC, 2013). BEAS-2B 
cells, however, lack normal metabolic activity for the majority of cytochrome P450 family, 
an essential factor for the phase I bioactivation of some cigarette smoke toxicants such as 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (Garcia-Canton et al., 2013c). The 
limitation in the metabolic capability of the cell line would need to be considered in future 
experimental designs i.e. including an external source of metabolic activation in part of the 
experiments to have a more comprehensive genotoxicity evaluation of the WMCS. 
The Borgwaldt RM20S® smoking machine has been extensively used for the in vitro 
evaluation of WMCS (Massey et al., 1998; Phillips et al., 2005; Thorne et al., 2009). 
Although, some QC analyses have been reported for the accurate performance of the syringes 
(Kaur et al., 2010; Adamson et al., 2011) further QC tests for the accurate performance of the 
programmed dilutions have proved necessary. Our results in this study indicate that not all of 
the programmed dilutions deliver the expected amount of reference gas in PPM (Figure 2). 
We have observed that higher dilutions seem to produce less accurate deliveries; this effect 
could be caused by the smoking machine dilution programming. The smoking machine 
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performs a multistep process to dilute WMCS with laboratory conditioned air, the process 
requires the programming of more dilution steps for more higher dilutions, hence, the 
potential for more variation. The discrepancy between expected and delivered aerosol could 
affect the exposure to the cell cultures and ultimately the outcome of the assay. The same 
approach could be applied in the future to the particulate phase expected in the different 
dilutions employing Quartz Crystal Microbalances (QCM) previously described for this 
aerosol exposure system (Adamson et al., 2012). Nevertheless, the smoking machine 
performance has shown an overall good reproducibility and repeatability from dilutions 
delivering 50 PPM or above as can be seen in Figure 3. The performance of syringes and 
dilutions can be carried out using the same methodology and apparatus already in place for 
the standard QC checks. Moreover, the extended QC check could easily be incorporated into 
the routine service of the Borgwaldt RM20S® smoking machine. 
The H2AX results obtained during the assessment of two reference cigarettes seem to 
indicate that the in vitro H2AX assay by HCS was able to detect the genotoxic potential of 
WMCS, however the correlation between the dose and the response was low for both 
reference cigarettes evaluated in this study across all the tested dilutions (Figure 4). 
Nevertheless, the H2AX response obtained after BEAS-2B cells were exposed to a range of 
3R4F WMCS dilutions for 3 hours was in general more potent than the response obtained for 
M4A WMCS, and can be visually observed in Figure 4C. If the genotoxicity response was 
primarily associated to the gas phase we would have expected a better H2AX dose-response 
correlation with the different dilutions tested. Therefore, we have considered that the 
particulate phase may have a significant  effect in driving the genotoxic potential. This could 
be further investigated by characterising the level of particulates deposited at different 
dilutions with tools such as the QCM balance mentioned earlier in this discussion. 
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It is important to notice that 3 hour continuous exposure as recommended by ICH guidelines 
(ICH, 2011) could be the longest exposure time a submerged monolayer culture might be 
exposed at the ALI. In our experiments, the cell cultures were immediately fixed after the 
exposure to evaluate the DNA damage in the form of H2AX. Pilot experiments were 
conducted where the cell cultures were left to recover for a further 24 hours submerged in 
media to evaluate potential DNA repair after the acute 3 hour exposure. The proliferation of 
the BEAS-2B cells was greatly affected in WMCS and air control samples. Interestingly, the 
same effect was not observed in incubator control cultures where the humidity is maintained 
at a higher level (data not shown). We concluded that for in vitro assays using submerged 
cultures as cell systems, 3 hour exposure at the current conditions of ALI exposure system 
would cause irreversible damage due to drying as opposed to aerosol exposure. 
Following the optimisation described in this study, further investigations employing different 
exposure times, a larger number of products and an external source of metabolic activation 
would be necessary to support the applicability of the in vitro H2AX assay for the evaluation 
of tobacco products in aerosol exposure. Future work could also carry out an in-depth 
characterisation on the effect that product variations such as different tobacco blends have in 
H2AX induction to understand the differences in response.  
Nevertheless, the optimisation performed here could also be applied to the genotoxicity 
evaluation of other aerosols such as aerosolised drugs, pollutants and cigarette smoke 
toxicants present in the gas phase (e.g. benzene).  
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APPENDIX 1 – SUPPLEMENTARY DATA 
CHAPTER III
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Supplementary graphs: graphical representation from the 22 compounds used during the assessment 
of the in vitro H2AX assay. Left Y-axis represents H2AX frequency (continuous line) and right Y-
axis represents cell viability (%) (dotted line).  Triangle (-▲-) represents short treatment and circle (-
●-) represents long treatment. Asterisk (*) indicates the minimum concentration that shows 
genotoxicity compared to the vehicle treated control after short treatment. Hash (#) indicates the 
minimum concentration that shows genotoxicity compared to the vehicle treated control after long 
treatment. 
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CHAPTER IV 
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Supplementary graphs: graphical representation from the 4 cigarette smoke toxicants tested in the in 
vitro H2AX assay. [A to E] Left Y-axis represents H2AX frequency (continuous line) and right Y-
axis represents cell viability (% RCC) (dotted line).  Triangle (-▲-) represents short treatment and 
circle (-●-) represents long treatment. Asterisk (*) indicates the minimum concentration that shows 
genotoxicity compared to the vehicle treated control after short treatment. Hash (#) indicates the 
minimum concentration that shows genotoxicity compared to the vehicle treated control after long 
treatment. [F] Graphical representation of the mixture permutation cell viability (% RCC). 
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APPENDIX 2 – ACRONYMS 
2AAF – 2-Acetylaminofluorene 
8-MOP – 8-Methoxypsoralen 
ALI – Air Liquid Interfase 
ATM – Ataxia Telangiectasia-Mutated 
ATR – ATM- and Rad3-Related 
aut-aucPAGE – acid-urea-cetyltrimethylammonium bromide Polyacrylamide Gel 
Electrophoresis 
B[a]P – Benzo[a]pyrene 
BEGM – Bronchial Epithelial Growth Medium 
BPDE – Benzo[a]pyrene Diol-Epoxide 
BSA – Bicinchoninic Acid protein Assay 
CBMN – Cytokinesis-Blocked Micronucleus  
cDNA – complementary DNA 
CHO – Chine Hamster Ovary  
CSC – Cigarette Smoke Condensate  
CSE – Cigarette Smoke Extract 
CSS – Cigarette Sidestream Smoke 
Ct – threshold Cycle  
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COM – Committee Of Mutagenicity 
CYP – Cytochrome P450 
DDR – DNA Damage Response 
DMEM – Dulbecco’s Modified Eagle Medium   
DMSO – Dimetyl Sulfoxide 
DNA/ADN - Deoxyribonucleic Acid / Ácido Desoxirribonucleico 
DNA-PKc – DNA-dependent Protein Kinase 
DSBs – Double Strand Breaks 
ECACC – European Collection of Cell Cultures 
ECVAM – European Centre for the Validation of Alternative Methods 
ELISA – Enzyme-Linked Immunosorbent Assay 
FDA – Food and Drug Administration 
FDA CTP – Food and Drug Administration Center for Tobacco Products 
FISH – Fluorescence In Situ Hybridization 
GFP – Green Fluorescent Protein 
HCS – High Content Screening 
HPHCs – Harmful and Potentially Harmful Constituents 
Hprt – Hypoxanthine-guanine phosphoribosyl transferase 
IARC – International Agency for Research on Cancer 
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ICH – International Conference on Harmonisation 
iPS – induced Pluripotent Stem cell 
ISO – International Standard Organization 
JRC – Journal Citation Reports 
LDH – Lactate Dehydrogenase 
Luciferin-CEE – Luciferin 6' Chloroethyl Ether 
MI – Mitotic Index 
MLA – Mouse Lymphoma Assay 
MN – Micronucleus 
MNNG – Methylnitronitrosoguanidine 
MoA – Mode of Action 
M-PER – Mammalian Protein Extraction Reagent 
MRN – MRE11-RAD50-NBS1 complex 
mRNA – messenger RNA 
NC3Rs – National Centre for the Reduction, Refinement and Reduction of Animals in 
Research 
NHBE – Normal Human primary Bronchial Epithelium 
NNK – 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone 
NNN – N´-nitrosonornicotine 
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OECD – Organisation for Economic Co-operation and Development 
PAH – Polycyclic Aromatic Hydrocarbons 
PBS – Phosphate Buffered Saline 
PCA – Principal Component Analysis 
PM – Particulate Matter 
PIKK – Phosphatidylinositol 3-Kinase-like family of Kinases 
PPM – Parts Per Million 
QCM – Quartz Crystal Microbalances 
qPCR – quantitative Polymerase Chain Reaction 
RCC – Relative Cell Count 
RH – Relative Humidity 
RLU – Relative Luminescence Units 
RNA –  Ribonucleic Acid 
ROS – Reactive Oxygen Species 
RPD – Relative Population Doubling 
SARs – Structure-Activity Relationships 
SD – Standard Deviation 
SSB – Single Strand Break 
TCDD – 2,3,7,8-tetraclorodibenzo-p-dioxina 
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TK – Thymidine Kinase 
T&N-free – Tobacco and Nicotine free 
TPM – Total Particulate Matter 
trpE – tryptophan synthesis operon 
TSNAs – Tobacco Specific Nitrosamines 
WHO – World Health Organisation 
WHO FCTC – World Health Organisation Framework Convention on Tobacco Control 
WMCS – Whole Mainstream Cigarette Smoke 
WoE – Weight of Evidence 
 
 
 
 
 
 
 
 
 
